Search this site

Strategic Analysis of the ResMed and Oura Partnership: Bridging Consumer Wearables and Clinical Sleep Medicine On May 19th, 2026, ResMed (NYSE: RMD, ASX: RMD), a prominent global health technology company specialising in sleep, breathing and home-delivered respiratory care and ŌURA, the manufacturer of the leading smart ring, announced a strategic partnership. This cross-industry collaboration represents a structured initiative to connect daily consumer wellness tracking with professional medical diagnostic and treatment networks. By linking Oura's passive biometric telemetry with ResMed's established clinical software and device ecosystem, the partnership seeks to systematically address the persistent diagnostic gap in Obstructive Sleep Apnea (OSA). In the United States alone, approximately 80% of individuals with OSA remain undiagnosed and untreated, posing a massive clinical challenge and creating a significant commercial opportunity for out-of-hospital care systems. This partnership emerges at a time of rapid transformation in the consumer health technology sector, where sleep monitoring has moved from a novel trend to an essential component of clinical preventive medicine. This shift is supported by epidemiological data indicating a rise in sleep disorders, driven by an aging global population and climbing obesity rates. Furthermore, legislative momentum, such as the Supplemental Oxygen Access Reform (SOAR) bill, which seeks to improve patient access to respiratory therapists and liquid oxygen, highlights a broader regulatory focus on optimising home-based respiratory support. Simultaneously, initiatives like the Main Street Competition Coalition, established by the National Community Pharmacists Association (NCPA) and the National Grocers Association (NGA), underscore the shifting dynamics of community-level healthcare distribution, where accessible health screening is increasingly decentralised. Technical Architecture and Wearable Biometrics The core of the partnership relies on translating passive, consumer-grade biometric tracking into clinically actionable events. The Oura Ring Gen3 and Oura Ring 4 collect near-continuous physiological data using advanced photoplethysmography (PPG) sensors, skin temperature sensors, and multi-axial accelerometers. The Oura Ring 4, utilising its proprietary Smart Sensing platform, increases the number of available signal pathways from eight to eighteen compared to previous generations, dynamically adapting to the user’s finger to optimise signal capture and battery efficiency. This architecture delivers a 120% improvement in blood oxygen saturation signal quality, resulting in a 30% increase in overnight average measurement accuracy and a 15% more accurate estimation of the Breathing Disturbance Index (BDI). Unlike standard smartwatches worn on the wrist, the finger-worn ring form factor benefits from closer arterial proximity, reducing motion artifacts and light pollution. In clinical validation studies comparing consumer sleep trackers (CSTs) with the gold standard of in-lab polysomnography (PSG) which simultaneously records electroencephalography (EEG), electrooculography (EOG), electromyography (EMG), respiratory effort, nasal airflow, snoring, heart rate and body movement, wearables have demonstrated variable performance. For instance, a multi centre study assessing 11 commercially available CSTs, including the Google Pixel Watch, Galaxy Watch 5, Fitbit Sense 2, Apple Watch 8, Oura Ring 3, and nearable devices like the Withings Sleep Tracking Mat, revealed significant differences in sleep stage classification. Wearable devices often show a proportional bias in sleep efficiency metrics, while nearables exhibit higher bias in sleep latency measurements. Specifically, the Oura Ring's four-stage sleep classification algorithm has demonstrated a 79% accuracy rate when validated against polysomnography, establishing it as one of the most reliable consumer-grade trackers tested. The monitoring framework deployed under this partnership operates on a graduated notification scale. Within the Oura app, users can view their overnight breathing disturbances visualised as a timeline indicating "Optimal," "Fair," or "Pay Attention" states. Occasional minor disturbances are common and typically represent movement or positional changes, characterised by sparse blue lines on the app’s graphic interface alongside a normal average range of 95% to 100%. However, frequent, dense clusters of breathing disturbances paired with overnight oxygen desaturation drops below 90% trigger critical notifications, signalling potential sleep-disordered breathing and prompting the user to explore clinical evaluations. Monitoring Modality Primary Biometrics Tracked Clinical/Regulatory Status Typical Use Profile Oura Ring Gen3 & 4 Heart rate, HRV, breathing disturbances, sleep stages, skin temperature, respiratory rate Wellness tracking; continuous monitoring, not intended for direct diagnosis Continuous 24/7 wear; 5 to 8 days of battery life Apple Watch (Series 9 & newer) Heart rate, ECG, limb movement, sleep apnea notifications FDA-cleared sleep apnea notifications based on breathing disturbances Daily wear; 18 to 48 hours of battery life requiring regular charging ResMed NightOwl Peripheral arterial tone, heart rate, oxygen saturation, accelerometer-based motion FDA-cleared Home Sleep Apnea Test (HSAT) Single-use/short-term diagnostic application; finger-worn sensor with adhesive tape Polysomnography (PSG) EEG, EOG, EMG, ECG, nasal airflow, abdominal/thoracic effort, snoring, body position Gold standard clinical diagnostic method Single-night evaluation conducted in a specialized sleep laboratory Strategic Analysis of the ResMed and Oura Partnership: Bridging Consumer Wearables and Clinical Sleep Medicine The Integrated Referral Pathway and Care Funnel The operationalisation of the partnership commenced with a gradual rollout on April 28th, 2026, followed by the formal public announcement on May 19th, 2026. The integration is currently active for users of the Oura Ring Gen3 and Oura Ring 4 with active Oura memberships within the United States. The mechanism relies on a direct-to-consumer digital referral tunnel. When the Oura application flags a persistent pattern of elevated nighttime breathing disturbances, a dedicated home card is presented to the user. Tapping this card redirects the user to a co-branded, secure digital portal hosted by ResMed. Upon entering the ResMed environment, the user is guided through a comprehensive sleep assessment questionnaire. This assessment is derived from established clinical screening protocols designed to quantify risk factors such as daytime hypersomnolence, loud snoring, and witnessed apneas. To support the subsequent clinical encounter, the portal generates a downloadable, co-branded PDF guide that summarises the user's longitudinal breathing disturbances, sleep efficiency trends and assessment results. This document is structured to bridge the typical communication gap between patient experience and professional medical evaluation, enabling primary care physicians or sleep specialists to rapidly interpret home-recorded sleep metrics. The clinical navigation pathways are supported by ResMed’s digital search tools, including the Sleep Lab Locator and the Dealer Locator, which allow users to locate local sleep diagnostic centers or durable medical equipment (DME) suppliers. Additionally, patients have the option to connect virtually with independent sleep specialists for remote diagnostic evaluation and prescription management. This virtual pathway is designed to lower geographic barriers and expedite the time to therapy, helping to bypass the traditional bottleneck of physical sleep laboratories. Pathway Phase User Action & Biometric Trigger Backend System / Provider Integration Regulatory & Compliance Controls 1. Triage Ring detects frequent breathing disturbances; overnight oxygen drops below 90% Oura App processes biometric data locally; displays co-branded sleep-care card FTC/HIPAA-compliant; no automatic data transfer without explicit user opt-in 2. Assessment User taps app card; completes online screening; downloads discussion guide ResMed host portal runs clinical algorithms; compiles longitudinal trend PDF Structured screening using clinically validated sleep assessment templates 3. Clinical Engagement User matches with telemedicine provider or searches local sleep centers Integration with ResMed Sleep Lab Locator & independent clinical partner platforms State-specific medical licensing compliance; independent clinical decision-making 4. Therapy Initiation Patient undergoes Home Sleep Apnea Test (HSAT); receives CPAP or alternative therapy Integration with DME networks; listings updated via onlinestore.resmed.com FDA-cleared medical diagnostics and therapy prescription compliance Macro Market Synergies: GLP-1 Medications and Comorbidity Management A primary driver for ResMed's consumer-facing strategies is the shifting landscape of obesity management, particularly the widespread adoption of GLP-1 receptor agonists like tirzepatide (Zepbound) and semaglutide. Although initial market assumptions suggested that effective weight loss therapies could diminish the long-term demand for sleep apnea treatments by resolving anatomical airway obstructions, longitudinal market surveillance indicates the opposite effect. Data collected over a two-year surveillance period demonstrates that patients prescribed a GLP-1 medication are 11% more likely to initiate CPAP therapy than those who are not on these weight loss drugs. This acceleration is primarily a funnel effect: the high profile of modern weight loss therapies has drawn historically disengaged populations into primary care settings. When these patients seek medical assistance for weight management, clinicians systematically evaluate their overall health, identifying untreated co-morbidities such as hypertension, type 2 diabetes and obstructive sleep apnea. While weight loss occurs over a prolonged period, treating active sleep apnea is medically urgent due to the immediate risk of stroke or cardiovascular events, leading to high rates of concurrent CPAP prescriptions. Furthermore, ResMed’s tracking of patient compliance indicates that GLP-1 users demonstrate superior long-term adherence. At one year of therapy, GLP-1 patients are 3% more likely to reorder replacement masks from ResMed, and this metric rises to 5% at the two-year mark. This persistent demand is particularly significant given that real-world discontinuation rates for GLP-1 medications typically exceed 50% at one year and continue to climb at two years. As patients discontinue their weight loss medications and potentially regain weight, their reliance on mechanical airway support is reinforced, driving continued utilisation of ResMed's core technologies. This patient flow aligns with ResMed’s broader out-of-hospital care ecosystem, which features cloud-connected therapeutic devices monitored via the myAir and AirView software platforms. These platforms are designed to enhance patient adherence using AI-enabled digital coaching assistants such as Comfort Match, which acts as an automated sleep coach to optimise comfort settings and long-term compliance. Additionally, ResMed’s joint venture with Verily, known as Primasun, and its collaboration with digital platforms like Ognomy Sleep, which offers virtual sleep apnea care and integrates with ResMed’s Pathway program, further support this patient pipeline. Patient Adherence Metric Standard CPAP Cohort Concurrent GLP-1 Cohort Strategic Implication for Supply Chain CPAP Therapy Initiation Rate Baseline +11% higher initiation probability Accelerates equipment deployment and initial diagnostics 1-Year Mask Reorder Rate Baseline +3% higher reorder probability Stabilises high-margin recurring supply revenue 2-Year Mask Reorder Rate Baseline +5% higher reorder probability Offsets typical long-term patient attrition patterns Medication Adherence at 1–2 Years N/A <50% retention (medication discontinued) Reinforces mechanical airway therapy as a permanent baseline Financial Performance and Capital Allocation From a corporate perspective, the partnership is a key component of ResMed’s newly unveiled 2030 Strategy. This plan targets high-single-digit revenue growth and faster earnings growth over the next five years, underpinned by a continuous reinvestment of 7% of revenues into R&D to develop an integrated digital health ecosystem. ResMed has also expanded its manufacturing capabilities, doubling production capacity in major U.S. logistics hubs such as Atlanta and Indianapolis to align with domestic supply chain goals. Financially, ResMed demonstrates strong fundamentals, with a market capitalisation of approximately $29.28 Billion to $29.61 Billion. The company's trailing twelve-month revenues reached $5.3 Billion, characterised by solid gross margins of 62.2% and non-GAAP operating profit margins exceeding 33%. Two-thirds of ResMed’s revenue is generated in the Americas, with the remaining third distributed across Europe, Japan, Australia and other global regions. The company operates with a strong cash flow of $1.8 Billion generated over the trailing twelve months, which supports a balanced capital allocation strategy prioritising research, strategic acquisitions, share buybacks and dividend payments. Despite these strong operational metrics, ResMed’s stock (NYSE: RMD) has recently faced valuation pressures. Trading at approximately $204.15, the shares remain below their 200-day moving average of $251.82 and are down about 30.52% from their 52-week high of $293.81. This compression has driven ResMed's P/E ratio to 19.69, which is very close to its 10-year historical low of 19.47, indicating a favourable valuation for long-term investors. Market analysts also monitor insider activity, which showed approximately $4.9 Million in shares sold by company executives over the preceding three months. Furthermore, ResMed's executive leadership, including Chairman and CEO Mick Farrell and CFO Aaron Bloomer, are scheduled to present at the 46th Annual William Blair Growth Stock Conference on June 2nd, 2026, where they are expected to address market trends, supply chain developments, and long-term growth targets. Market Indicator Current Recorded Value Historical Context / Boundaries Long-Term Strategic Context RMD Share Price $204.15 52-Week Range: $198.61 to $293.80 Trades below the 200-day moving average of $251.82 Trailing P/E Ratio $19.69 10-Year Historical Low: $19.47 Suggests substantial historical undervaluation GF Score™ $95/100 Maximum score potential of $100 Indicates strong profitability (10/10) and growth (10/10) Insider Action $4.9 Million (net sales) Prior 3-month rolling window Warrants investor monitoring regarding executive sentiment Market Value of Oura $11 Billion Standing as the most valuable private wearable firm Underpins strong consumer appeal and brand leverage Strategic Outlook and Regulatory Challenges The partnership between ResMed and Oura reflects a broader transition in sleep medicine from basic tracking toward comprehensive, diagnostic-adjacent monitoring. This transition is driving innovation across multiple device classes, including smart oral appliances developed by firms such as ProSomnus, Dianyx Innovations, and Slow Wave Sleep. These oral appliances, such as the Slow Wave DS8 (marketed as BROSA), have received dual FDA clearance for mild-to-moderate OSA and sleep bruxism, allowing dentists to fit patients with custom 3D-printed devices while patients track physiological responses via consumer devices like the Apple Watch or Oura Ring. The accumulation of continuous biometric data is also shifting clinical focus from raw frequency metrics, such as the Apnea-Hypopnea Index (AHI), toward more predictive risk markers like hypoxic burden and pulse rate variability. The integration of AI-driven diagnostic platforms, such as EnsoSleep PPG, which utilises machine learning to analyse photoplethysmogram signals captured by pulse oximeters, is expected to accelerate home-based diagnosis. Additionally, independent platforms like SleepHQ have emerged, allowing users to integrate sleep data from Apple Health, Oura Ring, and Withings Sleep Tracking Mats with detailed therapy data from cloud-connected CPAP machines. This trend toward open data sharing empowers patients to take a more active role in managing their long-term health, bridging the traditional gap between consumer wellness and clinical care. Regulatory dynamics present another complex layer of consideration. Chief Medical Officer of Oura, Dr. Ricky Bloomfield, has advocated for the development of new, streamlined regulatory pathways for wearable health features.While the FDA has established clearance protocols for specific notification algorithms, such as those utilised by the Apple Watch or Samsung Galaxy Watch, the process remains highly complex for multi-biometric wearables tracking general sleep health. Overcoming these regulatory hurdles will be crucial as companies seek to expand their devices' capabilities from simple risk identification to proactive medical screening, ultimately transforming how the global healthcare system manages chronic sleep and breathing disorders. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

The Operator Led Evolution in European Healthcare M&A: The Rise of Founder Bankers in HealthTech, MedTech, FemTech and Healthcare AI Executive Summary European healthcare M&A is undergoing a structural transformation that extends well beyond deal volumes and capital flows. The defining shift of the 2025–2026 cycle is not macroeconomic, it is epistemological: the question of who is best qualified to advise on the sale, acquisition and strategic positioning of healthcare technology assets has been fundamentally reopened. For three decades, the architecture of healthcare M&A advisory was dominated by generalist bulge-bracket institutions, Goldman Sachs, J.P. Morgan, Morgan Stanley, Rothschild, whose authority derived from balance-sheet capability, broad institutional relationships and league-table prestige. In 2026, that architecture remains intact for large-cap, cross-border mega-deals exceeding €500 Million. But for the far larger universe of founder-led, venture-backed and growth-stage HealthTech, MedTech, FemTech and Healthcare AI companies, the middle market that generates the majority of European deal volume, a new class of advisor has emerged and, in many sub-sectors, taken primacy. They are called Founder Bankers: former entrepreneurs and clinicians who built, scaled and exited their own healthcare technology ventures before transitioning into the advisory role. The model fuses deep operational pedigree with sophisticated investment banking methodology, offering what traditional finance cannot easily replicate, fluency in the lived experience of company-building, clinical pathway navigation and the psychological complexity of founder exit events.​​ This report analyses the structural drivers of this advisory evolution, the anatomy of the Founder Banker archetype, the market dynamics reinforcing its ascendancy across HealthTech, MedTech, FemTech and Healthcare AI, and the strategic outlook for founders, investors and acquirers navigating this new landscape. Part I: The Great Rationalisation — Macroeconomic Context for Advisory Evolution From Speculative Exuberance to Industrial Maturity The European HealthTech and MedTech market entered 2026 in a phase termed the "Great Rationalisation", a structural recalibration away from the venture-subsidised experimentation of 2019–2022 toward a disciplined, metrics-driven era of industrial maturity. The decade of cheap capital that enabled a proliferation of fragmented "point solutions", single-feature apps, unvalidated clinical tools and consumer wellness platforms with limited integration into healthcare pathways, is over. The post-pandemic valuation corrections of 2023 acted as a clearing event. Investors who had tolerated "growth at all costs" narratives were confronted with portfolio companies that had burned through capital without achieving clinical validation, reimbursement traction or sustainable unit economics. The result was a decisive shift in the criteria by which healthcare technology assets are valued: away from raw revenue growth toward clinical utility, regulatory resilience, EBITDA generation and integration into existing care pathways. This transition did not reduce market activity, it redirected it. Global healthcare M&A deal value rose 38% to $546.7 Billion in 2025, one of the strongest years since the post-pandemic peak, even as overall deal volumes declined modestly. European healthcare PE deal value reached approximately $80.9 Billion in 2025, up from $59.9 Billion in 2024. The character of this activity changed: fewer transactions completed at higher average values, reflecting a concentration of capital in fewer but larger, high-conviction assets. The Bifurcation Dynamic The most striking feature of the current M&A environment is a bifurcation between volume and value and between asset categories. On one side: premium AI-native platforms, value-based care companies, MDR/IVDR-certified MedTech devices and clinical-grade data systems commanding revenue multiples of 6x–8x and EBITDA multiples of 15x–18x. On the other: undifferentiated SaaS tools, unprofitable point solutions, and consumer wellness apps trading at 2x–4x revenue or entering distressed M&A processes. This bifurcation is the economic logic behind the Founder Banker's ascendancy. When every healthcare technology asset looked like a growth story in 2021, financial engineering was sufficient advisory value. In 2026, when an acquirer must distinguish between a genuinely validated clinical AI platform and a statistically impressive but operationally fragile tool, the intellectual currency is domain fluency and that currency is disproportionately held by advisors who have lived the journey themselves.​​ Private Equity as Volume Engine While strategic M&A attracts the headline transactions, Private Equity (PE) remains the dominant volume driver in European healthcare. European sponsor buyout deal value surged 276% year-to-date in 2025 compared to 2024, reflecting both accumulated dry powder (approximately $2.5 Trillion globally) and increasing pressure to deploy capital from the 2019–2021 vintage. PE portfolios contain a significant backlog of long-held assets requiring exit, making 2026 a year disproportionately shaped by exits rather than new platform formation. The PE consolidation playbook has evolved beyond simple platform buyouts. Add-on acquisitions, secondary buyouts, and continuation funds are the dominant structural mechanisms, as sponsors build pan-European champions across dental, fertility, ophthalmology and veterinary services before eventual strategic exits. Specialist advisors who understand both the operational reality of these roll-up strategies and the buyer psychology of PE exits are in disproportionate demand. Part II: The Anatomy of the Founder Banker, A New Professional Archetype The Founder Banker is defined by a career trajectory that generalist investment banking cannot produce through its traditional analyst-to-managing-director pipeline. These advisors have personally experienced the full lifecycle of company-building: ideation, fundraising, product development, clinical validation, regulatory navigation, commercial scaling and, ultimately, an exit transaction. They carry what is described as "operational empathy", an ability to understand, and critically to credibly communicate, the anxieties, trade-offs and ambitions of a founder navigating their first major liquidity event.​ The comparative profile versus the traditional investment banker is materially different: Feature Traditional Investment Banker Founder Banker Career Path Linear: Analyst → Associate → VP → MD Non-linear: Founder → Exit → Strategic Advisor Core Value Proposition Financial engineering; institutional market access Operational empathy; technical fluency; founder credibility Advisory Philosophy Transactional; prestige-driven; process-oriented Relationship-driven; "Founders for Founders" Diligence Focus Top-line growth; market share; financial ratios Clinical utility; regulatory resilience; unit economics Technical Depth Broad but generalist across sectors Deep vertical specialisation (AI, MDR, NHS procurement) Exit Psychology Process management; information memorandum Empathy with founder motivations; managing valuation resets ​​ The Nelson Advisors Case Study The most visible embodiment of the Founder Banker model in European HealthTech is Nelson Advisors, a London-based boutique founded by Lloyd Price and Paul Hemings, both of whom are former healthcare technology entrepreneurs with successful exits. Lloyd Price brings over 25 years in consumer internet and HealthTech, most notably founding Zesty, a patient engagement platform that navigated complex NHS procurement frameworks before being acquired by Induction Healthcare Group PLC (FTSE:INHC) in 2020. His experience of integrating with hospital legacy systems, navigating clinical pathways, and managing the expectations of a public-company acquirer provides direct operational credibility in advising clients facing analogous exits. Price is also a Health Executive in Residence at UCL's Global Business School for Health and regularly guest lectures at Oxford, Cambridge and IESE Business School Barcelona. Paul Hemings combines senior investment banking experience at Credit Suisse (over $50 Billion in M&A) and Invesco with entrepreneurial experience as co-founder of Neutrally, a metabolic health venture, providing direct founder credibility alongside institutional financial engineering capability. His dual profile, having been both the banker structuring complex cross-border transactions and the founder making the sale decision, is a rare combination that Nelson Advisors explicitly markets as the defining differentiator of their "Founders advising Founders" model. Nelson Advisors team also includes analysts and directors with backgrounds from Rothschild, Citi, Morgan Stanley, ETH Zurich, Johnson & Johnson and Bristol Myers Squibb, reflecting a deliberate strategy of combining traditional investment banking rigour with healthcare operational depth.​ The Broader Ecosystem of Specialist Boutiques Nelson Advisors is the most explicitly "Founder Banker" firm in European HealthTech, but it operates within a broader ecosystem of specialist boutiques that collectively challenge generalist hegemony in the mid-market: Arma Partners — independent advisor to the digital economy with a sophisticated Digital Health and Healthcare AI practice, widely cited for its depth in Health IT and SaaS-in-healthcare​ Clipperton — Paris-headquartered European tech specialist bank with a fast-growing Digital Health and SaaS-in-healthcare franchise, frequently advising venture-backed health platforms on growth capital and strategic exits (e.g. Hublo, DentalMonitoring) ConAlliance — healthcare-only M&A advisor with a strong European MedTech footprint, increasingly active across digital and technology-enabled healthcare assets​ TH Healthcare & Life Sciences — partner-led healthcare M&A advisor working across Europe with private equity and VC-backed digital health and health services technology​ WG Partners — London-based life sciences boutique with over £8.4 billion in completed transactions and an international practice spanning UK, Europe, USA, Asia and Australia Van Lanschot Kempen (formerly Kempen & Co) — premier pan-European specialist investment bank in life sciences and healthcare, with particular strength in biotech and diagnostics​ These firms have collectively taken the primary advisory role for founder-led exits in the €10M–€500M transaction range, the segment that constitutes the majority of European HealthTech deal volume. Part III: Market Dynamics Driving the Founder Banker's Ascendancy, Regulatory Darwinism as Deal Catalyst Perhaps the most powerful structural force driving Founder Banker demand in 2026 is what analysts are calling "Regulatory Darwinism", the use of EU regulatory architecture as a competitive weapon that forces consolidation. The convergence of three regulatory frameworks is creating an unprecedented compliance burden: Regulation Milestone M&A Implication EU AI Act Full enforcement, early 2026 Mandatory "glass box" interpretability; audit-ready AI systems required EU MDR / IVDR Class III deadline, May 2026 MDR certificates become primary financial assets and key valuation levers EUDAMED Mandatory registration, May 2026 Registration prerequisite for exit; competitive intelligence platform The costs of Notified Body certification under MDR/IVDR and the compliance requirements of the EU AI Act are untenable for undercapitalised standalone SMEs, driving them into the arms of larger strategic acquirers who possess the necessary regulatory infrastructure. Acquirers are explicitly purchasing smaller firms to bypass multi-year regulatory bottlenecks and secure immediate market access, a pattern described as "compliance-driven M&A". Advisors who understand the regulatory valuation mechanics, how to price a CE mark, an AI Act audit trail, or an IVDR certificate, command a significant premium over generalists who view compliance as a checkbox rather than a financial asset. The EU AI Act imposes specific obligations on high-risk medical AI systems that materially affect advisory practice: mandatory "glass box" interpretability under Articles 13 and 14 means that investors are rigorously avoiding "black box" AI models in 2026, favouring transparent architectures that satisfy both regulatory requirements and acquirer diligence standards. Founder Bankers, who have typically navigated these frameworks with their own products, are uniquely positioned to translate regulatory exposure into commercial opportunity or risk during transaction processes. The AI Premium in Valuation Healthcare AI has become the single most powerful driver of valuation premiums across European HealthTech. Companies with proprietary algorithms, rigorous clinical validation and deep workflow integration are commanding EV/Revenue multiples of 6x–8x, versus 4x–6x for general HealthTech SaaS. Capital is concentrating around AI-powered diagnostics, ambient clinical intelligence, and research acceleration tools, which jointly captured the majority of AI funding in H1 2025. This "AI premium" is no longer theoretical, it is directly visible in transaction rationales, where strategic acquirers and PE sponsors explicitly target AI-native platforms to modernise legacy portfolios. However, the spread between premium and average assets has widened dramatically, and distinguishing genuine clinical AI from AI-washed marketing requires precisely the technical fluency that Founder Bankers bring. The "Rule of 40", where the sum of a company's revenue growth rate and EBITDA margin must exceed 40%, has become the new benchmark for premium multiples, replacing the growth-at-all-costs metrics of earlier cycles. In Q4 2025, each 10-point improvement in a company's Rule of 40 score was associated with approximately a 1.1x increase in EV/Revenue multiple.​ The Series B+ Capital Gap and Transatlantic Flows A defining feature of the 2025–2026 period is the intensity of transatlantic capital flows into European HealthTech. US corporate and growth funds participated in 62% of late-stage European deals in 2025, a triple increase from 2023 levels. This activity is helping bridge the historical "Series B+ Gap" that has constrained European founders' ability to raise large late-stage rounds domestically.​ Notable transactions illustrate the trend: the $900 Million Series E for Finnish health-tech company Ōura and the $600 Million strategic round for UK-based Isomorphic Labs demonstrate that US capital is actively targeting European innovators who have already navigated the stringent EU regulatory environment, viewing them as "de-risked" assets ready for global deployment. Europe's digital health funding jumped 82% year-on-year to $2.0 Billion in Q1 2025, its second-highest quarterly total on record. For advisors, transatlantic cross-border work requires a dual fluency: understanding how US acquirers (from Alphabet to UnitedHealth to Philips) evaluate European assets, what regulatory questions they ask, how NHS or European public payer relationships translate into US strategic value, and how valuation gaps between US and European markets can be bridged. Founder Bankers who have managed cross-border scaling journeys are naturally positioned to navigate this translation. Part IV: Sub-Sector Dynamics, HealthTech and Digital Health European digital health funding increased by 52% year-on-year in H1 2025, reaching $3.4 Billion across 182 deals. The overall HealthTech M&A deal volume in H1 2025 reached 277 deals, projecting a full-year total well above the 467 deals recorded in 2024, with disclosed deal value reaching $10.3 Billion in H1 2025 and on pace to surpass the 2024 total of $19.2 Billion.​ The most valued sub-segments are AI-driven clinical decision support, EHR integration platforms and value-based care infrastructure. The shift away from B2C consumer health toward B2B enterprise and NHS/EU health system deployments has been decisive, acquirers reward assets with demonstrable ROI for payers, not consumer engagement metrics. Vendor sprawl fatigue among hospital CIOs is driving demand for integrated platforms over point solutions, creating a market structure that rewards consolidation advisors. MedTech Global MedTech deal value surged to $97.6 billion in 2025 — the highest level in over a decade, driven by three mega-deals, though overall deal count remained below historical norms at 46 announced deals through November. The European MedTech landscape is defined by surgical robotics maturation, AI-driven medical imaging, and the compliance-driven consolidation wave triggered by MDR/IVDR. Surgical robotics has transitioned from experimental to challenger platforms seeking global expansion. Companies including CMR Surgical (Versius, $1Bn+ total funding), Noah Medical (Galaxy Lung System, $400M) and Distalmotion (Dexter Hybrid, $300M) represent European innovators in active pursuit of strategic partnerships and acquisition processes. Medical imaging and diagnostics saw venture investment reach $19.1 Billion in 2024, with acquirers focusing on AI tools that automate patient episode management from intake through treatment.​ The advisory challenge in MedTech is distinct from Software: technical diligence on hardware, clinical evidence packages, Notified Body relationships and post-market surveillance data require advisors who can speak the language of regulatory bodies, clinicians and financial buyers simultaneously, a rare combination that favours specialists over generalists. FemTech By early 2026, FemTech had evolved from a niche sub-sector into a major pillar of global healthcare acquisition strategy. The European FemTech market reached €2.4 Billion in 2024 and is projected to nearly quadruple to €9.7 Billion by 2033, growing at approximately 16% CAGR. The sector has attracted over £480 Million in investment funding in the UK alone, growing at 30%. The McKinsey 2024 report estimated that improving women's health outcomes could add £1 Trillion to the global economy by 2040, a macro-economic argument that has catalysed strategic acquirer interest from pharmaceutical groups, health systems and consumer health conglomerates. The 2025 BCG X survey highlighted that only 41% of women believed sufficient health services existed for their concerns, a TAM signal that strategic buyers find compelling. M&A dynamics in FemTech mirror the broader sector shift: fertility platforms (IVI, FutureLife) have established consolidation playbooks through PE-backed roll-ups of regional clinic networks. FutureLife's 2024 acquisition of Bristol-based BCRM expanded its UK regional presence beyond London in a landmark deal. Phoenix PE invested in London Gynaecology in 2024, targeting scaling of private gynaecology care against long NHS waiting times. Flo Health's unicorn valuation in 2024 as the first women's health unicorn established benchmark valuations for digital FemTech platforms.​ The advisory opportunity in FemTech is compounded by the historically low analyst coverage: most generalist investment banks lack dedicated FemTech practices, creating a significant gap that specialist advisors fill. Founder Bankers with direct experience in women's health, consumer health or adjacent clinical areas carry immediate credibility with both founders (who often have personal motivations for building in the space) and acquirers (who need to understand clinical outcome differentiation). Healthcare AI Healthcare AI has emerged as the fastest-growing and most contested sub-sector in European HealthTech M&A. The top-funded sub-sectors in European HealthTech H1 2025 were drug discovery (including TechBio using AI/bioinformatics), medical diagnostics (AI-driven radiology and pathology) and digital health platforms with embedded AI. Three acquisition playbooks are consolidating the Healthcare AI landscape:​ Platform Acquisitions — Corporate buyers acquiring AI-rich assets to embed decision support across care pathways and accelerate digital transformation AI-Native Roll-Ups — PE-backed mergers of traditional healthcare software businesses with AI start-ups, creating scaled platforms with differentiated data and automation Regulatory Arbitrage Consolidation — EU MDR/IVDR, EU AI Act and EHDS raising the compliance bar, pushing sub-scale SMEs into better-capitalised consolidators The advisory challenge in Healthcare AI is the most technically demanding in the sector: distinguishing between genuinely clinical AI (with validated algorithms, real-world evidence, EHR integration and a regulatory pathway) and AI-adjacent marketing requires deep technical diligence that generalist advisors are often poorly equipped to perform. Founder Bankers who have built or operated clinical AI products understand the difference between a demo and a deployed system, and can translate that distinction into valuation arguments that hold up under buyer scrutiny.​ Part V: The Advisory Market Landscape, Specialists vs. Generalists, The League Table Reconfigured The advisory market for European healthcare M&A is best understood as segmented by deal size and asset complexity, rather than simply by advisory prestige: Advisor Primary Strength Deal Size Sweet Spot Key Sub-sectors Goldman Sachs Large-cap exits, IPOs ($97.5bn+ value, 2024) €500M+ Mega-deals, public M&A Rothschild & Co Mid-market ubiquity, PE relationships (132 deals, 2024) €100M–€2bn Broad mid-market healthcare J.P. Morgan Complex cross-border strategic M&A €500M+ Large-cap pharma, MedTech Morgan Stanley Financial sponsor relationships €200M+ PE-backed platforms Arma Partners Digital Health, SaaS, Healthcare IT €20M–€500M Digital health, tech-enabled care Nelson Advisors Founder-led exits, Healthcare AI €25M–€200M HealthTech, MedTech, AI, FemTech Clipperton High-growth Tech/SaaS-in-healthcare €10M–€300M Digital health, SaaS platforms Van Lanschot Kempen Biotech, Diagnostics, Life Sciences €50M–€500M MedTech, biotech, diagnostics The critical insight from this segmentation is that the competitive gap is not between bulge-bracket and boutique in terms of capability, it is between generic and specialised in terms of relevance to the asset. For a founder-led healthcare AI company with €15M ARR seeking a strategic exit, Goldman Sachs is not the natural advisor: they will not have a dedicated partner who understands AI Act compliance implications for valuation, can credibly articulate clinical validation to a NHS procurement-aware buyer, or empathise with the psychological complexity of a founder's first liquidity event. Even generalist mega-firms have acknowledged this dynamic. Goldman Sachs has been cited as hiring medical doctors to lead its EMEA healthcare teams, recognising that bio-technical diligence in Healthcare AI requires clinical depth, not purely financial acuity. This is itself evidence of the structural shift the Founder Banker embodies.​ The Consolidation of Advisory Firms The boutique advisory ecosystem is itself undergoing consolidation. Stifel's acquisition of Bryan Garnier and Houlihan Lokey's European healthcare expansion signal a maturing mid-market where successful specialist advisory firms are becoming acquisition targets for larger institutions seeking domain expertise. This dynamic validates the model: the value being created by specialist boutiques is real enough that larger platforms are acquiring it rather than building it organically.​ Part VI: Due Diligence Evolution, The Founder Banker's Operational Contribution, Beyond the Information Memorandum The Founder Banker's value is most tangible in the diligence and process phases of a transaction. Modern healthcare technology M&A diligence in 2026 extends far beyond financial review into technical architecture audits, regulatory compliance assessments, clinical evidence evaluation and integration planning, each requiring expertise that traditional investment bankers lack.​ Key diligence areas where Founder Bankers provide differential value: Diligence Focus 2026 Requirement Where Founder Bankers Add Value Model Architecture GPAI compliance; AI Act transparency obligations Distinguishing genuinely interpretable AI from marketing claims Data Provenance Audit of training datasets; IP provenance Understanding real-world data collection practices vs. theoretical claims Clinical Validation Real-world evidence; RCT vs. retrospective data Assessing clinical evidence quality and reimbursement implications Regulatory Status MDR certificates; AI Act audit readiness Translating regulatory certificates into valuation premiums Integration Reality EHR/legacy stack compatibility; CIO skepticism Managing acquirer expectations based on first-hand integration experience AI-Augmented Advisory Ironically, Healthcare AI is also reshaping the advisory process itself. AI-driven due diligence tools are enabling faster deal evaluations and superior risk detection through automated document review and machine learning-powered pattern recognition. Automated lease analysis has become 70% faster and error rates in compliance checks have dropped by 40% through AI-powered tools, changing the economics and speed of deal execution. Founder Bankers who embrace these tools can maintain quality while significantly improving deal velocity, a competitive advantage in auction processes where speed of diligence often determines mandate retention.​ Part VII: Strategic Recommendations and Outlook, For Founders Preparing for Exit The advisory selection decision is now strategic, not simply administrative. The choice between a generalist firm and a Founder Banker boutique should be driven by asset complexity, buyer universe, and the specific technical or regulatory narrative that needs to be constructed and defended. Prioritise clinical utility narrative: In 2026, value is determined by integration into clinical pathways and measurable ROI for health systems, advisors must be able to construct and defend this narrative with technical credibility Treat regulatory assets as financial assets: MDR certificates, AI Act compliance documentation and EUDAMED registration are valuation levers, not administrative formalities, advisors who understand this translate compliance investment into premium multiples Align with Rule of 40 benchmarking: The primary financial metric for commanding premium multiple is the Rule of 40, advisors should help prepare companies to present against this benchmark, including clarity on path to profitability Leverage transatlantic buyer intelligence: US acquirers participated in 62% of late-stage European deals in 2025; advisors with direct US relationships and cross-border execution experience are essential for competitive processes​ For Strategic Acquirers and PE Sponsors The Founder Banker model also changes how buyers should structure their advisory relationships. Buy-side M&A in HealthTech increasingly requires advisors who can assess operational reality, not just financial metrics, to avoid overpaying for technically impressive but commercially fragile assets. The three dominant acquisition playbooks for 2026, platform consolidation, AI-native roll-ups, and regulatory arbitrage, each require a different type of advisor expertise that the generalist advisory model struggles to provide at the sub-€500M tier. Market Outlook: 2026–2027 The European HealthTech market is valued at approximately $96.68 Billion in 2025 and projected to reach $222.22 Billion by 2030. Against this backdrop, several trends are likely to define the advisory landscape over the next 18–24 months:​ Continued bifurcation: The gap between premium AI-validated assets and undifferentiated point solutions will widen further, increasing the valuation sensitivity to advisory quality Distressed M&A expansion: The convergence of MDR/IVDR enforcement, EU AI Act obligations and PE exit pressure will accelerate distressed M&A as undercapitalised firms are forced to sell​ FemTech institutionalisation: As FemTech matures from niche to mainstream acquisition target, demand for advisors with specific women's health expertise will intensify Healthcare AI commoditisation risk: As more companies claim AI capabilities, the premium for genuine clinical AI will concentrate in a smaller number of genuinely differentiated assets, creating advisory mandate opportunities for specialists who can credibly separate signal from noise Founder Banker model replication: The success of the pioneer Founder Banker model will attract imitation; the differentiation will increasingly shift to quality of exits, sector depth, and specific sub-sector specialisation (e.g., FemTech vs. surgical robotics vs. clinical AI) rather than the generic "founder background" credential alone Conclusion The emergence of the Founder Banker in European healthcare M&A is not a cyclical phenomenon or a niche trend, it is a structural recalibration of the advisory market to match the irreducible complexity of 2026's healthcare technology assets. When regulatory compliance determines enterprise value, when clinical validation is the primary M&A diligence question, and when the psychological complexity of founder exits requires advisors who have navigated them personally, the traditional linear career path of the investment banker is an insufficient preparation for the advisory role. The Great Rationalisation has made this mismatch visible. The firms and individuals who built their advisory practices on operational pedigree, Nelson Advisors, Arma Partners, Clipperton, ConAlliance, have found themselves structurally advantaged in precisely the market environment that 2026 has produced. The measure of this model's success will be its proof through exits: not the size of deals in the press release, but the quality of outcomes for founders, investors and health systems that trusted them with the most consequential decisions of their professional lives. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

10 Key Lessons in 'the Shift from CoPilots to Agents in Healthcare' The Shift from Copilots to Agents in Healthcare: Ten Key Lessons for Systemic Transformation The healthcare sector is undergoing a profound structural evolution as artificial intelligence (AI) transitions from an assistive, reactive tool into an autonomous execution layer. According to financial assessments, global AI expenditure is projected to rise from $1.76 Trillion in 2025 to $2.52 Trillion in 2026, before reaching $3.34 Trillion in 2027. A significant concentration of venture capital is driving this transformation; AI firms raised approximately $242 Billion in Q1 2026, accounting for around 80% of global venture funding during that quarter. Furthermore, a Silicon Valley Bank analysis revealed that for every venture capital dollar invested in crypto-related companies in 2025, 40 cents was directed to organisations simultaneously building AI products. Within healthcare systems, this macro capital allocation is accelerating a shift from conversational "copilots", which require constant human guidance, to "agents" capable of autonomous, goal-driven workflow execution. The contemporary healthcare AI architecture progresses from a standardised data foundation to a unified control plane, branching into distinct assistive and autonomous execution modules. At CAHOTECH, Keshri Kr. Asthana, Chief Technology Officer of Microsoft India's Public Sector, outlined this conceptual progression, illustrating how health systems must transition from traditional data storage toward proactive systems capable of independent execution. Architectural Attribute Deterministic Bots Reactive Copilots Autonomous AI Agents Operational Logic Predefined rules and decision trees. Machine learning models responding directly to prompts. Goal-directed, multi-step execution loops. State Management Stateless; each execution is processed independently. Short-term context maintained within an active session. Persistent memory modules and database logs. Integration Method Isolated application interfaces, such as web chat. Embedded assistance within existing office applications. System-wide integration via secure APIs and webhooks. Control Model Human-in-the-loop required for every direct interaction. Humans review, approve, and execute each step. Automated validation, exception handling, and guardrails. Clinical Use Case Basic appointment booking and symptom FAQ routing. Ambient clinical note summaries and history compilation. Prior authorisation, clinical triage, and care coordination. Understanding this structural blueprint is essential as organisations navigate the operational and clinical shifts detailed in the following ten lessons. Lesson 1: Transitioning from Reactive Task-Specific Assistance to Proactive Systems of Action The primary evolution of enterprise AI involves moving beyond "Democratisation 1.0", which focused on giving employees access to assistive tools, toward "Democratisation 2.0," which emphasises the architecture of autonomous action. Traditional copilots operate on a reactive basis, waiting for a human operator to provide an input before generating an output. In contrast, autonomous agents establish their own sub-goals, evaluate variable context and execute complex workflows across multiple systems with minimal human intervention. This marks the emergence of the "System of Action" as a critical software layer. Historically, enterprises relied on systems of record to store information and systems of engagement to facilitate interaction; the system of action assumes responsibility for execution, turning software into the default operator. Operational metrics underscore the urgency of this transition. Gartner research highlights that the share of organisations investing in new technology for business and IT transformation jumped from 15% in 2024 to 52% in 2025, with all surveyed organisations planning to deploy agentic AI by 2028. This momentum is reflected in active environments: in single day analyses of advanced conversational platforms, 45.7% of daily interactions were system triggered rather than user-initiated, demonstrating that a substantial share of operations is already handled by persistent agents running in the background. Lesson 2: Shifting the Development Paradigm from Deterministic Programming to Probabilistic Agent Evaluation The transition to agentic systems fundamentally alters how healthcare software is constructed. Traditional clinical systems are built on deterministic programming paradigms, where developers write code, assemble features, and run structured test suites to guarantee highly predictable, rule-bound behaviours. Conversely, agentic AI operates within a probabilistic model. This new paradigm requires a shift from writing static code to configuring bounded systems, designing natural language instructions and establishing real-time evaluation loops. As defined in modern healthcare stack frameworks, an agent is a logical composition of a large language model (LLM), instructions, and specific tools. The operational cycle of the agentic software layer relies on continuous feedback loops across four distinct phases: perception, cognitive processing and planning, action execution and active learning. Consequently, developers must pivot from micro-managing individual execution steps to orchestrating how systems analyse context, make decisions, and interact with external applications. Lesson 3: Overcoming Data Fragmentation and Legacy Silos through Agentic Orchestration A primary barrier to healthcare efficiency is the fragmentation of data across payers, providers, and legacy systems.Clinical records, claims data, eligibility parameters, and social determinants of health routinely exist in isolated databases that fail to communicate. Rather than forcing organisations to undergo costly legacy replacements, autonomous agents function as intelligent translation layers, pulling data from multiple sources into a unified interface and orchestrating workflows in real time. An illustration of this capability is the integration of multi-agent orchestration frameworks like Amazon Bedrock AgentCore with standardized healthcare data repositories. This architecture utilises AWS HealthLake to securely store structured, FHIR-compliant clinical data while using Amazon S3 for unstructured medical documents like radiology reports or handwritten notes. When a provider orders a procedure, an orchestrator agent can automatically detect the request, extract relevant clinical indicators across these distinct storage layers, and compile a complete prior authorisation packet in under ten minutes. This interoperability is further enhanced by open standards such as the Model Context Protocol (MCP). For example, the SAS Viya MCP Server exposes advanced clinical analytical models directly to agents built on various LLM interfaces (such as Claude). This allows agents to execute domain aware clinical tasks and explore real-time data cohorts without duplicating business logic or bypassing established enterprise security policies. Lesson 4: Re-Architecting Security and Risk Frameworks for Privileged Agent Identities As healthcare organisations transition to autonomous systems, traditional static security controls become obsolete. Agents act as privileged digital identities with direct access to database records, application interfaces and other agent systems.This high-velocity interaction requires security to be embedded natively into the AI agent stack itself. To mitigate these risks, organisations are adopting Secure-by-Design AI blueprints, such as the collaborative architecture developed by CrowdStrike and NVIDIA, which delivers continuous runtime enforcement and visibility across high-performance compute environments. Furthermore, operating agents in production requires managing "agent-native" infrastructure challenges. As fleet management platforms like Keycard enter enterprise production, they must handle thundering herd patterns, collapse latency variances and manage secure tool-calling protocols. To address these challenges, developers utilise specialised frameworks like the eight-goal C.O.P.I.L.O.T.S. framework, designed to govern agents once they transition from experimental demos into active operational environments. Lesson 5: Transitioning from Simple Retrieval-Augmented Generation to Advanced Knowledge Engineering Early generative AI implementations relied heavily on Retrieval-Augmented Generation (RAG) to provide context to models. However, as agentic workflows mature, simple retrieval tuning is proving insufficient for complex clinical decision-making. While RAG is equivalent to "bringing books to the exam," advanced Knowledge Engineering "teaches the agent how to study," emphasising memory architecture over simple search matching. To establish durable competitive advantages in the agentic economy, technology companies must build defensive moats based on workflow ownership and execution depth rather than superficial chat features. This defensibility is established through deep integration into critical clinical pathways, generating high switching costs. Furthermore, as these agents execute repetitive administrative and clinical tasks, they generate proprietary execution data that continuously refines their decision models, creating a compounding advantage. This model relies on specialised, highly efficient language models and value-based pricing aligned with clinical outcomes, rather than traditional, seat-based software licensing. 10 Key Lessons in 'the Shift from CoPilots to Agents in Healthcare' Lesson 6: Managing the Transition from Execution Velocity to Compressed Decision Latency The introduction of copilots drastically increases execution speed; however, if the surrounding decision-making model remains unchanged, severe operational friction emerges. In a copilot environment, humans still review, prioritise and approve actions at a manual, fixed cadence, resulting in a system bottleneck defined by "decision latency". Agents resolve this by compressing execution into continuous, automated flows. Operational Metric Manual / Copilot Workflow Agent-Led Workflow Submission Processing Time Several business days of manual collection and form entry. Under 10 minutes via automated multi-agent orchestration. System Validation Gates Scheduled approvals and deferred manual compliance checks. Continuous machine-consumable validation signals. User Interaction Hold Times Average of 11 minutes in patient-facing queues. Reduced to 1 minute, with a 24/7 active response rate. Clinical Terminology Migration Multiple days of manual verification and mapping. Completed in a few hours with a supervisor agent. At CAHOCON 2026, Ms. Soujanya Narala delivered a presentation titled "From Dependency to Enforcement: Designing Systems That Ensure Action," emphasising that successful transition requires moving decisions earlier into the system itself. Instead of deferring validation, organisations must build continuous control planes where compliance, safety, and operational constraints are encoded directly into the software pipelines. Human oversight then shifts from manually executing every step to defining high-level intent, managing complex exceptions, and refining system boundaries. Lesson 7: Mitigating Downstream Error Propagation via Constellation Architectures and Supervisor Loops In previous generative models, isolated errors (such as a flawed document summary) were easily identified and corrected by the human operator. However, because agents operate across multi-step, autonomous workflows, an incorrect decision made early in a cycle can propagate and compound downstream before a human has the opportunity to intervene.Healthcare systems require specialised architectures to isolate and mitigate these failures. One approach involves a supervisor-led agentic architecture. For example, at IMO Health, clinical terminology migration is managed by a Supervisor Agent that coordinates specialised sub-agents, including Term Inspection, Term Suggestion, and Revalidation Agents. The supervisor operates in a persistent cognitive loop: it interprets the clinical request, invokes the appropriate specialised tool, evaluates the output, and decides the next action, reducing a multi-day migration process to a few hours with 73% accuracy. For high-stakes, patient-facing voice interactions, organisations utilise advanced clinical constellation architectures.Hippocratic AI’s Polaris 3.0 and Polaris 5.0 systems deploy 22 specialised LLMs (ranging from 4.2 to 5 trillion parameters in total) that coordinate to manage safety. This constellation includes dedicated clinical models that triple-check lab values, verify drug contraindications with 99.95% accuracy, classify urgent symptoms across seven distinct body systems, and maintain natural multilingual conversations mid-call without context loss. Lesson 8: Earning Clinical Trust through Bounded Autonomy and the "Zero-Loss" Principle In healthcare, high performance alone is insufficient; powerful AI operating without strict clinical guardrails represents a severe operational liability, giving rise to the demand for "Zero-Loss AI Agents". Automated systems do not automatically translate to improved experiences, and poorly implemented interfaces risk eroding provider trust through opaque decision-making logic. At the MVA R&D Network seminar, industry experts emphasised that deploying agentic systems in highly regulated environments requires a workflow-first mindset, clearly defined boundaries, and strict accountability. Sonja Aits of Lund University highlighted the necessity of robust coordination frameworks and human-in-the-loop designs to ensure clinical transparency, while Søren Thorup of Adalyon urged organisations to "kill the proofs-of-concept (PoCs)" and design agentic AI directly for production with built-in auditability and bounded autonomy. Dr. Vandita Gupta's CAHOCON presentation, "What CEOs Want from MedTech: Proof, Performance and Predictability," reinforces that clinical and executive buy-in is earned through transparent, evidence-based performance rather than speculative claims. Lesson 9: Launching in Back-Office Revenue Cycle Management to Establish Safe Sandboxes for Validation To safely manage the risks associated with autonomous systems, healthcare organizations should prioritize deployment within back-office administrative functions. Back-office operations, including accounts receivable follow-up, denials management, underpayment tracking and clinical coding, are heavily governed by standardised, structured rules. This administrative sandbox provides a low-risk environment to test, validate and refine agent behaviours before scaling them into patient-facing clinical workflows. Healthcare Technology Platform Core Functionality Real-World Performance & Scope Ascertain Automates prior authorisations, eligibility checks, and referral workflows. Achieved a 95% faster post-acute submission rate and cut manual click volumes by 80%. AKASA Revenue cycle management automation, including inpatient encounter coding. Deploys Coding Optimiser and CDI Optimiser to identify documentation gaps. Suki Voice-activated clinical assistant and EHR integration platform. Partners with HealthEdge to bring ambient intelligence to health plan care managers. Corti Speech-to-text, medical coding, and prior authorisation documentation. Automatically extracts clinical context to generate evidence-based letters. McKinsey analysis indicates that utilising agentic AI to enable the revenue cycle can cut the cost to collect by 30% to 60%, accelerating cash realisation while freeing administrative staff to manage complex exceptions. In 2025, over 30% of healthcare providers prioritised the deployment of AI across seven specific revenue cycle use cases, illustrating the industry-wide focus on capturing back-office efficiencies. Lesson 10: Managing Organisational Inertia and Navigating the Performance Plateau Transitioning from copilots to agents is not merely a tooling upgrade; it is a fundamental restructuring of how control and labour are distributed across the enterprise. Large-scale case studies of agentic transitions demonstrate that replacing copilots with autonomous agents capable of handling 90% to 95% of operational workflows requires a willingness to "go flat" for a year, tolerating temporary performance plateaus during core system reconstruction, before achieving dramatic operational scaling on the other side of the transition. To navigate this organisational shift, leaders must actively bridge the gap between technical developers and clinical practitioners. Dr. Arun V Joy's CAHOCON presentation, "Stethoscopes to Smartphones - Bridging the Clinician-Tech Gap," highlights that managing workforce adoption is as critical as the underlying software architecture. Successful deployment depends on aligning clinical end-users with the continuous control plane, ensuring that clinical staff trust the autonomous actions executed by background agents. Strategic Recommendations for the Agentic Transition For clinical and technology executives preparing to transition from copilots to autonomous agents, the following structural roadmap is recommended: First, organisations should adopt the four-stage implementation framework: Identify, Align, Evaluate, Deliver. Leadership must identify the highest-volume, most error-prone administrative processes, specifically targeting back-office revenue cycle functions such as denials management or coding validation. The proposed agentic solution must then be aligned with existing clinical governance structures and payer policies. Second, engineering teams must evaluate existing data assets and clean fragmented data sources. This requires setting up robust, secure API integrations through modern middleware standards like the Model Context Protocol to ensure the agents have real-time, governed access to both structured clinical repositories and unstructured document storage. Third, organisations must design a continuous control plane that enforces "Secure-by-Design" principles. This involves implementing Constitutional AI with hard-coded, non-overridable rules for data sovereignty, continuous immutable audit logging and automated human-in-the-loop triggers for high-stakes clinical or financial exceptions. By prioritising bounded autonomy and supervisor-led validation loops, healthcare organisations can safely transition from human-dependent tools to scalable, trustworthy digital co-workers. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Key Metrics for a HealthTech and MedTech company to raise a Series A round in Europe in today's environment Key Metrics and Strategic Determinants for Series A Capital Raising in the 2025-2026 Environment The European healthtech and medtech sectors have entered a phase of disciplined maturity, transitioning away from the venture subsidised experimentation of the early 2020s toward an era characterised by industrialisation and regulatory Darwinism. In the current market environment of 2025 and 2026, the criteria for a successful Series A funding round have shifted fundamentally. Investors no longer prioritise raw user acquisition or speculative growth; instead, they demand a rigorous demonstration of clinical utility, regulatory fortitude and a clear line of sight to measurable return on investment (ROI) within strained healthcare systems. This structural transformation is driven by elevated costs of capital and the simultaneous enforcement of complex legislative frameworks, including the EU Medical Device Regulation (MDR), the In Vitro Diagnostic Regulation (IVDR), and the EU AI Act. For a startup to secure Series A capital today, it must navigate a landscape where capital is highly polarised, concentrating in a narrow cohort of "de-risked" assets that can prove their integration into clinical pathways and their ability to alleviate systemic burdens. The Macroeconomic Landscape and Venture Capital Dynamics The European healthtech market, valued at approximately $96.68 Billion in 2025, is projected to reach over $222 Billion by 2030, representing a compound annual growth rate (CAGR) of 18.11%. Despite this robust outlook, the venture capital environment is marked by a "cautious yet discernible rebound". While global digital health funding rose to $28.8 Billion in 2025, a 9% increase year over year, the number of deals fell to a five-year low. This divergence signifies a move toward "bigger cheques and fewer bets," where capital flows to companies with clear clinical, technological, or commercial validation. Europe has emerged as the fastest-growing region globally for digital health, with funding surging by 52% in the first half of 2025 compared to the same period in 2024. This resilience is supported by a surge in U.S. investor participation, which accounted for 62% of participants in late-stage European deals by 2025, a threefold increase from 2023. For a Series A founder, this globalised investor base provides access to deeper capital pools but also imposes more stringent US style due diligence requirements focused on commercial scalability and reimbursement visibility. European Healthcare Funding and Transaction Benchmarks (2024-2026) Metric 2024 Actual 2025 Estimated 2026 Projected Global Healthcare M&A Volume $417.8 Bn $450 Bn $3.9 Trn(Global all sectors) European Healthcare PE Value $59.9 Bn $80.9 Bn $95 Bn MedTech Deal Count (Europe) 41 42 50+ Average MedTech Deal Size $1.6 Bn $795.1M (Adj.) $900M Median Series A Valuation $37.4M $31.0M TBD Series B Capital Trend 84% vs 2021 Persistent bottleneck Tentative recovery Average Series A Round Size $10.2M $12.9M $15M The "Series B bottleneck" remains a critical factor for Series A founders to consider. With the time between Seed and Series A rounds extending to an average of 774 days, startups must manage their cash mechanics with extreme precision. Investors now scrutinize the "bridge round frequency," which sits at approximately 37% of deals, as a signal of a company's inability to reach meaningful inflection points on its original runway. Consequently, a Series A pitch must clearly articulate how the fresh capital will carry the company not just to its next round, but through to a "Series A Off-Ramp", an exit to private equity or a strategic acquirer if the venture path narrows. Financial Benchmarks and Valuation Multiples Valuations in 2026 are heavily dependent on sub-sector alignment and profitability profiles. The market has moved beyond the "growth at all costs" paradigm of the zero interest rate policy era, where valuations were often detached from unit economics. In the current environment, revenue multiples are compressed for companies with high burn rates, while those demonstrating the "Rule of 40", where the sum of the growth rate and free cash flow margin equals or exceeds 40%, command significant premiums Sub-Sector Valuation Multiples (January 2026 Outlook) Sub-sector EV / Revenue Multiple EV / EBITDA Multiple Strategic Rationale Premium AI & Data Platforms 6.0 - 8.0 15 - 18 Proprietary algorithms; Rule of 40 performance. Value-Based Care (VBC) 5.5 - 7.0 12 - 1 Demonstrable ROI for payers; population health impact. AI-First Drug Discovery 8.0 - 15.0 N/A High-risk, high-reward; biopharma capability multiplier. General HealthTech SaaS 4.0 - 6.0 10 - 13 Stable retention; predictable unit economics. MedTech Hardware (MDR-ready) 3.5 - 5.5 11 - 14 Regulated moats; high barriers to entry. Consumer Health & Wellness 2.0 - 4.0 8 - 11 Sensitive to discretionary spending; higher churn. Unprofitable / Early Stage 3.0 - 4.0 N/A Candidates for distressed M&A or consolidation. A defining metric for AI-native healthcare companies in 2026 is the Annual Recurring Revenue (ARR) per Full-Time Employee (FTE). Traditional healthcare services typically generate between $100,000 and $200,000 in ARR per FTE, while healthcare SaaS platforms pre-AI reached $200,000 to $400,000. In contrast, AI native platforms are now achieving ARR per FTE metrics between $500,000 and over $1Million, driven by the automation of administrative workflows and clinical documentation. This productivity leap allows these companies to achieve software-like margins even as they scale services, a factor that investors view as a "gold standard" for Series A investment. Regulatory Fortitude as a Series A Prerequisite The implementation of the EU Medical Device Regulation (MDR) and the In Vitro Diagnostic Regulation (IVDR) has fundamentally altered the competitive landscape, creating what industry analysts call "Regulatory Darwinism". These regulations have established a capital intensive barrier to entry that is often untenable for standalone small and medium sized enterprises (SMEs) lacking significant balance sheet depth. Consequently, the venture capital thesis has shifted from funding regulatory risk to backing companies that have already built "regulatory moats". For a Series A startup, regulatory planning must be integrated into the technical roadmap from day one. Investors now expect to see a clear EMA or FDA pathway, early risk classifications, and documented compliance with software safety standards such as IEC 62304. The regulatory phase in 2026 has shifted from rule making to enforcement, and companies that cannot provide a definitive timeline for Notified Body certification or conformity assessments see their strategic options narrow rapidly. Key Regulatory Milestones and Timelines (2025-2026) Regulation / System Key Milestone Date Implication for Startups EUDAMED Mandatory application (Modules 1, 2, 3, 5) May 28, 2026 Required for all economic operators; mandatory SRN. EU AI Act Full enforcement for "High-Risk" systems August 2, 2026 Stringent data governance and human oversight required. EHDS Full secondary use provisions roll-out Gradual to 2029 Unlocks patient data for R&D and AI training. Biotech Act Framework aimed at biomanufacturing Expected Q4 2026 Streamlined clinical trial procedures. IVDR Mandatory compliance for legacy IVDs May 27, 2026 High risk of supply interruption for non-compliant firms. The EU AI Act, in particular, has introduced a "binary filter" for healthtech investment. Medical AI tools categorized as high-risk must meet rigorous requirements for data governance, human oversight, and transparency. This has rendered "Black Box" AI models effectively un-investable in the clinical context. Investors are instead redirecting capital toward "Glass Box" or explainable AI architectures and companies that have built their technology stacks with privacy by design principles. Clinical Evidence and the EHDS Era In 2026, evidence has stopped being a differentiator and has become the "price of admission". Investors prioritise "more mature companies" that can provide clinical proof points, reimbursement visibility and a clear role within therapeutic strategies. The European Health Data Space (EHDS) is the single most significant structural driver for healthtech investment in this period. By mandating that data holders, such as hospitals and clinics, make electronic health data available for secondary use, the EU has effectively created a new asset class: curated clinical data. Startups that provide the "picks and shovels" for this data economy, such as interoperability layers, data cleaning tools, and de-identification platforms are commanding premium valuations. Clinical validation now requires moving beyond isolated pilots to demonstrating impact in real-world care settings. Procurement criteria in 2026 increasingly demand outcome measures mapped to local environments rather than controlled demo conditions, as health systems reject "isolated innovations" that fail to change broader economics. Clinical and Technical Due Diligence Focus Areas (2026) Diligence Focus Series A Requirement Strategic Rationale Model Architecture Mandatory transparency; explainability. Satisfy EU AI Act; avoid "Black Box" risk. Data Provenance Audit of training datasets; IP provenance. Mitigate legal risk; ensure data quality. Interoperability Fast FHIR endpoints; clean DICOM support. Reduce friction for hospital CIOs; enable scaling. Clinical Strategy Defensible claims; path to HTA. Secure reimbursement; satisfy investor scrutiny. Cybersecurity SBOM-ready releases; threat modeling. Meet NIS2/MDR expectations; build trust. The transition from "speculative science to practical infrastructure" is evident in the funding clusters of 2025. Health Management Solutions, which focuses on workflow and reimbursement ready tools, overtook research focused TechBio as the top funded cluster, attracting$5.45 Billion. For a Series A company, this means that the "clinical story" must be paired with a "workflow story" that proves the solution reduces total hospital days or optimises resource use. Market Access and Reimbursement Pathways Reimbursement is the ultimate validator for a European healthtech startup. Without a clear path to being paid by national or regional health insurers, a company is viewed as a high-risk gamble. Germany and France continue to lead the way with structured pathways, but both have introduced new requirements in 2026 that founders must address. The Evolution of the German DiGA Pathway Germany's DiGA (Digitale Gesundheitsanwendungen) scheme remains the global benchmark for digital health integration, but it has shifted toward a "performance based" model. As of January 1st, 2026, at least 20% of the remuneration for each DiGA must be based on its actual performance. This requires manufacturers to conduct "accompanying success measurements" focusing on patient-reported health status, satisfaction and usage frequency. The scope of DiGA is also widening in 2026 to include Class IIb digital medical devices, providing a significant opportunity for companies developing higher risk therapeutic interventions. However, the requirement for local German data remains "non-negotiable" and foreign data is only accepted if comparability to the German context is rigorously proven. French Market Access: Liste en Sus and ASA Ratings In France, the Liste en Sus mechanism provides a critical "add-on" reimbursement for innovative medical devices in the inpatient setting, allowing them to be paid for separately from the standard hospital tariff. To be included, a device must demonstrate "actual benefit" (Service Attendu, SA) and, ideally, an "improvement of expected service" (ASA) rating of I, II, or III. Statistics from 2025 indicate that only 25% to 30% of products successfully achieve these higher ASA ratings, highlighting the intensity of the clinical dossier requirements. Pricing negotiations with the healthcare products pricing committee (CEPS) are increasingly focused on Total Cost of Care (TCOC) modelling, where a higher device price must be offset by a reduction in long-term complications or hospital readmissions. Reimbursement Benchmarks and Success Factors Country Pathway 2026 Requirement Update Success Driver Germany DiGA 20% performanc -based pricing. Local real-world evidence (RWE). France Liste en Sus Mandatory resubmission every 3 years. ASA I-III rating for premium pricing. UK NHS Procurement Focus on ICS (Integrated Care Systems). Alignment with elective backlog priorities. Belgium m-health National reimbursement launched 2025. Clinical utility for chronic disease. Netherlands DRG / GHS Yearly package releases. Proof of healthcare professional safety/satisfaction. Intellectual Property as a Strategic Asset In the medtech and healthtech sectors, intellectual property (IP) is often the most valuable asset, directly influencing investor confidence and long-term competitive positioning. In 2024, over 15,700 patent applications were filed with the European Patent Office (EPO) in medical technology, making it the second highest sector for filings after digital communication. The ratio of granted patents to applications in this field stands at a healthy 70.1%, significantly higher than in pharmaceuticals (36%) or biotechnology (22%). The launch of the Unitary Patent (UP) system has provided a transformative tool for European startups. A UP covers 18 EU Member States with a single application, offering substantial cost savings compared to traditional national validations.Medtech companies have enthusiastically embraced the UP, leading filings across all technical fields. This trend reflects a broader strategy of building "IP moats" that provide territorial coverage centrally at the Unitary Patent Court (UPC). Evolving Legal Standards for IP Portfolios Investors in 2026 are applying heightened scrutiny to the quality of patent claims. Following recent legal decisions, acquirers are wary of "functional genus" claims, claims that define an invention by what it does rather than what it is. For AI-enabled devices, patent strategies must emphasise the technical integration of AI, specifically how the algorithm drives a tangible modification in device operation, rather than claiming data processing in isolation. For a Series A round, a startup’s IP strategy should evolve through several stages: Early Stage: Focus on protecting core technology with a comprehensive initial application and initiating international filings. Mid-Stage (Series A/B): Pursue granted patents with diverse claim coverage, including future product iterations and core technology in key international markets. Risk Mitigation: Utilise patent watching services to track competitor IP and consider using the European opposition process to challenge the validity of threatening patents. Key Metrics for a HealthTech and MedTech company to raise a Series A round in Europe in today's environment Team Composition and the "Founder Banker" Era The European healthtech sector has moved into an era where "operational empathy" is a primary value proposition for both founders and advisors. Investors now prioritise teams that include senior commercial leaders with hospital network experience and digital health operators who have navigated payer reimbursement in multiple markets. The "Founder Banker", an advisor who combines deep technical fluency with investment banking expertise, has become a key architect of Series A and B liquidity. The Medical and Strategic Advisory Board (2026) Advisor Profile Key Requirement Strategic Rationale Commercial Scaling Global medtech P&L experience. Guide international go-to-market; manage large accounts. Regulatory Specialist Deep knowledge of MDR and AI Act. Navigate "Regulatory Darwinism"; manage NB audits. Digital Health Founder History of scaling to enterprise contracts. Avoid common pitfalls in payer adoption and retention. PE / M&A Advisor Life sciences transaction experience. Bridge the gap between VC growth and PE exit. Technical / AI Expert Generative biology or AI infrastructure background. Ensure architecture meets explainability and transparency needs. The emergence of "Clinical Co-Pilots" and "Vertical Intelligence" has also shifted expectations for technical leadership. Startups are increasingly expected to have a Chief Medical Officer (CMO) who is not just a scientific figurehead but a key driver of the clinical-technical integration, ensuring that AI tools solve actual operational inefficiencies for clinicians. Exit Pathways and the Series A Off-Ramp A defining thesis for 2026 is the "industrialisation" of the healthtech exit landscape. The traditional "escalator" model, where a Series A lead predictably to an IPO, has broken down for many. In its place, the "Series A Off-Ramp" has emerged, driven by the increasing involvement of private equity (PE) firms moving downstream to capitalise on depressed valuations and market fragmentation. PE-backed "buy-and-build" playbooks are particularly intense in healthcare services and IT. These buyers value companies on EBITDA multiples rather than the revenue multiples typical of venture capital, creating a friction point for founders with unrealistic valuation expectations. However, as runways dwindle, the certainty of a PE exit is becoming a viable strategic alternative to the uncertainty of the venture market. Strategic Acquirers and Transaction Contexts (2024-2025) Target Company Sector Acquirer Deal Context / Driver Shockwave Medical Cardio interventions Johnson & Johnson $13.1 Bn EV; category leadership. V-Wave Structural heart Johnson & Johnson Up to $1.7 Bn (milestone-structured). Exscientia AI Drug Discovery Recursion (US) Strategic merger; platform consolidation. Medifox Dan Care Software ResMed (US) $958M deal; US strategic expanding in Europe. Inveox Pathology / Medtech Undisclosed Insolvency sale; restructuring via proceedings. Consolidation of "point solutions" into comprehensive platforms is a major theme in 2026. Hospital CIOs report "vendor sprawl fatigue," leading to a preference for acquisitions that bundle multiple services into a single clinical layer. For a Series A company, being "acquirable" means demonstrating that the product can seamlessly plug into larger legacy stacks and provide immediate cross-selling opportunities for an incumbent's sales force. Regional Frontiers and Therapeutic Hotspots The European funding landscape remains concentrated in the UK, Germany, and France, but regional shifts are evident.The United Kingdom remains the leader, attracting $2.11 Billion in 2025, while Finland surged into second place ($1.16 Billion) due to the presence of large, established players like Oura Health. Southern Europe (Spain, Italy) is being recognised as a "growth frontier" for private equity, particularly in fragmented markets like dental and veterinary care where roll-up strategies are highly effective. In terms of therapeutic focus, oncology remains the top-funded area in Europe, attracting $515 Million in the first half of 2025, a 66% year over year increase. Cardiovascular diseases and dermatology also show strong momentum, while geriatrics has experienced explosive growth due to the pressures on hospital capacity and the rise of home-based care models. Therapeutic Investment Vectors and Risk Profiles (2026) Investment Vector Risk Profile Primary Investor Type Key Driver AI Infrastructure Low / Medium PE / Growth VC Workforce automation; recession resilience. Surgical Robotics High Deep Tech / Sovereign Funds Shift to ambulatory centers; cost containment. TechBio High Specialized VC / Pharma CVA Biopharma patent cliffs; pipeline velocity. FemTech (Menopause) Medium Growth VC / Corporate CVA Employer demand for benefits; demographic shift. Services Roll-ups Low Private Equity Multiple arbitrage; market fragmentation. FemTech has matured significantly, moving beyond generic wellness apps to precision medicine and specialised diagnostics. A winning commercial strategy in this space for 2026 is selling to employers as a corporate benefit (B2B2C), bypassing the difficult economics of direct-to-consumer (DTC) marketing. Synthesis: Navigating the New Series A Standard The successful European healthtech or medtech Series A in 2026 is defined by "technical defensibility and evidence maturity". To raise capital in this environment, founders must present a narrative that balances innovation with operational reliability. Capital now flows toward "predictable performance," and the market filters out ventures that fail to change clinical outcomes or system economics. A compelling Series A case must explicitly address the following: The Regulatory Moat: A clear, understandable path through MDR/IVDR and the EU AI Act, with high-risk designations used as a barrier to competition rather than an administrative burden. The EHDS Data Strategy: A plan to leverage the European Health Data Space for secondary data use, turning clinical data into a defensible asset for AI training and validation. Reimbursement and ROI: Hard data on health economic outcomes, using models that prove the solution reduces the total burden on the healthcare system. Workflow Integration: Technical architecture built for interoperability, ensuring that the solution creates zero friction for overloaded clinicians and hospital IT departments. The "Rule of 40" Trajectory: Financial projections that demonstrate a clear path to software-like margins, underpinned by high ARR per FTE and a high percentage of recurring revenue. In an environment where capital is concentrated and investors are increasingly selective, the primary asset of a startup is no longer its technology, but its "execution excellence". Those that can translate regulatory and commercial uncertainty into clear, clinically validated milestones will continue to secure the funding necessary to transform the European healthcare landscape. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Key Metrics for a HealthTech and MedTech company to raise a Series C round in Europe in today's environment Strategic Benchmarking for Series C Healthtech and Medtech Financing in the European "Industrial Maturity" Era The European healthcare technology and medical technology landscape has entered a profound inflection point as it moves through 2025 and into 2026. This period is increasingly defined by a transition from the speculative fragmentation and "growth-at-all-costs" mindset of the early 2020s to a disciplined, professionalised era termed industrial maturity. For companies preparing to raise a Series C funding round in this environment, the requirements have shifted from simple user acquisition or technological promise to a rigorous demonstration of unit economics, regulatory resilience, clinical validation and structural integration into healthcare systems. The defining thesis for venture capital and private equity in 2026 is the industrialisation of the sector, where valuations are no longer detached from the realities of reimbursement and clinical outcomes. This shift is necessitated by an elevated cost of capital and a "Great Capital Polarisation" that favours de-risked category leaders over smaller, unprofitable ventures. The Macro-Economic Architecture of European Health Funding The deployment of venture capital into the European healthtech and medtech sectors is currently shaped by a unique "use it or lose it" dynamic. Global private equity and venture capital firms are managing an unprecedented accumulation of unallocated capital, estimated at approximately $2.5 Trillion in dry powder. Much of this capital resides in vintage funds from the 2019–2021 fundraising cycle that are nearing the end of their investment periods, creating an intensified deal environment in late 2025 and throughout 2026. Despite this abundance of capital, investors have become significantly more discerning, moving away from a momentum driven approach toward a focus on differentiation, maturity and clear de-risking data. Investment Trends and Ecosystem Growth The European healthcare sector witnessed a dramatic resurgence in investment value during 2025. Total healthcare investment in Europe reached approximately €75.9 Billion across 870 deals, representing a 2.2-fold increase compared to the previous year. This robust growth is partly supported by the European Commission’s strategy to position the bloc as the world’s most attractive location for life sciences by 2030, a program backed by over €10 Billion in annual EU budget allocations targeting accelerated innovation and improved market access. Metric 2024 Performance 2025/2026 Performance/Outlook Source Total Healthcare Investment (Europe) €33.7 Billion €75.9 Billion Various Global Medtech Funding (H1) $13.6 Billion $15.4 Billion Various Median Medtech Financing Round $16.2 Million $36.0 Million Various European Digital Health Funding (Q1) $2.1 Billion $1.2 Billion (normalized) Various Value of VC-backed European Deep Tech $560 Billion $690 Billion Various Deep Tech Share of total European VC 15-19% 32-36% Various The rise in average round sizes, particularly a 122% increase in average financing rounds globally in 2025, highlights the concentration of capital in advanced-stage companies. In the medtech sector specifically, Series B and later rounds now account for nearly 65% of all activity, signaling that investors are waiting for significant de-risking before committing meaningful capital. This concentration has created a "Series B gap" where the average time to close a Series B round now approaches 30 months, reflecting the rigorous clinical and commercial hurdles that companies must clear to reach the scale required for a Series C. Geographic and Sectoral Shifts Europe currently accounts for approximately 24% of global healthcare volume by deal value. Within this landscape, the United Kingdom has emerged as the leading nation for healthcare investment, recording 145 deals worth €16.2 Billion in 2025. France and Germany maintain strong positions, though investment in these regions has shown signs of concentration in high-growth assets rather than broad-based volume. Finland has surged to a prominent position in Northern Europe, largely driven by mega-rounds such as Oura Health’s $900 Million financing. The sector is currently divided into three main pillars. Medical devices remain the most stable segment, drawing consistent funding for cardiovascular and robotic technologies. In vitro diagnostics (IVDs) are recovering after a post-pandemic slowdown and digital health is the fastest-growing area, rebounding to billions in global funding driven by telemedicine, AI and connected health platforms. Financial Benchmarks for Series C Readiness Raising a Series C round in 2026 requires meeting stringent financial performance standards that bridge the gap between high-growth startups and sustainable, scalable enterprises. Investors are prioritising "Efficient Growth," a concept that balances rapid expansion with disciplined capital management. The median annual growth for private software-based healthtech companies has decelerated to approximately 25%, making outperformance in growth a significant differentiator. The Rule of 40 and Efficiency Metrics The Rule of 40 has transitioned from a SaaS-specific metric to a universal baseline for late-stage healthtech and medtech viability. This metric offers a snapshot of a company’s financial health by combining its growth rate and profit margin. While a combined score of 40% or higher is generally considered healthy, the 2025–2026 healthtech cohort is performing significantly above this benchmark, with an average Rule of 40 score of 65%. For a Series C company, failing to meet the 40% threshold can lead to a 5x difference in valuation multiples compared to peers that exceed it. This reflects the market's low tolerance for "high-burn, high-growth" models that lacks a clear path to profitability. Operational and Unit Economic Benchmarks Investors in 2026 scrutinise unit economics to ensure that customer acquisition strategies are scalable and that the "Trust Gap", the lingering discount on healthtech valuations compared to general cloud software, can be overcome by superior retention and lifetime value. Metric Target Benchmark (Series C) Rationale Source ARR Range $15 Million – $50 Million Maturity milestone for late-stage venture Various LTV:CAC Ratio 4:1 (Target) / 3:1 (Floor) 3:1 is the minimum for scalable economics Various CAC Payback Period 12 – 14 Months Reflects tighter capital efficiency post-ZIRP Various Net Revenue Retention (NRR) >100% (Target 110%+) Proof of product-market fit and expansion Various ARR per Employee (FTE) $200K - $400K (SaaS) AI-native platforms target $500K-$1M Various Gross Margin (Subscription) 77% – 81% High-margin software is required for scale Various Burn Multiple < 1.0 (Target for scale-ups) Measure of capital efficiency in generating ARR Various The shift toward expansion revenue is a critical indicator of maturity. For companies with more than $50 million in ARR, expansion revenue typically represents over 50% of total new ARR, signaling that a company's existing customer base is its most reliable growth engine. This necessitates a mature customer success infrastructure and a product portfolio that supports cross-selling and upselling. The Regulatory Darwinism Framework In 2026, regulation is no longer viewed merely as a compliance obligation but as the primary determinant of asset value and a significant competitive moat. The market is undergoing a phenomenon described as "Regulatory Darwinism," where the ability to navigate complex EU regulations dictates which companies survive the transition to late-stage funding. EU MDR and IVDR Implementation Companies raising a Series C must have moved beyond the initial panic of transitioning from the older Medical Device Directive (MDD) to the more stringent Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR). Compliance Moats: Companies with MDR-ready hardware command revenue multiples of 3.5x to 5.5x, as the high regulatory barriers to entry prevent new competitors from easily entering the market. Notified Body Engagement: The process of (re-)certifying approximately 35,000 IVDs and a comparable volume of medical devices has placed immense strain on Notified Bodies. Series C companies must demonstrate a stable, long-term relationship with their Notified Body to ensure business continuity. EUDAMED Transition: Compliance with mandatory modules of the EUDAMED database is now required, shifting clinical and technical documentation toward a digitized, transparent system for European regulators. The EU AI Act and High-Risk Categorisation The EU AI Act reached full enforcement for "High-Risk" systems in March 2026, creating a binary filter for healthtech investment. Most medical AI tools fall into this high-risk category, necessitating: Data Governance and Transparency: Companies must meet stringent requirements regarding data sets, data lineage, and the technical documentation of algorithmic decision-making. Human Oversight: The design of AI systems must allow for meaningful human intervention and clear interpretation of outputs by clinical professionals. Technical Integration: To maximise valuation, AI-enabled devices should emphasise the technical integration of algorithms, specifically how they drive tangible modifications in device operation or clinical outcomes, rather than merely processing data in isolation. Market Access and Reimbursement Evolution The path to a Series C in Europe requires more than just regulatory approval; it requires a validated path to commercial reimbursement. The focus has shifted from "pilots" to "system impact," as health systems across Europe seek to integrate proven, cost-effective technologies. Germany's DiGA Framework Reform Germany remains the benchmark for digital health reimbursement through its DiGA (Digital Health Applications) pathway. However, the framework became significantly more demanding as of January 2026. Performance-Based Remuneration: At least 20% of a DiGA’s remuneration must now be linked to the actual performance and healthcare outcomes of the application. Success Measurement: Manufacturers are required to collect and provide quarterly data on usage duration, frequency, patient satisfaction and patient-reported health status. Clinical Evidence (pVE): The burden of proof for a "positive healthcare effect" remains high, requiring quantitative comparative studies, ideally prospective randomised controlled trials (RCTs), conducted within the German care context. The UK's NHS Scaling Problem and DTAC Standards The UK’s National Health Service (NHS) offers a massive potential market but is historically perceived as difficult to navigate. To address this, the NHS has standardised its assessment through the Digital Technology Assessment Criteria (DTAC). DTAC Version 2: Launched in February 2026, the updated criteria consolidate core standards across clinical safety, data protection, technical security, interoperability and usability. Clinical Safety (DCB 0129): Compliance with DCB 0129 is mandatory and requires the development of a Hazard Log, a Clinical Risk Management Plan, and oversight by a named Clinical Safety Officer. MedTech Funding Mandate (MTFM): This policy mandates local funding for NICE-approved technologies that are cost-saving within three years and have a national budget impact below £20 million. Successful scaling in the NHS often depends on achieving this mandate, as it bypasses local commissioning complexities. Technological Drivers of Valuation Premium The investment thesis for 2026 has moved beyond the "Chatbot" hype of previous years. Investors are no longer funding generalist models but are instead looking for "Vertical Intelligence" and clinical co-pilots that solve specific, high-value problems. AI-Native Infrastructure and "The Plumbing" While patient-facing apps dominated previous cycles, the "smart capital" in 2026 is flowing into the backend infrastructure of healthcare, described as the "plumbing" that enables data interoperability. Curated Clinical Data: By mandating that hospitals and clinics make health data available for secondary use, the EU has effectively created a new asset class: Curated Clinical Data. Efficiency as Clinical Priority: With a shortage of 1.2 Million healthcare workers across Europe, solutions that automate documentation or reduce nurse staffing ratios command the highest valuation premiums. Precision Medicine and Femtech 2.0 The menopause opportunity has emerged as a major thematic pillar. By 2030, over 1 Billion women globally will be perimenopausal or menopausal, a demographic at the peak of their earning power that has been historically underserved. B2B2C Business Models: The winning strategy for 2026 is selling women's health support as a corporate benefit. This approach, used by leaders like Peppy and Maven, bypasses the difficult unit economics of direct-to-consumer marketing and aligns with corporate retention goals. Diagnostic Innovation: Startups are moving Femtech into rigorous diagnostics, utilizing novel form factors (e.g., tampons for microbiome screening) to provide clinical-grade data. Robotics and Minimally Invasive Surgery Robotics and cardiovascular devices continue to outpace the broader market in terms of both funding and valuation. High-growth procedural segments like neuro-stimulation, pulse field ablation and structural heart solutions are attracting significant interest from both private equity and large-cap strategics. The valuation impact is tied to the technology's ability to shift procedures to ambulatory surgery centres or improve surgical precision, thereby reducing overall system costs. Strategic Intellectual Property and Portfolio Management For Series C healthtech and medtech companies, maximising valuation in 2026 requires a shift toward a sophisticated intellectual property (IP) strategy that protects both the technology and the regulatory "moat". The Amgen Enablement Standard Following the US Supreme Court’s decision in Amgen Inc. v. Sanofi, patent portfolios are under intense legal scrutiny. Acquirers and late-stage investors are increasingly wary of "functional genus" claims, claims that define an invention by what it does rather than what it is. Structural Disclosure: To support high valuations, companies must ensure their patent specifications provide full structural disclosure commensurate with the scope of the claims. Enablement Threshold: Reliance on broad functional language without detailed technical specifications presents a substantial risk to the "investability" of a platform technology. Coordination of Patent and Regulatory Moats A crucial, often overlooked metric for Series C readiness is the consistency between IP filings and regulatory submissions. Consistency Risk: Arguments made to patent offices regarding "novelty" must not contradict "substantial equivalence" assertions made to regulators like the FDA to secure faster 510(k) clearance. Patent Term Protection: Strategically structuring parent and child applications is essential to protect the "commercial tail" of the patent term, particularly for products with long clinical development cycles. Design Patents: The 2025–2026 market has seen a surge in the use of design patents as enforcement tools, as they can be more decisive in securing import bans through the International Trade Commission (ITC) than complex utility patents. Key Metrics for a HealthTech and MedTech company to raise a Series C round in Europe in today's environment Valuation Multiples and Exit Dynamics The valuation landscape in late 2025 and 2026 reflects a "new normal" where multiples are grounded in fundamental business metrics rather than speculation. While general medtech multiples have stabilised, innovators in AI and digital surgery command significant premiums. Revenue and EBITDA Multiples by Sub-Sector The market hierarchy in 2026 reveals a clear preference for asset-light, high-growth, and recurring revenue models. Sub-Sector EV/Revenue Multiple (2026) EV/EBITDA Multiple (2026) Valuation Drivers Source AI-First Drug Discovery 8.0x – 15.0x N/A (Pipeline-based) Upfront payments and R&D speed Various Premium AI & Data Platforms 6.0x – 8.0x 15x – 18x Proprietary datasets and Rule of 40 Various Value-Based Care Solutions 5.5x – 7.0x 12x – 15x Demonstrable ROI for payers Various MedTech Hardware (MDR-Ready) 3.5x – 5.5x 11x – 14x Strategic compliance moats Various General HealthTech SaaS 4.0x – 6.0x 10x – 13x Predictable unit economics Various Small/Unprofitable Startups 3.0x – 4.0x N/A Valuation compression Various Publicly traded medtech companies such as Siemens Healthineers (3.6x revenue) and Straumann (5.5x revenue) provide a baseline for established entities, but private Series C "champions" often command premiums if they can demonstrate higher growth endurance and superior technical talent. The M&A and IPO Landscape The IPO market, while stagnant for much of the previous three years, showed signs of recovery in late 2025 with significant debuts like Medline on the Nasdaq. However, M&A remains the primary exit path for European healthtech. Strategic vs. Financial Buyers: Private equity firms, possessing significant "dry powder," are paying premiums for stable, cash-flowing assets, with median EV/EBITDA multiples around 11.2x. Corporate acquirers are focusing on "capability-building" acquisitions that strengthen their positions in high-growth procedural segments. The Trust Gap: Despite strong performance, healthtech 2.0 stocks often trade at a discount compared to general software, a legacy of the 2020-2021 market correction. To maximise exit value, Series C companies must articulate a clear, evidence-backed value creation story. Conclusion: The Series C Playbook for 2026 To successfully raise a Series C round in the current European environment, companies must present a profile that balances technological innovation with industrial maturity. The metrics of success have evolved from simple growth to a multi-dimensional assessment of capital efficiency, regulatory strength and clinical integration. The "Golden Standard" for a Series C company in 2026 includes a Rule of 40 score exceeding 60%, an LTV:CAC ratio above 4:1 and a clear "compliance moat" established through early and proactive alignment with the EU AI Act and MDR/IVDR. Geographically, while the UK continues to lead in volume, the ability to navigate the complex reimbursement landscapes of Germany (DiGA) and the UK (NHS) remains the ultimate proof of a scalable business model. Ultimately, the market has transitioned to a "winner-takes-most" environment. Capital is no longer flowing to speculative bets but is instead concentrating in a handful of category leaders who can demonstrate "Hard ROI" and a structural integration into the future of healthcare. For the companies that can clear these high bars, the availability of $2.5 Trillion in unallocated capital ensures that the rewards for success are greater than ever before. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Key Metrics for a HealthTech and MedTech company to raise a Series B round in Europe in today's environment Performance Benchmarks and Capital Efficiency Requirements for European HealthTech and MedTech Series B Financing in 2026 The European healthcare technology and medical technology sectors have reached a definitive inflection point in 2026, transitioning from a period of speculative experimentation into what industry analysts categorise as the era of industrial maturity. This evolution is characterised by a "flight to quality," where the market has bifurcated into a high-conviction environment for category leaders and a severe capital squeeze for mid-stage ventures that fail to demonstrate immediate, systemic value. As the aggregate data suggests a resilient recovery, evidenced by European digital health funding rising to an estimated $6.2 Billion in 2025, the underlying mechanics of the Series B round reveal a persistent "Series B Gap," with the time to close funding rounds now approaching 10 to 12 months. Investors are no longer captivated by technological promise in isolation; instead, they prioritise deep integration into clinical workflows, robust unit economics and a transparent path to profitability. The Macroeconomic Context of the 2026 European Series B Landscape The transition into 2026 represents a departure from the "growth at all costs" paradigm that defined the zero-interest-rate policy (ZIRP) era. In the current landscape, the cost of capital remains elevated, forcing a recalibration of investment criteria toward "Industrialisation", a concept signifying that startups must serve as essential infrastructure rather than discretionary software layers. Global digital health venture funding reached $7.1 Billion in Q1 2026 across 216 deals, reflecting a modest year-on-year decline of 6.6% in value but a staggering 48.6% decline in deal count. This indicates a profound concentration of capital: while fewer deals are being struck, the average VC deal size has surged to $38.4 Million globally, up significantly from $21.4 Million in early 2025. In Europe, the Q1 2026 funding metrics reveal a similar trend of disciplined maturation. The ecosystem deployed $1.2 Billion in venture capital across 67 active deals. While this value represents a decline from the exuberant highs of early 2025, the average European deal size has climbed to $21.1 Million. The funding distribution by stage underscores the dominance of growth-stage ventures, which absorbed $622 Million of the quarterly total, compared to $378 Million for early-stage and only $116 Million for late-stage rounds. European Digital Health Funding Metric (Q1 2026) Value Trend vs. Q1 2025 Total Venture Funding (Excl. Exits) $1.2 Billion ↓ 44% VC Deal Count 67 ↓ 46% Average VC Deal Size $21.1 Million ↑ 8% Mega-Deals (≥$100M) 3 Stable Growth-Stage Capital Share $622 Million Dominant This liquidity cycle is further shaped by an unprecedented accumulation of unallocated capital, with global private equity funds sitting on nearly $2.5 Trillion in "dry powder". Much of this capital is allocated to vintage funds from the 2019–2021 cycle that are nearing the end of their investment periods, creating a "use it or lose it" dynamic expected to intensify deal activity throughout 2026. However, this capital is increasingly focused on defensive moats, specifically clinical validation and regulatory status, as the primary currencies of value. Financial Benchmarks: The Pivot to EBITDA and the Rule of 40 For Series B companies in 2026, the metric of choice for both private and public investors has shifted definitively toward EBITDA or a highly credible, near-term trajectory toward it. The "Rule of 40," which traditionally balanced growth and profitability, has seen its internal weighting shift heavily toward the profit component. In previous cycles, a venture might satisfy investor demands with 50% growth despite -10% margins; in 2026, such high-burn profiles face revenue multiple compression into the 3x–4x range, whereas moderate growth platforms demonstrating consistent profitability command premiums of 10x–14x EBITDA. The Rule of 40 and Performance Tiers The Bessemer Health Tech Index and other 2026 benchmarks identify a "Health Tech 2.0" cohort that consistently outperforms broader SaaS indexes. Investors at the Series B stage now look for "sustained hypergrowth" characterised by year-over-year revenue growth exceeding 150% and net revenue retention (NRR) above 120% to justify billion-dollar valuations at a $30 Million ARR run rate. Revenue and Growth Requirements for European Series B Raising a Series B round in the 2026 environment requires a baseline of commercial traction that would have been sufficient for a Series C round just three years prior. For HealthTech and digital health companies, the annual run-rate revenue (ARR) requirement typically sits between $10 Million and $30 million, with a mandatory year-over-year growth rate of 80% to 100%. Metric Category Series A Median Series B Best-in-Class (2026) Strategic Signal ARR Growth (YoY) 80% – 100% >150% Top-of-funnel efficacy Net Revenue Retention 100% – 105% >120% Product-market fit; expansion Gross Margin 68% – 72% >80% Unit economics ceiling ARR per FTE $200K – $400K $500K – $1M+ AI-driven productivity In the MedTech hardware sector, where regulatory barriers are higher, the revenue requirements for an equivalent funding round are often lower in absolute terms, typically $5M to $15M, but are paired with more stringent clinical evidence and regulatory milestones. The Health AI X-Factor: Productivity as a Valuation Multiplier The implementation of artificial intelligence has moved beyond experimental pilots to become a fundamental valuation multiplier in 2026. The "Health AI X-Factor" framework identifies companies that deserve a premium based on their ability to achieve unprecedented efficient growth and platform expansion. AI-native healthcare companies are now reaching $100 Million to $200 Million in ARR in under five years, significantly faster than the 10+ years typical for previous healthcare software generations or the seven years common for broader cloud companies. ARR per Full-Time Employee (FTE) The most critical metric reflecting this shift is the evolution of ARR per FTE. Traditional healthcare services generate $100,000 to $200,000 in ARR per employee, whereas AI-native platforms are achieving metrics between $500,000 and over $1 Million. This productivity leap allows for software-like margins even at an industrial scale, justifying the premium valuations observed for AI-first drug discovery and imaging assets. Maturity Category ARR per FTE Benchmark Valuation Multiple Context Traditional Healthcare Services $100K – $200K Low (3x – 6x EBITDA) Healthcare SaaS (Legacy) $200K – $400K Moderate (10x – 13x EBITDA) AI-Native Platforms $500K – $1M+ High (15x – 18x+ EBITDA) Investors scrutinise whether AI is embedded in mission-critical workflows, such as imaging, revenue cycle management (RCM), triage and operational optimisation, rather than existing as a peripheral feature. Assets with proprietary, clinically validated datasets and AI that demonstrably improve workflow or outcomes command a clear premium, often 20–30% higher EV/revenue multiples than non-AI peers. Segment-Specific AI Multiples In 2026, the valuation of AI assets is heavily influenced by the specific domain of application and the associated regulatory or reimbursement clarity. AI Market Segment EV/Revenue Multiple Primary Valuation Drivers AI-First Drug Discovery 8.0x – 15.0x "Bio-bucks" potential; reduced R&D costs AI-Enabled Clinical Trial Ops 7.0x – 12.0x Speed to market; patient matching accuracy AI-Powered Medical Imaging 5.0x – 9.0x FDA/EMA clearance; radiologist efficiency AI Remote Monitoring 4.0x – 8.0x Scale (>100k lives); reduction in staffing Operational & RCM AI 3.0x – 6.0x Administrative relief; autonomous billing Capital Efficiency and the Burn Multiple In 2026, capital efficiency has replaced growth rate as the primary determinant of whether a Series B term sheet is issued.The "Burn Multiple", defined as net cash burned divided by net new ARR, has become the shorthand metric VCs use to judge capital discipline. A burn multiple of 1.0x means a company is spending one dollar to generate one dollar of new ARR. In the 2026 environment, a burn multiple below 1.5x is considered strong, while a multiple above 2.0x is a significant red flag for Series B investors. AI-native SaaS companies are setting a higher bar, achieving burn multiples of 0.8x to 1.2x. Unit Economics: LTV:CAC and Payback Periods The LTV:CAC ratio remains the floor for evaluating whether unit economics will work at scale. For a Series B company in 2026, an LTV:CAC ratio of 3:1 is the absolute minimum, while top-quartile companies maintain 4:1 to 6:1. Funding Stage / Motion Typical CAC (Order of Mag) Typical Payback Typical LTV:CAC Seed / Bootstrap (Self-Serve) £200 - £600 6 - 9 Months ~4.0x Series A (Repeatable Channels) £800 - £1,500 9 - 15 Months ~3.5x Series B (Enterprise Sales-Led) £2,500 - £6,000 12 - 24 Months ~3.0x The CAC payback period, the number of months required to recover the cost of acquiring a customer, is the single clearest signal of go-to-market efficiency. For Series B ventures, investors favour a payback period under 12 months, although enterprise motions can stretch to 24 months if retention is exceptionally strong and expansion revenue is real. Regulatory Darwinism: The Compliance Moat as a Financial Asset One of the most profound shifts in the 2026 valuation landscape is the emergence of "Regulatory Darwinism". Regulatory status has surpassed traditional financial metrics to become the single most critical filter for acquisition and investment. In 2026, a valid MDR/IVDR certificate is no longer merely a permit to sell; it is a significant financial asset that creates a defensible competitive moat. The Triple Regulatory Convergence of 2026 Three major regulatory milestones have converged in 2026 to redefine deal value and timing for European HealthTech and MedTech companies : MDR/IVDR Full Enforcement: Class III custom-made devices must reach full compliance by May 26th, 2026. The scarcity of Notified Bodies has led to an 18–24 month regulatory risk profile for non-certified devices, making those with existing certifications highly sought after. The EU AI Act: Full enforcement for "high-risk" medical AI systems began in early 2026. Investors are rigorously avoiding "black box" models, favouring ventures that have engineered "glass box" interpretability to satisfy transparency and data governance requirements. Mandatory EUDAMED Usage: The European Database on Medical Devices (EUDAMED) became fully functional and mandatory as of May 28, 2026. This requires significant system integration, serving as an operational filter for startups. Regulation Implementation Milestone (2026) Impact on Series B EU MDR Transition ends May 28, 2026 Non-compliant devices removed from market EU IVDR Transition ends May 28, 2026 Critical for all diagnostic startups EU AI Act High-risk obligations apply August 2026 Mandatory bias control & human oversight EUDAMED Modules 1, 2, 3, 5 mandatory May 2026 Full digital transparency required Clinical Evidence Maturity A believable regulatory plan tied to FDA or EMA pathways is a prerequisite for Series B in 2026. Investors heading into 2026 want early signals that a product works in real settings through pilot data, small observational studies, or performance benchmarks against standard-of-care tools. For MedTech diagnostics, this translates to a rigorous accumulation of regulatory approvals and peer-reviewed publications; in 2025 alone, the top 50 European healthtech startups achieved 40 regulatory approvals and 21 clinical trials. Commercial Validation and Reimbursement Pathways Reimbursement determines whether a device gets used, while the CE mark only opens the market. Each major European market operates independent national reimbursement systems with distinct timelines and evidence requirements. Germany: DiGA and NUB Germany's DiGA pathway remains the fastest reimbursement route for software medical devices (SaMD) in Europe, allowing listing in the BfArM directory within three months. Eligibility Expansion: Starting in 2026, eligibility will extend to include Class IIb devices, significantly widening the opportunity for complex digital therapeutics. Evidence Mandate: Every DiGA must demonstrate a positive healthcare effect (pVE), either a medical benefit (mN) or a patient-relevant structural and procedural improvement (pSVV). Local Data Requirement: Studies must generally be conducted in Germany to reflect local care populations and provider interactions. Foreign data is only acceptable if comparability is rigorously demonstrated. UK: National Healthtech Access Programme (NHAP) On February 9th, 2026, the UK launched the National Healthtech Access Programme (NHAP), which fundamentally changes how medical technology is funded. The NHAP expands NICE's Technology Appraisals programme to include health technologies, meaning a selection of high-impact medical devices, diagnostics, and digital tools will be reimbursed and made available consistently across the entire NHS. UK Pathway Focus / Stage Evidence Requirement NICE EVA Early Value Assessment Limited evidence; provisional NHS access NICE MTA MedTech Assessment Full HTA using QALY framework; 18-36 months NHAP National Access Programme Selected high-impact, cost-effective tools Joint Clinical Assessments (JCA) The Health Technology Assessment Regulation (HTAR) aims to standardise clinical evaluations through Joint Clinical Assessments starting in 2026 for high-risk medical devices and IVDs. This shift aims to stabilise the system while a broader revision of the MDR and IVDR remains the ultimate priority. Key Metrics for a HealthTech and MedTech company to raise a Series B round in Europe in today's environment MedTech Hardware vs. HealthTech SaaS: Divergent Benchmarks The 2026 market recognises distinct financial and operational profiles for MedTech hardware and HealthTech SaaS.MedTech companies, often building deep tech or robotics, are evaluated on procedural volume and clinical precision rather than pure subscriber growth. IPO and M&A Readiness Thresholds Rigorous financial benchmarks have been established for companies seeking exits or late-stage growth rounds. Metric MedTech (Hardware) HealthTech (Digital Health) Min. Annual Run-Rate Revenue $40M–$60M+ $200M+ Target Gross Margin 65%–80% 60%–80% (Hinge Health: 83%) Required Growth (2–3 yr CAGR) 25%–30% 20%–25% Profitability Target EBITDA positive trajectory Non-GAAP Op. Income or FCF+ MedTech hardware that is MDR-ready commands 3.5x to 5.5x revenue multiples and 11x to 14x EBITDA, reflecting high regulatory barriers and the strategic "compliance moat". In contrast, premium AI and data platforms in HealthTech can stretch to 6.0x–8.0x+ revenue multiples due to their scalability and proprietary clinical datasets. Biotech Series B Benchmarks Biotech valuations in 2026 are anchored in tangible scientific progress rather than today's revenue. Strong Series B biotech companies in 2025–2026 have often exceeded $150 million in valuation. Clinical Advancement: Investors prioritise companies showing positive Phase 2 or early Phase 3 trial data. Valuation Methodology: The industry standard is the Risk-Adjusted Net Present Value (rNPV), using probability-weighted cash flows based on clinical trial success rates, with discount rates typically averaging around 19%. Provider Adoption and Operational KPIs As health systems enter 2026, digital transformation is no longer measured by tool deployment but by deep and broad adoption. C-suites track the percentage of eligible encounters where a tool is activated during a real decision making window, such as an order placed or a discharge finalised. The AI Readiness Gap in Health Systems While 85% of healthcare organizations adopted or explored AI by the end of 2024, only 18% were actually ready to deploy AI in care delivery as of early 2026. Organisations that successfully integrate advanced analytics see an average ROI of 147% within three years. However, the cost of data breaches—averaging $7.42 Million per incident and the presence of "shadow AI" in 40% of hospitals create significant regulatory and financial hurdles. Patient Engagement and Clinical Outcome Benchmarks The healthcare industry's shift toward value-based and patient centred care models is the primary driver of the patient engagement technology market, which is projected to grow from $41.3 Billion in 2026 to $193.22 Billion by 2034. Patient Activation and Utilisation The Boston Medical Center research highlights that highly activated patients (PAM Level 4) have approximately 43% lower rates of 30-day post-discharge hospital utilisation than the lowest activation patients. PAM Level Patient Behaviour Profile Engagement Risk Level 1 Passive; relies entirely on provider Highest Level 2 Aware but lacks confidence to act High Level 3 Beginning to take action but inconsistent Moderate Level 4 Proactive; maintains healthy behaviours Low Clinics that invest in structured engagement infrastructure, such as automated recall, digital intake and two-way messaging, outperform those relying on ad-hoc communication. Appointment reminders via SMS consistently rank as the highest-ROI engagement touchpoint for reducing no-show rates, which typically range from 10-30% in private clinics lacking such tools. Regional Ecosystem Analysis: Concentration of European Innovation The European HealthTech market in 2026 is at a pivotal juncture, with success predicated on navigating a landscape defined by regulatory maturation and selective funding. The European digital health market, valued at $96.68 Billion in 2025, is projected to reach $222.22 Billion by 2030, advancing at a CAGR of 18.11%. Geographic Powerhouses and Funding Trends The distribution of capital remains highly concentrated in the United Kingdom and Northern Europe. United Kingdom: Remains the regional leader, attracting $2.11 Billion in funding. Its ecosystem is supported by AI-enabled pathways that have reduced clinical trial approval timelines. Finland: Surged into second place with $1.16 Billion, heavily influenced by the Oura Health mega-round. France and Germany: Experienced funding declines in 2025, falling to $731 Million and $612 Million, respectively, suggesting investor concentration around specific high-growth assets. Southern Europe: Emerging as the "growth frontier" for private equity roll-ups in fragmented markets like dental and veterinary clinics. The Role of Foreign Capital By early 2026, funding dynamics have been reshaped by aggressive US capital entry, with US investors accounting for 61% of late-stage deals, up 20 percentage points from 2024. This "American Underwriter" dynamic has introduced "American-style" pricing to European ventures but also raises questions about whether the ecosystem can generate exits that justify such valuations in a fragmented regulatory environment. Venture Capital Deal Terms and Governance in 2026 The Series B deal terms in Europe for 2026 reflect an investor preference for safer bets and companies with proven track records. The broader trend of increased cost of capital is reflected in both financing valuations and the structural protections embedded in term sheets. Investor Safeguards: Liquidation and Anti-Dilution Liquidation preferences have become market standard, with a 1x non-participating preference being the most common protection. Participating Preferences: These continue to be an anomaly in healthy rounds, typically reserved for distressed or high-risk scenarios. Anti-Dilution Clauses: Weighted-average formulas are widely used to calculate the subscription price in a subsequent down round. Broad-based protection is more favourable to existing investors as it includes the fully diluted issued share capital in the denominator. Pay-to-Play: These clauses, which incentivise existing investors to participate in down rounds by granting them continued economic rights, are less common in Germany and France than in the US market. Leaver Provisions and Founder Revesting Governance requirements often differ between US-led and European-led rounds. In the US, the default assumption is that a departing founder is a "good leaver", they keep their vested equity unless there is fraud or willful misconduct.European rounds are more likely to include broader "bad leaver" provisions, potentially allowing investors to reclaim a portion of equity in wider circumstances. Term 2026 Market Standard (Series B) Founder Impact Liquidation Preference 1x Non-Participating Protects downside; pro-rata above 1x Anti-Dilution Weighted-Average Moderate dilution in down rounds Dilution at Series A/B ~20% per round Standard market expectation Leaver Provision US-Style "Good Leaver" default Retain vested equity unless misconduct The Exit Landscape: M&A, IPOs, and Consolidation Exit activity remained subdued in early 2026 compared to peak years, with strategic and sponsor-backed M&A continuing to dominate. Large-cap healthcare companies, having avoided transformational deals in 2024 and 2025 are now re-entering the market to optimise their portfolios. M&A Trends and Specialisation Acquirers are prioritising capability-building acquisitions that strengthen their positions in high-growth procedural segments like sports medicine, cardiovascular and neuro-stimulation. Specialty Practice Sub-Sector EV/Revenue (Typical) EV/EBITDA (Typical) Growth Catalyst Cardiology 1.0x – 1.5x 8x – 11x Integration of monitoring tech Oncology 0.9x – 1.3x 8.0x – 8.5x Clinical complexity; reimbursement Orthopedics 0.8x – 1.2x 7x – 10x Ambulatory surgery shift Gastroenterology 0.8x – 1.2x 8x – 10x High procedure volume; PE interest Primary Care 0.5x – 0.7x 3x – 5x Value-based care targets The Persistence of the "Trust Gap" Despite showing metrics that rival or exceed high growth software companies, such as twice the revenue growth and stronger FCF margins, health tech stocks still trade at a 10–20% discount to their cloud counterparts. This "trust gap" lingers from the 2020–2021 market correction, though 2025 saw a strong recovery for "Health Tech 2.0" stocks, which rose 18% in line with the NASDAQ. Conclusion: Strategic Imperatives for European Series B Success The European HealthTech and MedTech sectors enter the second half of 2026 at a profound inflection point. The speculative fragmentation of the early 2020s has given way to an "Industrialised" era where clinical validation and regulatory moats are the primary currencies of value. For founders, the strategic mandate is clear: compliance is not a mere cost of doing business but a critical competitive advantage, and business models must demonstrate tangible, evidence-based value to unlock capital. To successfully raise a Series B round in this environment, ventures must hit the following targets: Capital Efficiency: Maintain a burn multiple below 1.5x and a CAC payback under 12-15 months. Productivity Leap: Achieve $500k+ ARR per FTE through AI-native integration into mission-critical clinical or administrative workflows. Regulatory Maturity: Secure full MDR/IVDR compliance before mandatory deadlines and align with the EU AI Act's data governance standards. Commercial Moat: Secure early signals of reimbursement (e.g., DiGA listing or UK NHAP inclusion) and demonstrate a clear ROI for providers through first-pass claim success or clinician time savings. Ultimately, a simpler and more predictable system is not a shortcut on safety but the condition for safety, timely patient access, and Europe's long-term competitiveness in a global market increasingly defined by evidence-backed innovation. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

IBM is re-entering the healthcare space: Less "Jeopardy!" and more "Efficiency" The Industrialisation of Healthcare AI: IBM’s Strategic Pivot to Secure Hybrid Infrastructure and Operational Efficiency in 2026 The healthcare industry in 2026 has transitioned from a period of experimental artificial intelligence fervour to a phase of rigorous industrialisation, where the value of technology is measured by its ability to stabilise margins and secure sensitive data rather than its capacity for high-profile public spectacle. International Business Machines (IBM), having navigated a decade of volatility in its Watson Health division, has executed a profound strategic re-entry into the sector. This shift is defined by a move away from being the clinical "face" of healthcare AI, once epitomised by the Jeopardy winning Watson, toward becoming the "neutral plumbing" of the industry: the secure, hybrid-cloud infrastructure foundation that enables hospitals to run their AI ecosystems with verifiable safety and predictive economics. In a climate defined by severe workforce shortages and acute margin pressure, hospitals are increasingly rejecting monolithic, proprietary "black box" solutions in favour of open, interoperable platforms that prioritise backend efficiency and data sovereignty. The Institutional Collapse of Cognitive Computing: A Strategic Post-Mortem The current 2026 strategy is rooted in the lessons learned from the "cognitive computing" fallacy that dominated IBM's previous healthcare efforts. The original Watson Health era, which peaked between 2015 and 2021, was characterised by a fundamental misunderstanding of the clinical domain's complexity. While the Watson supercomputer excelled at parsing static, encyclopaedic factoids for competitive trivia, it proved fundamentally ill-equipped for the non-deterministic, nuanced decision-making required in oncology and genomic medicine. The institutional collapse of Watson Health was not merely a failure of algorithms but an operational mismatch between marketing hyperbole and clinical reality. Research into the Watson failure identifies the "technical paradox" of natural language processing (NLP) in clinical settings. Approximately 80% of all healthcare data remains unstructured, held in pathology reports, discharge summaries, and handwritten notes. Watson’s NLP architecture struggled to distinguish between a patient’s historical medical events and their current acute symptoms, often providing recommendations that were inappropriate or unsafe. Furthermore, the reliance on synthetic data trained by a narrow group of elite physicians at Memorial Sloan Kettering Cancer Center (MSKCC) created an inherent bias that made the system incompatible with the protocols of community hospitals and international healthcare systems. In June 2022, IBM divested the assets of Watson Health to Francisco Partners, rebranding the remains as Merative and signalling the end of IBM’s direct clinical tool development. CEO Arvind Krishna explicitly stated that the company lacked the requisite "vertical expertise" for healthcare, choosing instead to refocus on horizontal AI and hybrid cloud offerings. This divestiture served as a "clearing of the decks," allowing the company to shed billions in underperforming acquisitions and pivot toward the 2026 "Efficiency" model. Metric Watson Health Era (2015-2022) Infrastructure Era (2026) Operational Focus Clinical Diagnosis & Oncology System-wide Efficiency & AIOS Architectural Model Monolithic "Black Box" Open, Modular Hybrid Cloud Data Philosophy Centralized Cloud Ingestion Move AI to the Data (On-Prem/Edge) Primary Goal Replacing Human Expert Tasks Redesigning the Business Model Regulatory Approach Static Policy Statements Runtime Sovereignty Enforcement Interoperability Low (Siloed within IBM) High (Standardized MCP/Layer 8) The 2026 Macroeconomic Imperative: Why Hospitals Prioritise Efficiency The re-entry of IBM as an infrastructure provider aligns with a period of unprecedented financial strain for health systems. In 2026, US healthcare spending is projected to reach $5.7 Trillion, yet many hospitals operate on razor-thin margins, with median growth for 450 of the Fortune 500 companies remaining in the single digits. The industry is facing a global shortfall of 18 Million healthcare workers by 2030, a crisis that has elevated the reduction of "administrative toil" from a tactical goal to a survival imperative. The "Efficiency" model appeals to these cash-strapped entities by targeting the revenue leakage and operational waste that plagues manual processes. Statistical analysis of 2026 healthcare operations reveals the depth of this challenge: Denied Claims: Hospitals spend approximately $19.7 Billion annually trying to overturn denied claims, with each claim costing $118 to process. Workflow Inefficiency: Initial claim denial rates have climbed to 11.8%, with 86% to 90% of these denials classified as avoidable through better data automation. Shadow AI Risks: Shadow AI, unauthorised AI usage by clinicians, is present in 40% of hospitals, adding an average of $670,000 to the cost of data breaches. Breach Penalties: The average healthcare data breach cost has risen to between $7.42 million and $10.9 million per incident. In this context, hospitals are increasingly wary of "AI tourists", providers offering shallow pilots that fail to scale.Instead, they are seeking "neutral plumbing" that can integrate disparate agents, manage non-human identities, and enforce compliance at the infrastructure level. The AI Operating Model: Layer 8 and the AIOS Architecture IBM’s 2026 Technology Atlas for Hybrid Cloud outlines a paradigm shift from individual AI models to integrated AI systems that function as an "Operating System for AI" (AIOS). This architecture is built on the premise that AI innovation has entered a new application and protocol layer, often referred to as "Layer 8". This layer evolves middleware to manage the entire stack: models, tools, persistence, and application orchestration. The Model Context Protocol (MCP) A central pillar of the infrastructure re-entry is the adoption of the Model Context Protocol (MCP). In a heterogeneous hospital IT environment, connecting 20 different AI models to 20 legacy enterprise systems (EHRs, PACS, RCM platforms) could require up to 400 custom connectors. The MCP eliminates this "NxM problem" by acting as a universal translator and traffic controller. The MCP allows AI agents to securely and dynamically interact with trusted data sources in real-time, facilitating standards-based access to clinical evidence. As of early 2026, 80% of Fortune 500 companies are deploying active AI agents, with 28% having already implemented MCP servers to unify their data ecosystems. Early deployments indicate substantial operational gains, including up to 70% reduction in AI operational costs and 40% faster agent deployment. Real-Time Data Streaming via Confluent The $11 Billion acquisition of Confluent is regarded as IBM’s most strategically significant "plumbing move" of the current cycle. Traditional enterprise architectures were built for batch processing, which creates latencies incompatible with real-time patient monitoring. Confluent provides the streaming, governed and contextual data required for agentic AI to act "in the moment". By integrating Confluent's Tableflow with watsonx.data, real-time streams of clinical data are made immediately available as open table formats for analysis. This enables a shift from "passive monitoring" to "intelligent response," where the network can detect actual system-to-system communications and identify anomalies that human telemetry sources often miss. Component Technical Function Impact on Hospital Efficiency watsonx.data Hybrid, Open Lakehouse Unified access to structured and unstructured datasets across multi-cloud environments. watsonx.ai Model Tuning & Deployment Fine-tuning domain-specific models (like Granite) on private clinical data. watsonx Orchestrate Agentic Control Plane Managing fleets of agents to handle referrals, scheduling, and RCM. IBM Concert Intelligent IT Operations Correlating signals across apps and infrastructure to reduce recovery time. IBM Sovereign Core Operational Independence Verifying control over where models run and how inference is governed. Operational Sovereignty: Securing the Regulated Frontier Digital sovereignty has moved from a regulatory compliance checkbox to a strategic differentiator in 2026. For healthcare providers, sovereignty now extends beyond simple data residency to include control over infrastructure operations and AI system behavior. IBM Sovereign Core, which became generally available in May 2026, was designed specifically for organisations in critical infrastructure sectors that cannot compromise on authority over their digital estates. The Four Pillars of Digital Sovereignty IBM defines digital sovereignty across four core domains, each of which addresses a specific vulnerability in modern hospital cloud adoption : Operational Sovereignty: Control over how environments are operated, including a customer-operated control plane that allows the hospital full authority over configurations and lifecycle management. Data Sovereignty: Direct control over data at rest, in use, and in motion, utilising in-boundary encryption and "Keep Your Own Key" (KYOK) technology. Technology Sovereignty: An open, modular architecture based on Red Hat OpenShift that avoids vendor lock-in and ensures workload portability across private and public clouds. AI Sovereignty: Precise control over where models run and how inference is governed, ensuring that AI reasoning occurs within defined jurisdictional boundaries. Verifiable Compliance Evidence For regulated entities, sovereignty must be observable and provable to auditors. Sovereign Core provides continuous integrated monitoring and automated evidence generation, mapping system operations against 160 global regulatory frameworks, including GDPR, HIPAA, and the EU AI Act. This eliminates the manual burden of periodic, point-in-time audits, which currently consume a disproportionate share of hospital IT budgets. Sovereignty Feature Technical Implementation Benefit to Regulated Entities In-Boundary Identity Localized Secret Manager Authentication remains within the perimeter, preventing external access. Drift Detection Real-time policy monitoring Immediate alerts if AI model behavior deviates from clinical or legal guardrails. KYOK Encryption FIPS 140-2 Level 4 HSM Ensures the provider—and only the provider—can access raw patient data. Open Source Stack Red Hat Enterprise Linux/OpenShift Predictable economics and the ability to re-host apps without re-platforming. The Agentic Pivot: Automating the Hospital Workflow In 2026, artificial intelligence is no longer an "optional bolt-on" but a part of the core day-to-day operating model. IBM’s agentic ecosystem, comprised of watsonx Orchestrate, IBM Bob, and IBM Concert, moves AI from episodic pilots to resilient, systemic infrastructure. This ecosystem allows organisations to manage "fleets" of specialised AI agents that handle thousands of tasks across the business. Case Study: Providence and Workflow Modernisation Providence, one of the largest health systems in the United States, collaborated with IBM Consulting to address the severe hiring shortages in nursing and caregiver roles. The collaboration utilized an AI-powered HR agent built on watsonx Orchestrate and integrated with Providence's existing systems. The results after eight months were transformative: Hiring Speed: Managers spent 90% less time on hiring steps, and internal transfers were accelerated by 12 days on average. Process Accuracy: Job requests created through the agent were 70% more accurate, reducing the need for costly downstream corrections. Economic Impact: The time to fill positions and the cost of transfers were both reduced by 60%, allowing Providence to get caregivers to the bedside significantly faster. This "workforce multiplier" effect is critical for an industry expecting 29% of its employees to require reskilling by 2028. By automating administrative toil, hospitals can redirect their human talent toward the high-value clinical interactions that define patient outcomes. The Human Side of Adoption IBM’s 2026 CEO Survey highlights that 83% of executives believe AI success is dependent on organizational adoption rather than the technology itself. This has led to the introduction of "Process Studio," a tool that helps enterprises convert legacy Standard Operating Procedures (SOPs) into agent-ready workflows. In a recent project, IBM used AI to analyse 1,400 procedures and uncover 1,000 improvement opportunities, projecting a 25% reduction in operating costs over 18 months. IBM is re-entering the healthcare space: Less "Jeopardy!" and more "Efficiency" Hardware and Performance: The Power of On-Chip AI IBM’s infrastructure differentiation hinges on the unique integration of hardware and software, bringing AI acceleration to where the data already lives. The z17 Mainframe and Spyre Accelerator The IBM z17 mainframe remains the unquestioned leader in secure, high-performance transaction processing. For healthcare finance and fraud detection, the z17 uses on-chip AI accelerators to run billions of inferences at sub-millisecond latency. This allows for the screening of 100% of billing transactions in real-time, rather than relying on sampled checks. The IBM Spyre Accelerator, made commercially available in late 2025, enables hospitals to scale generative and agentic AI workloads directly on their z17, LinuxONE, and Power systems. This hybrid architecture reduces the carbon footprint of AI workloads through high-density, energy-efficient designs that deliver higher performance per watt than traditional GPU-heavy clusters. Collaboration with NVIDIA and Arm To counter the dominance of public cloud hyperscalers, IBM has formed deep hardware alliances. The collaboration between Red Hat and NVIDIA aligns hybrid AI solutions with the NVIDIA AI stack, allowing enterprises to deploy AI-accelerated applications across any environment from the data centre to the public cloud using a unified, automated infrastructure. Simultaneously, IBM and Arm are developing dual-architecture hardware to help enterprises run future AI and data-intensive workloads with greater power efficiency. This ensures that hospitals have a choice in their silicon strategy while maintaining the reliability and security of mission-critical systems. The Quantum-AI Flywheel in Life Sciences IBM has positioned quantum computing not as a distant science project, but as a practical component of the 2026 research computing environment. The "quantum-and-AI flywheel" is a new paradigm where quantum systems solve complex molecular problems, such as protein folding and optimisation, that are mathematically impossible for classical compute, while AI models operationalise those findings for clinical use. The Cleveland Clinic Quantum Milestone In May 2026, researchers at Cleveland Clinic, RIKEN, and IBM announced the simulation of a 12,635-atom protein complex, the largest biological molecule ever modeled using quantum hardware. This simulation utilised the EWF-TrimSQD algorithm, which reduced computational overhead and increased accuracy by 210x compared to previous methods. Cleveland Clinic now operates its own IBM quantum computer on-site, using it to advance drug discovery, enzyme behavior modeling, and vaccine development. For hospital systems, this represents a transition to "Intelligent Research Operations," where the hybrid cloud provides the connective tissue between laboratory breakthroughs and the patient's bedside. Quantum Milestone Technical Achievement Industry Impact Protein Modeling 12,635-atom simulation Accelerating drug discovery for complex diseases like Alzheimer’s. Accuracy Gains 210x improvement in key steps Moving from theoretical results to clinically actionable data. Scaling Factor 40x increase in molecule size Enabling the study of larger, more biologically meaningful systems. Hybrid Workflow Integration of Quantum & AI AI agents operationalize quantum-discovered molecular structures. Comparative Analysis: IBM vs. The Hyperscalers in 2026 The healthcare cloud infrastructure market is characterised by a "three-way dynamic" among the hyperscalers, with IBM occupying a distinct, high-margin niche in regulated environments. Microsoft Azure: The Clinical Desktop Leader Microsoft remains the dominant force in the clinical interface layer, leveraging its $20 Billion acquisition of Nuance and its deep partnership with Epic. Microsoft’s DAX Copilot is the most widely deployed ambient documentation tool, processing over 500 Million clinical notes. Its primary advantage is native integration into Microsoft 365 and the Epic Hyperspace, making it the preferred "face" for frontline clinicians. AWS: The Scale and Flexibility Leader AWS maintains the largest overall cloud market share (approx. 31%) by offering unmatched scale and model diversity through Amazon Bedrock. Its healthcare-specific services, such as HealthLake and HealthScribe, provide developers with modular tools to build custom AI solutions. AWS is the default choice for hospitals that prioritize granular infrastructure control and global scalability. Google Cloud: The Analytical and Research Leader Google Cloud Platform (GCP) distinguishes itself through clinical AI model quality (MedLM) and petabyte-scale analytics via BigQuery. It has found success with research-heavy institutions like Seattle Children's, focusing on clinical decision support and complex differential diagnosis. Google also leads in multi-language support, which is a differentiator for health systems serving diverse patient populations. IBM: The Infrastructure and Sovereignty Challenger IBM’s strategy is not to compete on "model size theatrics" but to build the AI equivalent of enterprise middleware. IBM differentiates itself by acknowledging that "AI won't live in a single cloud". Its combination of on-premises capability, mainframe integration, and Sovereign Core governance is difficult for the hyperscalers to match in the regulated hybrid-enterprise space. While AWS and Azure support mature virtual machine estates, IBM Cloud is favoured by teams that require air-gapped deployment support and deep governance across the entire AI lifecycle. Feature Microsoft Azure AWS Google Cloud IBM Market Share ~25% ~31% ~11% Focused Niche Clinical Strength Epic/Nuance Integration Model Choice/Bedrock Analytical Accuracy Sovereignty/Mainframe Technical Edge Desktop UI Ecosystem Granular Control BigQuery Analytics Layer 8/MCP Plumbing Pricing Model Pay-as-you-go Serverless/PMPM Competitive/Transparent Subscription/Consumption Best For Microsoft-Native Custom Development Research-Intensive Regulated Infrastructure The Identity Governance Crisis: Managing the Non-Human Workforce A significant structural problem keeping healthcare AI stuck in the pilot phase in 2026 is identity governance. As hospitals deploy hundreds of specialised agents, for medical transcription, lab validation, and RCM, they generate non-human identities that most legacy IT systems cannot scope, inventory, or revoke at machine speed. This "visibility gap" has created a trust deficit, with only 5% of enterprise AI agents currently reaching production despite 85% participation in pilots. IBM has responded to this by integrating identity management for agents directly into the runtime layer of the AIOS. This ensures that when a medical transcription agent updates an EHR, the action is cryptographically verified and tied to a traceable identity, mitigating the risk of unauthorised access or AI-enabled vulnerability discovery. Implementation Strategy: The Move to "Low-Code" Efficiency Recognising that the technical complexity of AI can be a barrier to adoption, IBM has introduced several initiatives to simplify how hospitals procure and deploy automation. The eCommerce Pilot for AI Agents To remove friction from the "evaluation to production" path, IBM launched an eCommerce pilot that allows hospitals to purchase pre-vetted AI agents directly from IBM.com. These agents are bundled with watsonx Orchestrate subscriptions, allowing hospitals to access "proven AI agents" for tasks like insurance verification and data access without navigating complex multiple-vendor contracts. Pro-Code to Low-Code Visualisations IBM Consulting has expanded its "Consulting Advantage" platform to allow technical teams to view complex pro-code workflows as low-code visualisations. This supports faster debugging and lifecycle management, which is essential for hospital IT departments that are often under-resourced. Furthermore, the introduction of "IBM Bob" as an agentic development partner helps developers modernise legacy COBOL and mainframe code faster, resolving security risks as the code is written. Conclusions The re-emergence of IBM in the healthcare sector in 2026 is defined by a rigorous focus on "Efficiency" and the provision of a secure, hybrid-cloud foundation. By abandoning the high-risk endeavor of clinical tool development and doubling down on "neutral plumbing," IBM has addressed the specific pain points of a cash-strapped industry: margin pressure, workforce shortages, and regulatory uncertainty. The transition from "Jeopardy!" to "Efficiency" is a strategic acknowledgement that in a highly regulated, high-stakes domain like medicine, the most valuable technology is the one that operates reliably in the background, securing the data and automating the administrative toil that has long hindered the progress of digital healthcare. Strategic success for health systems in the next three years will be determined by their ability to treat AI not as a science project, but as core infrastructure. IBM’s blueprint for the AI Operating Model provides the necessary framework for this transition, offering hospitals the "peace of mind" required to scale AI safely and responsibly in the industrial era of medicine. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Whoop and the Future of the Quantified Self The Strategic Evolution of the Health Operating System: Clinical Integration and Generative AI in Wearable Technology The global health technology sector has entered a transformative phase characterised by the convergence of continuous biometric monitoring, generative artificial intelligence, and synchronous clinical care. This paradigm shift is most prominently evidenced by the recent strategic expansion of WHOOP, a human performance company that has historically focused on the optimisation of elite athletic performance but is now aggressively repositioning itself as a clinical-grade "Health Operating System". The introduction of on-demand telehealth services, advanced electronic health record (EHR) synchronisation, and a persistent AI context layer represents a direct challenge to the legacy model of episodic, snapshot-based healthcare. By bridging the gap between passive sensor data and active medical intervention, the industry is witnessing the maturation of the "quantified self" movement into a formal component of the healthcare continuum. The Synchronous Care Paradigm: In-App Telehealth and Clinical Oversight The cornerstone of the 2026 strategic update is the integration of live, on-demand video consultations with licensed clinicians directly within the mobile application environment. This feature, slated for a staggered rollout in the United States beginning in the summer of 2026, aims to solve the primary friction point in consumer wearables: the data-action gap. While modern sensors are capable of capturing high-fidelity streams of heart rate variability (HRV), resting heart rate (RHR), and blood oxygen saturation, most consumers lack the clinical literacy required to interpret these signals in the context of their medical history. Longitudinal Data vs. Episodic Snapshots The fundamental innovation of the telehealth integration lies in the presentation of longitudinal data to the clinician. Traditional primary care and urgent care visits rely on "brief, episodic snapshots," where vitals are measured at a single point in time, often under the influence of immediate stressors or the "white coat" effect. In contrast, the consultations facilitated by this new platform begin with a comprehensive dashboard encompassing months of continuous biometric history, as well as integrated bloodwork and medical records. This allows a physician to observe how physiological baselines react to specific interventions, such as the introduction of a new medication, changes in training load, or the onset of a chronic condition. For example, a clinician reviewing a member's profile can analyse how a specific pharmaceutical intervention for hypertension impacts the user's recovery score and cardiovascular strain over a thirty-day window. This temporal density of data transforms the clinical encounter from a reactive diagnosis of symptoms into a proactive management of health trends. The service is structured as a paid add-on, reflecting the high operational cost of maintaining a 24/7 network of licensed providers compared to purely algorithmic coaching. Technical Infrastructure and the Role of Synchronous Video The delivery of telehealth is supported by a sophisticated digital health infrastructure designed to handle high-bandwidth video streams alongside real-time data visualisation. Members initiate consultations through the application, where they are matched with virtual experts who can interpret complex biometric datasets. These clinicians have the authority to provide medical guidance, though the company has clarified that the service is intended to work alongside, rather than replace, primary care physicians or emergency services. Feature Component Implementation Status Infrastructure / Partner Regional Availability Video Consultations Launching Summer 2026 Undisclosed Clinician Network United States Only EHR Synchronisation Active/Q2 2026 HealthEx United States Only Advanced Labs Analysis Active Integrated Lab Partners United States Only Blood Pressure Insights Active (MG Only) Proprietary PPG/BPI Model US (subject to FDA 2026 guidance) ECG Heart Screener Active (MG Only) FDA-Cleared ECG Module US, EU, GCC (partial) The decision to launch exclusively in the United States initially is a strategic response to the complex landscape of state-level medical licensing and the specific telehealth reimbursement models prevalent in the American market. Technical Infrastructure: EHR Synchronisation and the HealthEx Partnership The efficacy of clinical telehealth depends heavily on the interoperability of the wearable platform with traditional healthcare systems. To facilitate this, the company has partnered with HealthEx, a unified health records platform, to enable secure Electronic Health Record (EHR) synchronisation. This integration allows members to push their clinical history, including diagnoses, medications and surgical procedures, directly into the application profile. The TEFCA Framework and Data Portability HealthEx utilises the Trusted Exchange Framework and Common Agreement (TEFCA) network, which is supported by the Center for Medicare and Medicaid Services (CMS) and covers more than 80% of healthcare providers in the United States. This network facilitates a seamless "patient-first" privacy model where the user maintains sovereignty over their data. Members must provide explicit consent for the synchronisation of their records, and they retain the ability to revoke access or edit specific data entries at any time. The implications of this synchronisation for clinical workflows are significant. By integrating EHR data with continuous biometrics, the platform can identify causal relationships that were previously obscured. A patient with a diagnosis of asthma, for example, can see exactly how a change in local air quality, detected via GPS and environmental data, correlates with a drop in respiratory rate or sleep quality. The AI coach and human clinicians can then provide personalised recommendations that account for these medical realities. Security Protocols and the Regulatory Gap While the HealthEx integration utilizes encryption and HIPAA-compliant frameworks for data transfer, industry observers have highlighted a persistent "regulatory gap" in the wearable sector. Under current U.S. law, consumer wearable companies are often not classified as "covered entities" under HIPAA unless they are acting as business associates for a healthcare provider. This means that biological signals collected by the device may receive fewer federal protections than those collected in a traditional clinical setting. The company has attempted to mitigate these concerns by emphasising that it "never sells" personal data and that all biometric metrics are anonymised before being processed by third-party large language models (LLMs) used for coaching. However, a 2025 class-action lawsuit (Lomeli v. Whoop) alleging unauthorised data sharing with a third-party tracker called Segment has forced the company to defend its privacy practices in court. The AI Context Layer: My Memory and Proactive Coaching Parallel to the clinical expansion is a significant evolution of the platform's artificial intelligence capabilities. The launch of "My Memory" and "Proactive Check-Ins" signals a move toward a generative AI model that is not only responsive but anticipatory. The My Memory Framework: Architecting Personal Context The "My Memory" feature acts as a persistent repository for qualitative context that sensor data alone cannot capture. The system organises this information into seven distinct categories, creating a multidimensional profile of the user's life. Goals: Short-term and long-term objectives, such as training for a specific race or improving sleep consistency. Identity: Foundational personal factors, including occupation, family status (e.g., "new parent"), and geographic location. Lifestyle: Established habits and routines, such as dietary preferences or specific workout times. Preferences: The desired tone and frequency of coaching, ranging from direct, concise feedback to educational support. Events: Upcoming disruptions to normal routine, such as travel, weddings, or medical procedures. Health History: Chronic conditions, past injuries, and ongoing medications that impact physiological baselines. Mood: Qualitative daily assessments of mental and emotional state. By layering this context over raw heart rate and sleep data, the AI Coach, powered by OpenAI’s GPT-4, can deliver highly nuanced guidance. For example, if the device detects a significant drop in recovery scores, the AI can cross-reference the user's "Memory" to see if they recently logged a "new parent" status or an upcoming international trip.Instead of issuing a generic warning about potential illness, the system can provide specific recommendations for managing sleep debt while traveling or caring for an infant. Proactive Check-Ins and Behavioural Accountability The transition from a reactive "dashboard" to a proactive "partner" is realised through the "Proactive Check-Ins" feature. Utilising push notifications, the system initiates conversations at "moments that matter most," such as before a key event or after a period of poor sleep. This move is designed to replicate the psychological accountability provided by a human coach. If a user has shared a goal of improving their morning routine, the AI may check in after a successful week to reinforce the behaviour, or flag if increased work stress, as detected through the Stress Monitor, is beginning to erode those habits.The system is designed to "stay quiet" when no action is warranted, ensuring that notifications remain relevant and avoid "alert fatigue". Hardware and Sensor Innovation: WHOOP 5.0 and the Medical Grade Sensor The software and AI updates are supported by a bifurcated hardware strategy. The company’s current lineup includes the WHOOP 5.0 and the WHOOP Medical Grade (MG) sensor, each catering to different levels of health intensity. The WHOOP 5.0: Miniaturisation and Battery Efficiency The WHOOP 5.0 represents a significant advancement in sensor housing and energy management. Despite being 7% smaller than its predecessor, the 5.0 delivers more than triple the battery life, reaching upwards of 14 days on a single charge. This is achieved through a redesigned photoplethysmography (PPG) sensor that provides cleaner heart rate signals and a more accurate accelerometer for activity classification. Hardware Feature WHOOP 4.0 WHOOP 5.0 / MG Dimensions 34.7mm x 24mm x 11.5mm 34.7mm x 24mm x 10.6mm Weight ~33 grams ~26.5 grams Battery Life 4-5 Days 14+ Days Waterproofing IP68 (10m) IP68 (10m) ECG Capability None MG Only (with Luxe band) Blood Pressure None MG Only A key technical challenge addressed in the 5.0 is the "wearability" of the device. The platform continues to leverage its "Any-Wear" apparel line, allowing the sensor to be moved from the wrist to other body locations, such as bras, boxers, or sleeves, while maintaining data integrity. However, the 5.0 introduces a redesigned buckle and charging system that is not backward-compatible with 4.0 accessories. The WHOOP MG and Clinical-Grade Metrics The WHOOP MG (Medical Grade) sensor is the exclusive hardware for the "Life" tier membership. This version includes the specific sensors required for on-demand ECG readings and "Blood Pressure Insights". To take an ECG, members must use a compatible band, such as the SuperKnit Luxe, which incorporates metal accents that act as electrodes. By placing a thumb and index finger on the clasp, the user can generate a snapshot of their heart's electrical activity, which is then analysed for signs of atrial fibrillation (AFib). The "Blood Pressure Insights" (BPI) feature utilises a proprietary model that estimates systolic and diastolic ranges during sleep. After an initial calibration with a traditional cuff, the system uses HRV, heart rate, and blood flow patterns to provide a morning estimate of blood pressure when the body is at rest. This is positioned as a wellness tool to help users understand how stress and recovery impact cardiovascular trends, rather than a diagnostic replacement for a clinical monitor. Regulatory Dynamics: The FDA Standoff and 2026 Wellness Guidance The push into clinical health has brought the company into direct friction with the U.S. Food and Drug Administration (FDA). In July 2025, the FDA issued a warning letter regarding the "Blood Pressure Insights" feature, asserting that it met the definition of a medical device requiring 510(k) clearance. The "Medical-Grade" Controversy The core of the regulatory dispute centred on the specific linguistics used in marketing. The company’s website originally described the BPI feature as delivering "medical-grade health and performance insights". The FDA argued that the term "medical-grade" implies clinical validation and diagnostic intent, which could lead consumers to rely on the device for the management of hypertension or hypotension. This standoff lasted approximately six months, during which the company maintained that BPI was a wellness feature designed for habit change and awareness. The impasse was largely resolved in January 2026, when the FDA released updated "General Wellness" guidance. This new framework established that non-invasive blood pressure estimations via optical sensing could remain in the wellness category, provided that companies make no claims of diagnostic accuracy and explicitly avoid terms like "medical-grade". Global Regulatory Variations While the company has secured FDA clearance for its ECG feature, regional availability remains dependent on local regulatory bodies. As of early 2026, ECG and IHRN (Irregular Heart Rhythm Notifications) are available in the U.S., EU and several GCC countries, but remain "pending" in territories such as Jersey, Guernsey, and the Isle of Man due to specific local health tech certifications. This creates a fragmented user experience for international travelers and highlights the challenges of scaling a regulated health platform globally. Market Competition: The Fitbit Air and Google Gemini Response The strategic timing of WHOOP's announcement, arriving exactly 24 hours after the launch of the Google Fitbit Air, indicates a fierce competitive battle for the "screen less" wearable market. Philosophical Divergence in Health Coaching The competition between Google and WHOOP represents a fundamental philosophical split in the industry. Google's approach with the $99 Fitbit Air is centred on the commoditisation of health interpretation. By integrating its Gemini-powered AI coach, Google aims to drive the cost of personalised health guidance toward zero through pure automation.The Gemini coach generates workout plans, summarises health records, and answers fitness questions without human oversight. WHOOP, conversely, is doubling down on a premium "human-in-the-loop" model. While its annual memberships are significantly more expensive ($199–$359), the inclusion of clinical consultations argues that the accountability of a human medical license is worth the price. Metric Google (Fitbit Air) WHOOP (Peak/Life) Hardware Cost $99 Included in Membership Subscription $99/year (Premium) $199 - $359/year AI Foundation Gemini (Google) GPT-4 (OpenAI) Interpretation Pure AI AI + Human Clinician Target Segment Mass Market / Budget Performance / Clinical Enthusiasts The industry analysis suggests that the Fitbit Air is a "defensive" threat to WHOOP's market share, particularly among users who prioritise a lower price point over high-touch clinical services. However, the company maintains a loyal base of approximately 2.5 Million users who are "locked in" to its high-fidelity data ecosystem. Whoop and the Future of the Quantified Self Intellectual Property and Legal Challenges: Trade Dress and Data Privacy As the digital health space becomes increasingly crowded, the company has turned to the legal system to protect its market position. Defending the "Moat": WHOOP v. Bevel and Lexqi In March 2026, the company filed a trade dress infringement lawsuit against Bevel, a startup health analytics app. The suit alleges that Bevel copied the "look and feel" of the platform, including the specific visual organisation of recovery, strain, and sleep metrics. This is a rare instance of trade dress doctrine being applied to digital user interfaces (UI) rather than physical packaging. The company also secured a preliminary injunction against Shenzhen Lexqi Electronic Technology, a Chinese manufacturer. The federal court ordered Lexqi to halt U.S. sales of a wearable that was deemed to be an infringing copy of the "iconic" screenless fabric band design. These legal actions indicate a strategy of reinforcing "moats" through litigation as the functional features of wearables become harder to differentiate. Privacy and the California Class Action The company’s data practices remain under scrutiny due to multiple active class-action lawsuits. Lomeli v. WHOOP (2025): Alleges unauthorised sharing of sensitive biometric data with Twilio’s Segment tracker. Sanderson v. WHOOP (2023): Alleges deceptive enrolment and renewal practices in violation of California's Automatic Renewal Law. Rowe v. WHOOP (2025): Targets allegedly false advertising of "medical-grade" blood pressure insights. The Lomeli case is particularly problematic as it alleges that granular data, including stress levels, sleep patterns, and even video-watching history within the app, was transmitted to third parties without consent. This creates a tension between the company’s "we never sell data" marketing and the technical realities of using third-party SDKs for app analytics. Business Strategy and Financial Outlook: Funding, Hiring, and the IPO Roadmap The expansion into clinical care is supported by a massive capital infusion that positions the company for a transition to the public markets. Series G and the $10.1 Billion Valuation In late March 2026, the company announced a $575 Million Series G funding round at a $10.1 Billion valuation. The round was led by Collaborative Fund and included strategic investments from the Qatar Investment Authority (QIA), Mubadala Investment Company and importantly, healthcare heavyweights like Abbott and the Mayo Clinic. The participation of Abbott and the Mayo Clinic underscores a "strategic alignment" with mainstream medicine, lending clinical credibility to the company’s aspirations. The 2026 Hiring Surge To support this growth, the company announced plans to add over 600 new roles in 2026 across software, research, hardware, and marketing. The majority of these roles will be based at the Boston headquarters, with additional hiring in Europe, the GCC, and Asia. CEO Will Ahmed has framed this expansion as a dual investment in "exceptional talent and world-class AI tools" to own the "Health Operating System" category. IPO Speculation and Global Pricing Dynamics The Series G round is widely believed to be the company’s final private funding before a public debut. This trajectory has led to concerns among some members that a post-IPO focus on quarterly earnings could lead to price increases or a degradation in service quality. Region Membership Tier Hardware Version Annual Renewal (USD/GBP) USA One / Peak / Life 5.0 / MG $199 - $359 UK One / Peak / Life 5.0 / MG £155 - £359 EU One / Peak / Life 5.0 / MG €199 - €359 GCC / Asia One 4.0 (CPO) Variable In the United Kingdom, athletes often face significant markups and stock delays compared to the U.S. market, leading to a vibrant secondary market for importing U.S. hardware to save upwards of £115 per year. This highlights a "strategic error" in the international rollout, as fans in London and Manchester often wait months for inventory that is plentiful in U.S. warehouses. Conclusion: The Future of the Quantified Self The transformation of the wearable fitness tracker into a clinical health platform marks a decisive shift in how individuals and the medical community interact with personal health data. The integration of synchronous telehealth, generative AI, and EHR synchronisation suggests that the "Quantified Self" movement is graduating from a hobbyist pursuit to a formal medical utility. The architectural shift from reactive monitoring to proactive guidance, facilitated by the "My Memory" framework and the clinical interpretation of longitudinal biometrics, addresses the long-standing criticism that wearables provide data without context. By positioning the AI as a "physician’s assistant" rather than a replacement for human medical expertise, the company is navigating a middle path that balances the efficiency of algorithms with the accountability of medical licensing. However, the path forward is fraught with regulatory and legal risks. The standoff with the FDA and the ongoing privacy class actions underscore the vulnerability of health tech companies operating in the "regulatory gap" between consumer gadgets and regulated medical devices. Furthermore, the aggressive competition from Google and the Fitbit Air suggests a period of intense pricing pressure that may force a choice between high-touch human care and affordable algorithmic health. As the company moves toward an anticipated IPO in 2026, its ability to maintain high standards of data security while scaling its clinical offerings will be the ultimate determinant of its long-term viability. The evolution of the platform from a "strap" to a "Health Operating System" represents a gamble that the future of medicine is continuous, conversational, and deeply personalized. The success of this model will likely establish the blueprint for the next generation of digital health ecosystems worldwide. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Digital Health and HealthTech IPO Performance Analysis The landscape of healthcare technology and digital health equity markets from late 2024 through mid-2026 has been characterised by a structural revaluation that industry analysts define as the emergence of "Health Tech 2.0". This transition represents a definitive pivot away from the speculative, growth-at-all-costs models of the 2015 to 2021 era, frequently termed Health Tech 1.0, which were often defined by poor unit economics and a reliance on pandemic-driven temporary tailwinds. The new cohort of companies that have entered the public markets in the last 12 to 24 months, including Tempus AI, Waystar, Caris Life Sciences, Hinge Health, Omada Health and Kestra Medical, are distinguished by significantly more robust business metrics, including a clear path to profitability, deeply embedded artificial intelligence infrastructure and clinical-grade evidence that justifies their inclusion in standard medical workflows. The collective performance of these stocks in 2025 demonstrated a "comeback story" for the sector, with the Health Tech 2.0 cohort adding approximately $36.6 Billion in fresh market capitalisation. This cohort rose by an average of 18% during 2025, matching the gains of the S&P 500 and the NASDAQ Composite, and notably eclipsing the 7% decline observed in the Nasdaq Emerging Cloud Index. However, as the market progressed into the first half of 2026, the performance of individual entities within this group became highly bifurcated. Investors began to differentiate between companies achieving "Infrastructure Grade" status, those with high net revenue retention and software like margins and those facing traditional healthcare service headwinds or valuation compression due to lingering skepticism from previous market cycles. Comparative Performance and Valuation Metrics of the 2024-2025 IPO Cohort The 2024-2025 IPO class has been subjected to rigorous fundamental analysis, with the market increasingly applying the "Rule of 40" (the sum of revenue growth and free cash flow margin) and "ARR per FTE" (annual recurring revenue per full-time employee) as primary barometers of value. The following data highlights the performance and valuation dispersion across the six primary companies of interest as of May 2026. Equity Performance and Market Valuation Summary Company Ticker IPO Date IPO Price Current Price (May 2026) Performance Since IPO Market Cap (May 2026) Tempus AI TEM June 14, 2024 $37.00 $48.46 +31.0% $8.84B Waystar WAY June 7, 2024 $21.50 $21.38 -0.5% $3.82B Hinge Health HNGE May 22, 2025 $32.00 $55.00 +71.9% $4.24B Omada Health OMDA June 6, 2025 $19.00 $14.58 -23.3% $0.87B Caris Life Sciences CAI June 18, 2025 $21.00 $16.15 -23.1% $4.57B Kestra Medical KMTS March 6, 2025 $17.00 $21.83 +28.4% $0.84B Data reflects closing prices and market capitalisation figures recorded between May 7 and May 11th, 2026. The performance indicates that specialised medtech (Kestra) and high-margin, AI-driven platforms (Hinge Health, Tempus AI) have outperformed, while chronic care platforms (Omada Health) and molecular profiling services (Caris Life Sciences) have faced a post-IPO cooling period despite robust operational growth. This bifurcation is further reflected in the "Health AI X Factor" framework, which assigns premium valuations to companies capable of achieving unprecedented growth through AI-native automation. Efficiency and Growth Benchmarks (FY 2025 - Q1 2026) Company EV / Revenue (2026E) Revenue Growth (YoY) FCF Margin Rule of 40 Score ARR per FTE (Est.) Hinge Health 5.7x 72% 26% 98 $500K - $1M Tempus AI 9.3x 85% -22% 63 $400K - $600K Caris Life Sciences 8.9x 117% -7% 110 $350K - $500K Waystar 6.9x 12% 27% 39 $250K - $400K Omada Health 2.5x 65% -1% 64 $300K - $450K Sector Average 7.2x 67% -2% 65 $400K - $700K Comparison against typical cloud benchmarks where Rule of 40 average is 38 and ARR per FTE for non-AI SaaS is $200K-$400K. The analysis of these metrics suggests that while the Health Tech 2.0 cohort demonstrates significantly higher sustainability than the broader cloud index, they continue to trade at a 10–20% "trust gap" discount. This discount is attributed to the market's need for continued validation of AI's ability to drive long-term operating leverage in clinical settings. Tempus AI: The Data-Centric Valuation Leader Tempus AI, listing on the NASDAQ on June 14, 2024, under the ticker TEM, has served as a central pillar of the AI-native healthcare narrative. The company’s share price has followed a volatile but ultimately rewarding trajectory for long-term investors. After an IPO price of $37.00, the stock experienced a significant surge in late 2025, reaching an all-time high of $103.25 in October 2025. This peak was driven by the market's realisation of the value of Tempus’s proprietary datasets, which integrate clinical and genomic information for over seven million patients. As of May 2026, the stock has settled at approximately $48.46, with a market capitalization of $8.84 billion. While the price has retraced from its 2025 highs, the company maintains a 31% gain over its IPO price, outperforming many of its peers in the broader digital health sector. The recent trading history in April and May 2026 shows a period of consolidation. Between April 13 and April 15, 2026, the stock jumped from $45.98 to $56.41, a reaction to positive sentiment surrounding its molecular profiling scale and its inclusion among the largest companies by market capitalisation in its sector. Tempus AI's strategic value is derived from its "data moat," which enables it to achieve high revenue growth (85%) even as it invests heavily in FCF-negative operations (-22% margin). This "Health AI X Factor" is particularly relevant in the context of drug discovery, where Tempus’s data is increasingly utilised by pharmaceutical companies to identify novel biomarkers and optimise clinical trials. The market currently rewards this data-heavy approach with one of the highest EV/Revenue multiples in the cohort at 9.3x. Waystar Holding: Navigating 52-Week Lows Amid Strategic Integration Waystar (Nasdaq: WAY), which listed in June 2024, provides a starkly different performance narrative. Despite being a leader in revenue cycle management (RCM) technology, the stock has struggled to maintain its valuation in the face of shifting analyst sentiment and technical resistance. In early May 2026, Waystar’s stock hit a series of 52-week lows, trading as low as $19.77, which is slightly below its estimated IPO price of $21.50. This downturn occurred despite the company reporting strong financial results for the first quarter of 2026. Waystar surpassed expectations with revenue of $313.9 million, representing 22% year-over-year growth. Subscription revenue, a key driver for long-term valuation, grew by 38%, and adjusted EBITDA increased by 26%. However, the market’s focus has been on the downward revision of forward consensus EPS estimates. In early 2026, the consensus outlook for the fiscal year 2026 EPS was lowered from $0.97 to $0.839, leading to a reduction in the average price target from approximately $46.00 to between $37.00 and $38.27. Waystar Financial and Strategic Indicators (May 2026) Metric Value Significance Market Capitalisation $3.82B - $4.14B Reflects a 50.3% loss from the 52-week high of $41.49. EV / EBITDA 12.4x Relative good value compared to peer average of 14x-18x for AI platforms. Debt-to-Equity 0.66 Manageable leverage after the $1.1B acquisition of Iodine Software. Institutional Ownership 74.9% Dominance of BlackRock, Bain Capital, and EQT suggests long-term backing. The primary driver for Waystar’s future recovery is the deployment of its AltitudeAI platform, which targets "silent denials", payer recoupments that represent an estimated $40 Billion in annual provider revenue loss. The company’s acquisition of Iodine Software in late 2025 for $1.1 Billion is progressing ahead of schedule and is expected to contribute significantly to cross-selling into clinical and financial workflows by 2027. Analysts remain divided, with TD Cowen maintaining a "Buy" rating and a $42.00 price target based on valuation, while UBS trimmed its target to $37.00 citing "guidance cadence". Hinge Health: The Outperformer of the 2025 Class Hinge Health (NYSE: HNGE) has emerged as the clear performance leader of the 2025 IPO class. Pricing its IPO at $32.00 on May 21, 2025, the company’s shares surged immediately, closing at $37.56 on the first day of trading. By May 2026, Hinge Health shares have climbed to $55.00, representing a 71.9% increase from the IPO price. The stock's momentum is backed by a "Rule of 40" score of 98, the highest in the cohort, driven by 72% revenue growth and a 26% FCF margin. The company’s Q1 2026 results were a significant catalyst for this momentum. Hinge reported revenue of $182 Million, a 47% year-over-year increase that surpassed its own guidance of $171 Million to $173 million. More importantly, the company demonstrated massive operating leverage; gross margins reached 85%, and non-GAAP income from operations grew by 208% to $46.2 Million. Hinge Health’s success is attributed to its "non-commodity" hardware component, the Enso neuromodulation device, which was recently cleared by the FDA for the treatment of migraines. This expansion beyond musculoskeletal (MSK) care into a condition affecting one in six American adults represents a significant addressable market expansion. The company’s move into migraine care is already seeing adoption by over 125 clients, representing more than two million eligible lives. Hinge Health Capital and Operational Efficiency (Q1 2026) Metric Q1 2026 Q1 2025 YoY Change Revenue $182M $123.8M +47% Gross Margin 85% 81% +400 bps Free Cash Flow $41.6M $4.2M +890% Cash on Hand $407M $500M (Q3 2025) Reflects $105M share buyback Client Count 2,849 2,311 +23% Hinge Health’s ability to maintain high gross margins while doubling the distribution of its Enso hardware as a percentage of its member base is a key differentiator. The company utilises AI to enhance care team efficiencies, offsetting the costs of physical device production. Furthermore, the company authorised a $250 Million share repurchase program in November 2025, signalling management's belief in the stock's intrinsic value and reducing the diluted share count by 2.5% in Q1 2026. Omada Health: Member Scale vs. Valuation Compression Omada Health (Nasdaq: OMDA) priced its IPO at $19.00 on June 6th, 2025, raising $150.1 Million. Despite achieving significant operational milestones, the stock has struggled in the public market, trading at $14.58 as of May 11th, 2026. This represents a 23.3% decline from its listing price, positioning it as one of the relative under-performers of the cohort in terms of share price appreciation. However, Omada’s financial trajectory has seen a fundamental improvement in 2026. In its Q1 2026 results, the company reported reaching 1.025 Million total members, a 51% year-over-year increase. Revenue reached $78 Million, up 42% from $55 Million in Q1 2025. Most notably, Omada achieved a key profitability milestone by reporting its first quarterly adjusted EBITDA of $1 Million, compared to a loss of $4 Million in the previous year. The disconnect between Omada’s performance and its share price is largely a function of its valuation multiple. Trading at only 2.5x EV/Revenue, the market appears to be valuing Omada more as a traditional chronic care provider than an AI-driven technology platform. This is despite the company’s extensive data infrastructure, which processes 75,000 data points every hour and has recorded over 130 Million blood glucose readings. Omada’s strategic positioning in the GLP-1 medication market is its most potent growth catalyst for 2026. The company’s GLP-1 Care Track has demonstrated that members lose 1.8 times the total weight and more than double the percentage of body fat compared to a control group. By partnering with all three major US PBMs—Express Scripts, CVS Caremark, and now Optum Rx—Omada has secured a massive distribution channel for its cardio-metabolic suite of programs. Caris Life Sciences: Molecular Profiling at a Break-Even Inflection Caris Life Sciences (Nasdaq: CAI) represents the high-beta segment of the Health Tech 2.0 cohort. After completing its IPO on June 18, 2025, at $21.00 per share, the stock has faced volatility, trading at $16.15 by May 12, 2026. Like Omada, Caris has seen its share price decline by over 23% from its IPO price, yet its top-line growth remains the highest in the group. In Q1 2026, Caris reported a staggering 79% increase in total revenue to $216.2 Million. This growth was driven primarily by an 85% increase in Molecular Profiling Services revenue. The company’s gross margins improved from 47% to 65%, and it achieved a break-even EPS of $0.00 for the quarter, significantly exceeding analyst expectations of a $0.12 loss. Caris’s competitive advantage lies in its Whole Exome Sequencing (WES) technology, which it markets as superior to the targeted gene panels used by competitors. A study published by the company in May 2026 showed that WES-measured tumor mutational burden (TMB) was discordant with targeted panel estimates in 10-15% of cases, with WES more accurately predicting survival in pembrolizumab-treated patients. This clinical-grade evidence is crucial for the company's long-term adoption in oncology workflows. Caris Life Sciences Capital Structure and Insider Activity (May 2026) Attribute Value Context Market Capitalisation $4.57B - $5.61B Significant reset from the $7.83B private valuation. Cash from Operations $32.9M 205% improvement from the ($31.3M) used in Q1 2025. Total Revenue Guidance $1.0B - $1.02B Reaffirmed for full year 2026, representing 23-26% growth. Insider Buying $501,426 Director Jeff Vacirca purchased 31,050 shares at ~$16.15 in May 2026. Caris has also taken steps to stabilise its balance sheet, refinancing a $400 Million credit facility at a lower borrowing cost and securing strategic capital from Blue Owl and Blackstone. This refinancing, coupled with insider buying from board members, suggests a valuation floor may be forming as the company approaches consistent profitability. Kestra Medical: Niche Medtech Performance Kestra Medical (Nasdaq: KMTS) listed on March 6, 2025, pricing its upsized IPO at $17.00. By May 2026, the stock has appreciated to $21.83, a 28.4% increase that makes it one of the stronger performers in the medtech segment of the cohort. Kestra has benefited from its specialised focus on the wearable cardioverter defibrillator (WCD) market, where its ASSURE WCD has been worn by more than 17,000 patients. The company’s Q3 FY2026 results (ended January 31, 2026) showed 63% year-over-year revenue growth to $24.6 million. Kestra’s gross margin reached 52.6%, up from 43.4% in the previous year, and the company raised its full-year 2026 revenue guidance to $93 million. This specialised medtech success highlights a broader market trend: investors are rewarding companies with defined, highly regulated products that possess "compliance moats". The "Health AI X Factor" and the Productivity Transformation A primary insight derived from the performance of the Health Tech 2.0 cohort is the emergence of AI as a fundamental valuation multiplier. The "Health AI X Factor" framework distinguishes companies that achieve superior growth by shifting from the mere digitisation of manual workflows to the actual reduction of cognitive workloads. In 2026, AI-native healthcare companies are achieving $100M to $200M in ARR in under five years—nearly twice the speed of previous healthcare software generations. This efficiency is measured by the ARR per FTE metric, which has evolved as follows: Traditional Healthcare Services: $100K–$200K ARR per FTE. Healthcare SaaS (Pre-AI): $200K–$400K ARR per FTE. AI-Native Healthcare (2026): $500K–$1M+ ARR per FTE. Companies like Hinge Health and Tempus AI exemplify this shift. Hinge uses its "Robin" AI and automation tools to increase clinician throughput, while Waystar’s agentic AI network has reduced reconciliation times by 80%. This productivity leap allows these companies to maintain high gross margins (65%–85%) while operating at a scale that was previously labor-prohibitive. Macroeconomic Sentiment and Thematic Market Drivers The broader equity market environment in early 2026 has been defined by a "Great Rebalancing". After several years where technology and AI infrastructure dominated, the healthcare sector emerged as a primary engine of growth in the final quarter of 2025 and the first half of 2026. The "Warsh Shock" and Early 2026 Volatility The market experienced a significant "technological shock" in early February 2026, often referred to as the "Warsh Shock". On February 3rd and 4th, the tech-heavy Nasdaq fell 1.4%, and the S&P 500 slid 0.8% as investors rotated away from high-beta growth names toward defensive assets. During this period, healthcare technology and digital health ETFs like HTEC and EDOC experienced total declines of approximately 7.9% over a 10-day period. However, the recovery for Health Tech 2.0 names was supported by their "Infrastructure Grade" status. By late April 2026, the healthcare sector had become the best-performing sector quarter-to-date, up 7% compared to the S&P 500’s 1% gain. This recovery was driven by clarification around earnings and the easing of policy headwinds as the market digested the first few months of the new US administration. The Impact of the MAHA Agenda The "Make America Healthy Again" (MAHA) agenda, a central theme of the second Trump administration, has introduced new deregulatory tailwinds that favor sector consolidation. This "laissez-faire" approach to antitrust has facilitated a resurgence in mergers and acquisitions (M&A) activity. With major pharmaceutical companies facing a "patent cliff", the $300 Billion in revenue at risk from expirations by 2030—there is significant "dry powder" (over $1 trillion) being deployed to acquire innovative medtech and biotech firms. MAHA Priority Voter Support (MAHA) Impact on Healthtech Stocks Lowering Health Costs 42% Drives adoption of RCM (Waystar) and value-based care (Omada). Restricting Food Additives 21% Bolsters platforms focused on metabolic health and weight loss. Vaccine Policy Re-eval 10% Increases focus on personalized medicine and genetic screening (Tempus, Caris). Deregulation / Laissez-faire High (Admin) Facilitates consolidation and M&A for mid-cap healthtech names. While public opinion on MAHA priorities is divided, the cost of healthcare remains the primary motivator for voters across all parties, ensuring a bipartisan appetite for technologies that improve system efficiency. International Expansion and Regulatory Harmonisation The 2025–2026 period has seen a major breakthrough in UK-US regulatory cooperation, which has material implications for companies like Hinge Health and Tempus AI that are pursuing global expansion. The UK-US Economic Prosperity Deal In December 2025, the UK and US signed an Economic Prosperity Deal that includes a three-year commitment to 0% tariffs on pharmaceutical and medical technology exports. This deal is especially beneficial for UK-based medtech firms and US innovators expanding into Europe. Additionally, the UK reduced the "clawback tax" (VPAG payment) that companies pay the NHS from 23% to 15%, improving the profitability of international product launches. NICE Reform and Healthtech Evaluation On October 1st, 2025, the UK’s National Institute for Health and Care Excellence (NICE) expanded its evaluation program to put digital health and diagnostics on an equal footing with medicines. This "Healthtech Evaluation Programme" aims to end "postcode lottery" access to treatment, ensuring that recommended AI diagnostics and digital tools are implemented NHS-wide. Furthermore, the NICE cost-effectiveness threshold is set to increase from its 20-year range of £20,000–£30,000 to £25,000–£35,000 per QALY gained, effective April 2026. This adjustment provides greater "headroom" for premium-priced innovative technologies and is expected to convince global pharmaceutical and healthtech companies to prioritise the UK in their launch sequences. Institutional Ownership and Market Sentiment Analysis The ownership structure of the Health Tech 2.0 cohort remains heavily institutional, providing a degree of stability despite retail-driven volatility. Waystar, for instance, is 74.9% owned by institutions and 24.2% by VC/PE firms. The presence of top-tier investors like the Canada Pension Plan Investment Board (9.92%), BlackRock (8.58%), and Bain Capital (7.36%) indicates strong conviction in the long-term value of the revenue cycle automation model. However, there has been notable insider selling in the broader sector as share prices have surged in early 2026. For example, Gabriel Mecklenburg, Executive Chairman and Co-Founder of Hinge Health, sold 50,000 shares (valued at $2.75 Million) in May 2026 as the stock traded at a premium. Conversely, insider buying at Waystar and Caris Life Sciences suggests that management in those companies views their current stock prices as undervalued relative to their fundamentals. Future Outlook: Healthtech Infrastructure in late 2026 The strategic focus for digital health in the second half of 2026 is shifting from "experimentation" to "infrastructure". The winners of this next phase will be companies that resemble utilities: trusted pipes, models, and reimbursement mechanisms that are deeply embedded into the healthcare system. Key Predictions for the 2026/2027 Cycle Clinical-Grade Wearables: Consumer health data is becoming clinical-grade, as wearables are pulled into regulated workflows and procurement frameworks (e.g., Kestra Medical's integration into hospital WCD protocols). GLP-1 Stability: The initial hype around obesity medications is giving way to a focus on durable outcomes. Companies like Omada Health that pair medication with lifestyle coaching will be rewarded for long-term adherence metrics. AI ROI Mandate: By the end of 2026, AI will no longer be treated as a pilot. Hospitals and payers will expect a positive ROI for all AI applications, and those unable to provide tangible evidence of cost savings or clinical throughput will face valuation compression. M&A Consolidation: The "patent cliff" and favoUrable antitrust environment will likely lead to a series of high-value acquisitions in the oncology (Tempus/Caris) and MSK (Hinge) segments. In summary, the share prices of the digital health and healthtech companies that have IPOed in the last 12-18 months reflect a broader market rebalancing. While Hinge Health and Tempus AI represent the high-margin, data-rich winners of the current cycle, the operational progress at Waystar, Omada Health and Caris Life Sciences suggests that the valuation gap between "Health Tech 2.0" and the broader technology market is likely to close as these firms prove their durability in a complex regulatory and economic landscape. The sector's transition from speculative innovation to infrastructure-grade performance marks a structural turning point that promises to redefine the financial and clinical standards of the healthcare industry for the next decade. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

The Strategic Transformation of UK Primary Care Digital Infrastructure: TPG’s Acquisition of EMIS and the 2026–2028 Industry Outlook The acquisition of Optum UK, encompassing the EMIS Group, by the global alternative asset management firm TPG in March 2026, marks the beginning of a decisive era for the United Kingdom’s primary care technology landscape. This transition, occurring less than three years after UnitedHealth Group’s initial purchase of EMIS, signifies a fundamental shift in the stewardship of the data infrastructure supporting over half of the general practices in England. As the NHS navigates a pivotal "analogue to digital" transition defined by the 10-Year Health Plan, the strategic trajectory of EMIS under private equity ownership will be characterised by the aggressive modernisation of its cloud-native platform, EMIS-X and the integration of sophisticated artificial intelligence tools designed to mitigate a systemic workforce crisis. This transformation is set against a backdrop of intensifying competition from European entrants like Doctolib and a complex geopolitical and professional debate regarding data sovereignty and the role of the Federated Data Platform (FDP). The Transactional Architecture and Financial Restructuring The closing of the acquisition on March 13th, 2026, established Optum UK as a standalone business under the TPG umbrella. While speculative reports in early 2026 estimated the transaction value between £1.2 Billion and £1.4 Billion, UnitedHealth Group’s subsequent first-quarter filings indicated approximately $400 Million in net proceeds committed to the United Health Foundation. This suggests a significant divergence in valuation or a complex deal structure that may involve the retention of certain liabilities or the carve-out of specific assets not included in the TPG perimeter. The move is strategically aligned with TPG’s broader thematic investment approach, which prioritises mature businesses with established track records and high growth potential in sectors ripe for digital disruption. The regulatory environment surrounding this deal was shaped by the precedent set during the Competition and Markets Authority (CMA) Phase 2 inquiry into the UnitedHealth/EMIS merger in 2023. In regional jurisdictions like Jersey, the Jersey Competition Regulatory Authority (JCRA) determined that the transaction would not lead to a substantial lessening of competition, primarily because the government retains control over the procurement and pricing of electronic patient record (EPR) systems through centralized tender processes. This highlights a critical defensive moat for EMIS: its deeply embedded status within the NHS ecosystem makes it difficult to displace, but also subjects it to rigorous oversight that limits unilateral commercial manoeuvring. Key Transaction Metric Details of TPG Acquisition (2026) Transaction Status Closed March 13, 2026 Reported Net Proceeds $400 million Strategic Rationale Establishing EMIS as a standalone, investment-ready platform Asset Perimeter EMIS business and select Optum UK healthcare technology assets Primary Regulatory Approval JCRA (Jersey) unconditional approval; CMA precedents noted TPG’s Investment Philosophy: The WellSky and IQVIA Paradigms To understand the likely direction for EMIS over the next two years, one must analyze TPG’s historical behavior in the healthcare technology sector. TPG operates through a multi-platform model, with its "TPG Healthcare Partners" (THP) fund managing over $7.1 Billion dedicated to large-cap healthcare buyouts. The firm’s "playbook" typically involves a heavy focus on research and development (R&D), sales expansion and accretive business development to build a unified software backbone across fragmented markets. The evolution of WellSky serves as a primary case study for the projected EMIS roadmap. After TPG invested in the company (then known as Mediware) in 2017, it oversaw eight acquisitions and a comprehensive rebranding, transforming a niche software provider into a dominant post-acute and community care platform used by 15,000 client sites. Similarly, TPG’s 17-year relationship with IQVIA (formerly Quintiles and IMS Health) demonstrates a long-term commitment to transforming "big data" companies into high-value analytics and services platforms. For EMIS, this suggests that the "EMIS-X" platform will be used as a foundation to integrate complementary assets in pharmacy, social care, and clinical research, creating a "whole-person care" ecosystem. TPG Healthcare Portfolio Examples Strategy Applied Implications for EMIS WellSky Consolidation of 30+ brands into a single post-acute platform Unified integration of Primary, Community, and Pharmacy systems. IQVIA Transition from contract research to global data/analytics powerhouse Monetization of "Recruit" and real-world data tools for life sciences. Par Pharmaceutical Diversification from solid pills to international generics and R&D Shift from legacy EPR to AI-enabled "Software as a Medical Device". The Technical Transition: From EMIS Web to the Cloud-Native EMIS-X The technical centerpiece of EMIS’s future under TPG is the migration from the legacy "EMIS Web" desktop application to "EMIS-X". This is not merely a user-interface update but an architectural re-engineering designed to align with modern "internet-first" standards. EMIS Web relies heavily on Microsoft COM-based interfaces and desktop-based integrations, which constrain scalability and prohibit the kind of real-time, cross-platform interoperability demanded by the NHS Federated Data Platform (FDP). The rollout strategy is "evolutionary" rather than a "big bang" migration, allowing clinicians to adopt new functionality gradually while existing features remain in place. This approach is intended to minimize the cognitive load on overstretched clinical teams while enabling the deployment of cloud-native services like "Pathway," a proactive care tool, and "Local Services," which facilitates digital triage into community care settings. Architectural Advantages and API Modernisation EMIS-X introduces a RESTful interface for its APIs, a significant departure from the legacy Partner APIs. This modernisation is critical for third-party developers, who can now use a Developer Portal to build and test integrations against JSON-based endpoints rather than the more cumbersome XML-based EMIS Open schemas. For the NHS, this means that EMIS-X meets the Technology Innovation Framework (TIF) standards for secure, modern, and interoperable technology. Architectural Feature Legacy: EMIS Web Future: EMIS-X Hosting Model Local or Hybrid Public Cloud (Azure/AWS focus) Interface Technology COM-based (Desktop) JSON RESTful APIs (Web browser) Identity Management Local Login Single NHS Identity (CIS2) Network Requirement HSCN (N3) Secure Public Internet Data Strategy Local Caching Near Real-Time Sync AI and the Productivity Frontier: The Rise of EMIS Scribe The integration of Artificial Intelligence (AI) is the most immediate value driver for TPG in the 2026–2028 window. As clinicians spend up to half of their workday on medical record tasks, the documentation burden has become a safety issue as much as a wellbeing one. EMIS has responded by launching "EMIS Scribe," the first fully integrated ambient voice technology (AVT) for the EMIS-X ecosystem. Ambient Clinical Intelligence (ACI) works by capturing natural clinical conversations and using Large Language Models (LLMs) to extract structured clinical elements, such as chief complaints, physical exam findings, and treatment plans, directly into the patient record. This technology uses speaker diarisation to distinguish between the clinician and the patient, ensuring high-quality, specialty-specific note generation. Quantifiable Gains in Clinical Efficiency Internal and pilot data from early 2026 indicate that the combination of EMIS-X and EMIS Scribe can reduce the time spent on key administrative tasks by up to 70%. These efficiencies are vital as NHS England mandates a 4% productivity improvement to manage growing demand. Clinical Task Estimated Time Saved per Interaction Prescribing while reviewing investigations 27 seconds Prescribing while reviewing documentation 42 seconds Prescribing while reviewing consultation details 30 seconds Finding and viewing care record documents 12 seconds Adding consultation details to a referral 29 seconds Total Daily Documentation Recovery 30 minutes to 2+ hours The clinical significance of these metrics extends beyond mere time-saving. By allowing clinicians to replace "screen time" with "eye contact," AVT restores the patient-facing dynamic that is often eroded by keyboard-focused encounters. Furthermore, EMIS Scribe applies standardised SNOMED-CT coding during the transcription process, improving the accuracy of clinical data available for secondary uses like research and population health management. The Strategic Transformation of UK Primary Care Digital Infrastructure: TPG’s Acquisition of EMIS and the 2026–2028 Industry Outlook Competitive Disruption: Doctolib and the Challenger System medicus The UK GP IT market, which was effectively a duopoly between EMIS and TPP for a quarter-century, reached a definitive "inflection point" in May 2026 with the entry of Doctolib. By acquiring the London-based startup Medicus Health, Doctolib bypassed the "zero-to-one" hurdle of NHS national assurance and gained a strategic foothold in the primary care market. Doctolib plans to invest more than £100 Million in the UK over the coming years, hiring 150 people and establishing a research and development centre in London. The competitive threat to EMIS is significant because Medicus is a "cloud-native" system from inception, designed to avoid the "technical debt" associated with legacy systems. Medicus consolidates "front-door" triage, consultation management, and chronic condition monitoring into a single interface, aligning directly with the NHS Primary Care Recovery Strategy. Market Dynamics (2024–2026 Projection) EMIS Health (Optum/TPG) TPP (SystmOne) Medicus Health (Doctolib) Market Share (2024) ~57% ~42% <0.1% Market Share (2026 Proj.) ~52-54% ~38-40% ~1.5-2.0% Strategic Context Facing regulatory/TPG pressure Strong regional hubs; low churn First new entrant via TIF Primary Advantage Massive incumbency/scale High user inertia Cloud-native; AI assistants For TPG, the challenge will be to accelerate the EMIS-X roadmap to prevent "churn" as GP practices, empowered by the NHS "Primary Care Utilisation and Modernisation Fund", look to switch to more agile, integrated "Operating Systems". NHS Strategic Alignment: The 10-Year Plan and FDP Integration The future direction of EMIS is inextricably linked to the NHS "Medium-Term Planning Framework" (2026/27–2028/29), which outlines a major shift toward a "digital-first" operating model. The government’s 10-Year Health Plan, released in July 2025, rests on three "big shifts": from hospital to community, from analogue to digital and from sickness to prevention. The Federated Data Platform (FDP) as a Central Nervous System A critical requirement for EMIS over the next 24 months is its integration with the NHS Federated Data Platform (FDP), delivered by a consortium led by Palantir. The FDP is not an EPR replacement; rather, it sits on top of clinical systems as an operational intelligence layer to address data fragmentation. By March 2026, 86% of acute trusts had adopted the platform, exceeding national targets. For primary care, the FDP facilitates "population health management" (PHM), a market projected to reach $189.79 Billion by 2030. TPG’s stated focus on "automation, data and analytics" suggests that EMIS-X will become a primary feeder for the FDP’s "Canonical Data Model," allowing for near real-time bed visibility, elective recovery forecasting, and vaccination tracking. However, the integration of Palantir owned code within NHS trusts has provoked intense scrutiny regarding data sovereignty and vendor lock-in. The NHS App and "My NHS GP" By April 2026, 95% of GP appointments across all care settings must be available via the NHS App following appropriate triage. EMIS must therefore ensure that its "unified access" models are fully integrated with the national digital front door.This includes "My NHS GP" pathways that use data-driven logic to guide patients to self-care or appropriate clinician encounters via a single user interface. The Governance Crisis: BMA Collective Action and Data Sovereignty A significant obstacle to the TPG/EMIS strategic roadmap is the escalating conflict between general practitioners and the government. In May 2026, the British Medical Association (BMA) launched a "unifying" collective action focused on data sharing agreements (DSAs). GPs, as legal "data controllers," are being urged to "switch off" data-sharing agreements for secondary uses, such as planning, research, or commissioning by ICBs, that are not required for direct patient care. This move is a tactical response to the "imposed" 2026/27 GP contract, which was rejected by 99% of BMA members. Implications for the EMIS Business Model If practices withdraw from voluntary PHM data-sharing agreements at scale, it will severely impact the "real-world data" and research capabilities that made EMIS an attractive acquisition for TPG. The BMA’s action emphasizes that while data extracted for secondary uses is "non-essential for direct patient care," its withdrawal creates "challenges for the wider government agenda" regarding the FDP and commercial research. Stakeholder Perspective on Data Sharing (2026) Strategic Risk for EMIS BMA / GPC Data must only be shared for direct care. Reduced data value for TPG’s PHM tools. NHS England Federated ecosystem for "Population Health". Conflict between national goals and local GP autonomy. TPG / EMIS "Automation, data, and analytics" focus. Reputational damage if seen as a "vulture" entity. Palantir (FDP) Need for "aggregated and analyzed" patient records. "Switch-off" prevents system-wide analytics. Practice managers have expressed concern that "years of data sharing" are being reviewed under the BMA's "housekeeping" guidance, which could expose legacy governance gaps and create technical friction during the migration to EMIS-X. Economic Realities and Operational Risks of Private Equity The acquisition by TPG brings into focus the "core contradiction" of private equity in healthcare: the pursuit of short-term returns (often 3 to 7 years) against the requirement for long-term clinical safety and public interest. Critics, including Harvard health policy experts, have described private equity as the "sharp end of capitalism," noting that the financial gains in PE-owned facilities are often fuelled by increasing charges and reducing labour costs. Debt, staff and Quality Concerns Private equity firms often burden acquired organisations with significant debt, using the acquired entity’s assets as collateral, a "leveraged buyout" model that increases the risk of bankruptcy. In clinical settings, this has been linked to higher hospital-acquired complications and reduced nurse staffing levels. While EMIS is a software provider and not a direct care delivery organisation, the risk for the NHS lies in "asset stripping" or the avoidance of investment in critical, low-margin maintenance in favour of high-margin AI features. TPG, however, has traditionally positioned its "Impact" platform ($32B AUM) as a vehicle for societal outcomes alongside financial ones. A spokesperson for Optum claimed that the standalone status under TPG would provide "enhanced operational support and investment capacity" to deliver modern technology solutions aligned with NHS strategic priorities. The Potential 2026–2028 Strategic Roadmap for EMIS Over the next 24 months, EMIS is expected to follow a roadmap defined by three primary pillars: structural modernisation, clinical automation and ecosystem integration. Pillar 1: Structural Modernisation (EMIS-X) The transition from EMIS Web to EMIS-X must reach functional parity for pharmacy, community and secondary care systems by 2027. This includes the rollout of a "RESTful interface" that supports FHIR resource standards, enabling the "standards-based healthcare integration" required by the NHS. Pillar 2: Clinical Automation (AI Scribing and Decision Support) EMIS will move beyond transcription into "intelligent decision support" and "helpful automation". This involves multi-modal AI that can incorporate images, lab results and previous notes to suggest proactive interventions during a consultation. By late 2026, experts predict that the majority of providers will have adopted ambient AI, making it the "standard of care" for clinical documentation. Pillar 3: Ecosystem Integration (FDP and Clinical Research) EMIS will leverage its "Recruit" tool to automate clinical trial identification and payments for GP practices, turning primary care into a "vital hub for transforming clinical research". Simultaneously, it will finalise its "Solution Exchange" integration, allowing NHS developers to build and scale tools on top of EMIS data via the FDP. EMIS Strategic Milestone Estimated Timeline Impact on the NHS RESTful API Launch Q1-Q2 2025 (Initial rollout) Easier third-party integration; reduced technical debt. TIF Compliance (Web) 2024–2026 Eligibility for NHS modernization funds. EMIS Web "Sunset" Start 2026–2027 Transition of 4,000+ practices to cloud-native EMIS-X. Full FDP Onboarding 2028 Integration with national population health management. Enterprise-wide AI Late 2026 Recovery of 1–2 hours per day for clinicians. Macroeconomic Context: The Clinical Informatics Market The acquisition of EMIS by TPG occurs within a global clinical informatics market that is undergoing rapid expansion. Valued at USD $280.20 Billion in 2026, the market is expected to reach USD $801.39 Billion by 2033, growing at a CAGR of 16.2%. Software remains the largest component of this market, driven by the transition to cloud-native, AI-integrated platforms. In the UK specifically, the digital health market is estimated to grow from USD $18.40 Billion in 2026 to USD $43.98 Billion by 2031. The "Services" segment, encompassing implementation and integration support, is forecast to rise at a CAGR of 20.35%, highlighting the immense operational challenge of transitioning the NHS from legacy on-premise systems (which still hold 53.1% market share in 2026) to the cloud. Conclusions and Strategic Recommendations The acquisition of Optum UK and EMIS by TPG represents a high-stakes bet on the digital maturity of the UK’s primary care sector. For TPG, the challenge is to transform a legacy incumbent into a cloud-native, AI-first platform without alienating a disillusioned clinical workforce or falling foul of an increasingly protectionist data governance environment. For the NHS and Integrated Care Boards (ICBs), the next two years represent a window of opportunity to leverage TPG’s investment capacity to solve the "admin burden" crisis. However, the "left shift" of care into the community cannot succeed if the underlying IT infrastructure remains a source of "click fatigue" and administrative delay. The emergence of cloud-native competitors like Medicus/Doctolib indicates that the era of the "uncontested duopoly" is over. To maintain its market-leading position, EMIS must ensure that EMIS-X delivers the promised 70% productivity gains while maintaining the "trusted system" status that has defined the brand for decades. The success of this venture will ultimately be measured not just by financial returns for TPG investors, but by the ability of 4,000 GP practices to provide safe, integrated, and timely care to a population that is increasingly digitally demanding yet profoundly concerned about the stewardship of its most sensitive data. The integration of the Federated Data Platform, the rollout of ambient AI and the migration to EMIS-X represent a triple-helix of technological change that will redefine British general practice by 2028. In this volatile landscape, the "human-in-the-loop" principle and the preservation of clinician-as-data-controller will be the essential prerequisites for the successful digitalisation of the frontline. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Meditech Expanse EPR Implementation and Digital Transformation in the UK Healthcare Sector The healthcare ecosystem within the United Kingdom and Ireland is currently experiencing a profound digital metamorphosis, catalyzed by the NHS Frontline Digitisation programme and a systemic shift toward integrated care models. Central to this transformation is the emergence of the Meditech Expanse platform, a web-native, cloud-ready Electronic Patient Record (EPR) that represents a departure from the legacy host-based architectures of previous decades. This shift is characterised by a transition from static data storage to "intelligent" EHR environments that prioritise mobility, clinical decision support and patient engagement. For healthcare organizations ranging from large acute trusts in the National Health Service (NHS) to specialized private hospital groups, the selection of an EPR is no longer merely a procurement exercise but a strategic foundation for the next decade of clinical delivery and operational efficiency. The Evolution of the Meditech Architecture: From Legacy to Expanse To understand the current state of Meditech Expanse, it is necessary to examine the technological trajectory of Medical Information Technology, Inc. (Meditech) since its inception in 1969. Early iterations of the Meditech system, including the MAGIC and Client/Server platforms, were built on proprietary operating systems and languages that offered high levels of stability and low resource requirements but were often perceived as text-heavy and rigid in their user interfaces.The development of Meditech 6.x and eventually Expanse marked a fundamental pivot toward web-based technologies and modern graphical user interfaces (GUI) designed to align with the workflows of a mobile, digitally-literate workforce. Expanse is designed as an "intelligent" platform, integrating data from both internal and external sources to deliver insights directly within the clinician’s workflow. Unlike the siloed data structures of the past, Expanse utilizes a unified data layer that allows for real-time updates across all care settings—acute, ambulatory, emergency, and surgical. This architectural shift is critical for large-scale implementations, such as the Norfolk and Waveney Acute Hospital Collaborative, where three distinct trusts aim to operate from a single, shared instance of the record to ensure continuity of care for a population exceeding one million people. The platform’s web-based nature allows it to be hosted in the cloud, a model increasingly preferred by NHS trusts seeking to move away from the capital-intensive maintenance of on-premises data centers. Through the Meditech as a Service (MaaS) model, organizations can adopt Expanse via a subscription-based plan that includes cloud hosting, often on the Google Cloud Platform. This model reduces the Total Cost of Ownership (TCO) by eliminating the need for periodic, bulky hardware refreshes and providing a "forever green" infrastructure that scales dynamically with demand. Infrastructure Evolution and Market Shift Feature Legacy Meditech (MAGIC/CS/6.x) Meditech Expanse (Web-Native) Interface Primarily text-based, keystroke-heavy. Graphical, touch-and-swipe, mobile-first. Hosting Primarily on-premises server infrastructure. Cloud-native, subscription-based (MaaS). Access Stationary desktop terminals. Tablet, smartphone, and browser-based access. Interoperability Limited exchange via bespoke interfaces. Robust exchange via Traverse Exchange and FHIR. Analytics Static reporting via Data Repository. Real-time predictive analytics and AI integration. Clinical Workflow Transformation and the Burden of Documentation A primary driver for the adoption of Expanse in the UK is its focus on reducing clinician burnout—a pervasive challenge within the NHS. Legacy EPR systems often required clinicians to navigate through a "stepwise" process, picking a patient and then picking results, orders, or notes from separate, antiquated menus. Expanse addresses this through the use of personalised, roles-based portals and a "summarised" view of the patient story. Physician Mobility and "Expanse Now" The "Expanse Now" mobile application allows physicians to manage their workload remotely, reviewing charts, prioritising patient lists, and signing orders from a smartphone. This mobility is essential in modern hospital environments where consultants move frequently between wards, clinics, and theatres. The integration of voice navigation and ambient listening technologies further streamlines the documentation process. For instance, ambient listening can automatically draft a clinical visit note by processing the conversation between the doctor and patient, using the Fast Healthcare Interoperability Resources (FHIR) standard to ensure data integrity. Nursing Point of Care For nursing staff, Expanse provides Point of Care software that facilitates interventions at the bedside. This transition from paper-based observations or centralized workstations to handheld digital entry ensures that vital signs, medication administration, and fluid balance are recorded in real time. The clinical alerts and Nursing Status Board prioritise tasks based on patient acuity, notifying staff of scheduled interventions or deteriorating conditions via clinical indicators. In trusts like Northampton General Hospital, which transitioned to the Nervecentre EPR in 2025, the impact of such real-time documentation was evidenced by improved oversight of fluid consumption and nutrition management, a benefit that Expanse mirrors through its own surveillance and alert systems. Interoperability and the Integrated Care Landscape The UK’s shift toward Integrated Care Systems (ICS) necessitates a level of data fluidity that legacy systems could not support. Meditech has addressed this through its national data exchange network, Traverse Exchange. This platform consolidates and deduplicates patient data from multiple external sources, presenting it to clinicians within their existing workflow. Traverse Exchange and FHIR Standards Interoperability in Expanse is built on modern architecture and open APIs, promoting "data fluidity" while maintaining security. The use of FHIR APIs allows Expanse to connect with a wider ecosystem of third-party apps and national networks. In Ireland, where Meditech holds an 80% market share in the private healthcare sector, interoperability between public and private systems is critical. UPMC Ireland, for example, utilises Expanse across its hospitals, cancer centres, and sports clinics to create a safer and more efficient system that serves as a foundation for long-term innovation. The "Tell Your Story Once" Mandate A central ambition for NHS trusts is ensuring that patients only need to "tell their story once" as they move through different care settings. The Expanse EPR facilitates this by allowing seamless information sharing between acute trusts, primary care providers, community services, and social care agencies. In the Norfolk and Waveney ICS, the implementation of Expanse is viewed as a "backbone" for clinical data, enabling better coordination and smoother transitions to the next place of care. Market Dynamics: Meditech Expanse vs. Competitors In the competitive landscape of UK health informatics, Meditech Expanse is typically evaluated alongside Epic Systems, Oracle Health (Cerner), and increasingly, Nervecentre. Value-Based Positioning Meditech Expanse is widely recognised as a budget-friendly option, particularly for community hospitals and medium-sized acute trusts. While Epic excels in large, complex academic networks with unlimited budgets, its high implementation costs and resource-intensive nature can be prohibitive for smaller facilities. Meditech’s focus on high usability and efficient implementation provides a compelling alternative for organizations aiming to improve clinical workflows without the complexity of larger systems. Market Share and Implementation Timelines Vendor Market Presence (US/Global Context) Implementation Complexity Primary Market Epic Systems ~35-43% US market share; leader in large networks. High; 18-24 months; requires massive IT resources. Large Academic Medical Centers. Oracle Health (Cerner) ~19-25% market share; strong international footprint. Moderate/High; 9-18 months; transitioning to cloud. Mid-to-Large Health Systems. Meditech ~10-15% market share; leader in Canada. Lower; faster to deploy; cloud-hosted (MaaS) options. Community Hospitals and Specialty Trusts. Nervecentre Growing UK presence; 11+ acute trusts. Cloud-native; rapid deployment; mobile-first. UK NHS Trusts (Midlands focus). In the UK, the rise of Nervecentre represents a significant competitive shift. By early 2026, Nervecentre had signed a 10-year deal with Mid Yorkshire Teaching NHS Trust, becoming the second-largest EPR supplier in the UK by hospital beds.This domestic growth highlights the increasing demand for cloud-native, mobile-first solutions that prioritise regional collaboration, a domain where Meditech Expanse is also heavily invested. Key Implementation Case Studies in the UK Alder Hey Children’s NHS Foundation Trust: A Flagship Specialist Deployment Alder Hey, one of Europe's busiest children’s hospitals, achieved a major digital milestone by going live with Meditech Expanse in August 2024. This project, named 'Aldercare,' is central to the trust’s five-year digital strategy. As the first specialist trust in the UK to earn HIMSS Stage 7 accreditation, Alder Hey uses Expanse to support complex paediatric care across its 330,000 annual patient encounters. The trust has expanded its use of the platform to include Meditech Surveillance, a predictive analytics tool that identifies high-risk patients for early clinical intervention. Furthermore, the trust is implementing Meditech Oncology, an outpatient system that provides automated scheduling and evidence-based decision support for specialty teams. By December 2025, Alder Hey had approved an upgrade to Expanse version 2.2, aiming to integrate ambient voice technology and AI-driven risk analytics into its paediatric intensive care unit (PICU). Norfolk and Waveney Acute Hospital Collaborative: The Regional Model The collaboration between Norfolk and Norwich University Hospitals (NNUH), James Paget University Hospitals (JPUH), and The Queen Elizabeth Hospital King's Lynn (QEHKL) represents a landmark £88 million investment in a shared Meditech Expanse instance. This initiative aims to eliminate the reliance on paper records and disparate software across the three trusts, providing a single digital health record for each resident. The project, scheduled for a 2026 launch, focuses on: Establishing a common "Change Network" to standardise clinical workflows across the region. Reducing human error through real-time alerts for medication, allergies, and adverse events. Enhancing patient engagement through a digital front door—the Expanse Patient Portal—allowing for self-scheduling and secure messaging. Moorfields Eye Hospital: Integrating Specialist Needs Moorfields Eye Hospital, a global leader in ophthalmology, announced its selection of Meditech Expanse in early 2025, with a go-live date set for summer 2026. The Moorfields implementation is notable for its integration with OpenEyes, a bespoke clinical noting system. By using Expanse as the foundation, Moorfields will fully digitize departments like radiology, pathology, pharmacy, and A&E for the first time, ensuring that clinicians working across its 20 locations have real-time access to the same patient data. Advancements in Patient Engagement and the Digital Front Door Meditech Expanse places a heavy emphasis on the "Patient Experience," offering tools that deliver digital sophistication and convenience. The Patient and Consumer Health Portal serves as a welcoming digital front door, where patients can manage their health between visits. Digital Front Door Capabilities Self-Service Scheduling: Patients can view appointment details and pre-register for upcoming visits through a user-friendly calendar view. Bi-Directional Communication: Secure texting and messaging through the portal or MHealth app foster patient loyalty and reduce appointment no-shows. Access to Health Records: Support for Health Records on iPhone allows patients to see a consolidated view of their history, including data from other health systems connected via Traverse Exchange. Virtual Care: Integrated video visits enable remote consultations, which became particularly critical during and after the COVID-19 pandemic. Trusts using these tools, such as Nathan Littauer Hospital, have seen marked decreases in no-show rates and phone call volumes, as well as increased portal adoption. This shift not only improves the patient experience but also enhances the operational profitability of practices by filling last-minute cancellations and reducing administrative friction. Artificial Intelligence and the Future of the EPR The integration of artificial intelligence into Meditech Expanse is moving beyond experimental stages into real-world clinical application. In April 2026, Meditech received a Google Cloud Partner of the Year award for its implementation of AI into staff workflows. AI and Predictive Analytics The "Expanse Navigator" solution utilises AI and natural language processing (NLP) to search across the entire EHR, legacy data, and even handwritten notes to provide a longitudinal view of the patient. For providers, this results in an immediate impact on workflow efficiency, with some clinics reporting that staff were intuitively using section breakdown features within hours of going live. In specialty care, AI is being used for risk analytics. At Alder Hey, the Etiometry solution in the PICU provides real-time, AI-driven central monitoring. Such predictive tools allow care teams to prioritize high-risk patients and intervene earlier, potentially reducing complications and length of stay (LOS). Genomics and Precision Medicine Expanse Genomics is an industry-leading solution that integrates genetic data directly into the EHR. This allows community hospitals to maintain their independence while offering advanced precision medicine services. Clinicians can order tests, review results, and access genetic interpretation and guidance without leaving the Expanse interface. This integration is critical for the future of oncology and personalized treatment plans, where specific DNA data can determine the most effective course of action for an individual patient. Sustainability and the "Green Plan" in Digital Health Digital transformation in the NHS is increasingly aligned with environmental sustainability goals. The "Green Plan" at Moorfields Eye Hospital illustrates how an EPR implementation can drive ecological benefits. By integrating OpenEyes with Meditech Expanse, the trust aims to significantly reduce its paper use, targeting the elimination of millions of sheets of paper annually. Environmental Impact of Digitisation Moorfields handles approximately 657,000 appointments per year, and each paper letter generated generates roughly 0.64kg of CO2e. The transition to digital consent forms and the removal of paper from the referral process are projected to save over 100,000 pieces of paper annually. Furthermore, the replacement of traditional data centres with state-of-the-art, energy-efficient facilities is expected to complete by 2027-28, supporting the trust’s ambition for a greener healthcare system. This focus on sustainability was a core theme at the Digital Health Rewired 2026 conference, where Meditech demonstrated how digital transformation can lead to a more resilient and environmentally friendly NHS. Implementation Challenges and Strategic Success Factors Transitioning to a new EPR is a complex and resource-intensive process that requires careful planning, coordination, and strong leadership. Lessons from the Frontline The critical issues trusts experience during EPR rollouts often relate to incorrect system usage or the failure to follow new processes post-go-live. Alder Hey Children's Hospital addressed this by implementing a "best practice champion" user programme and delivering training to over 2,500 end users 6-8 weeks prior to their go-live. Such comprehensive training is essential to ensure a smooth transition from current-state to future-state workflows. Other trusts, like Northampton General, have highlighted that "teething problems" are common during the initial launch, and patients are often asked to bear with staff during the transition period. Successful implementations depend heavily on the expertise of the implementation partner and the involvement of frontline clinical, administrative, and operational teams from the outset. Managing Legacy Data A significant challenge for organisations migrating to Expanse is the management of legacy records. Typically, only about two years of clinical data is migrated to the new platform, leaving decades of financial, clinical, and business data in unsupported legacy systems. Active archiving solutions, such as the HealthData Archiver, provide a cost-effective way to consolidate these disparate legacy sources into a single, secure archive with single sign-on integration, ensuring regulatory compliance and uninterrupted access to historical information. The Competitive Threat of Localised Cloud Solutions While global vendors like Meditech, Epic, and Oracle dominate the landscape, the 2025-2026 period has seen the rapid rise of Nervecentre in the UK market. Nervecentre’s Regional Dominance Nervecentre has successfully built a regional community in the East Midlands, with trusts like Nottingham University Hospitals, Chesterfield Royal, and University Hospitals of Derby and Burton all joining the same cloud EPR platform.This "growing cloud EPR platform" allows for borderless collaboration, secure data exchange, and the rapid spread of best practices across multiple organisations. Mid Yorkshire Teaching NHS Trust’s 10-year deal with Nervecentre in February 2026 solidified the vendor’s position as a major contender, supporting nearly 14,000 beds and 10.5 million people. This highlights a growing preference in the NHS for cloud-native systems that offer rapid implementation (sometimes in as little as 2-4 weeks for specific modules) and a highly intuitive interface developed specifically for the UK market. Strategic Assessment and Conclusions The implementation of Meditech Expanse within the UK and Ireland represents a sophisticated balancing act between technological innovation, clinical usability, and fiscal responsibility. The platform has successfully moved beyond its legacy roots to offer a modern, mobile-first experience that aligns with the strategic goals of the NHS and private healthcare providers. Core Conclusions Platform Versatility: Meditech Expanse has demonstrated its ability to serve a wide range of organizations, from specialized paediatric hospitals like Alder Hey to large regional collaboratives like Norfolk and Waveney, and specialized providers like Moorfields. The Mobility Imperative: The "Expanse Now" app and Point of Care solutions are essential for reducing clinician burden and ensuring real-time data accuracy, which are foundational for patient safety and operational efficiency. Interoperability as a Competitive Advantage: Through Traverse Exchange and a commitment to FHIR standards, Meditech is enabling the integrated care models required by the modern NHS, allowing for a more holistic view of the patient journey. Sustainability and Future-Proofing: Digital transformation is proving to be a key lever for environmental sustainability, and the cloud-native, paperless goals of trusts like Moorfields highlight the broader impact of EPR selection beyond clinical outcomes. The Competitive Challenge: The rise of cloud-native competitors like Nervecentre indicates that the market remains dynamic. Legacy vendors must continue to innovate in mobile capabilities and AI to maintain their footprint in the UK market. As the UK’s digital health journey accelerates toward 2030, the success of Meditech Expanse will be measured by its ability to continue delivering "intelligent" solutions that empower clinicians, engage patients, and provide the data foundations for the next era of precision medicine and AI-driven care. For the 44 public and private sector systems currently supported by Meditech in the UK and Ireland, the transition to Expanse is not just an upgrade, it is a vital step toward a more connected, resilient, and patient-centred healthcare system. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

The Strategic Integration of Neuromodulation in Sleep Medicine: An Analysis of ResMed’s Acquisition of Noctrix Health The global landscape of sleep medicine is currently witnessing a paradigm shift, transitioning from a focus on primary respiratory disorders toward a comprehensive management model of neurological and sleep-disordered breathing conditions. Central to this evolution is the strategic acquisition of Noctrix Health, Inc. by ResMed (NYSE: RMD), a transaction valued at approximately $340 Million. This acquisition, announced during ResMed’s third-quarter fiscal year 2026 earnings call, represents a calculated expansion into the restless legs syndrome (RLS) market, a clinical segment that stands as the third most prevalent sleep disorder globally, following obstructive sleep apnea (OSA) and insomnia. By incorporating Noctrix Health’s flagship product, the Nidra™ Tonic Motor Activation (TOMAC) system, ResMed is effectively diversifying its portfolio beyond its core CPAP business and positioning itself as a vertically integrated leader in digital sleep health. The Financial Architecture and Market Dynamics of the Transaction The definitive agreement for ResMed to acquire Noctrix Health is structured as a strategic "tuck-in" acquisition, designed to leverage ResMed’s global scale and commercial infrastructure. Under the terms of the agreement, the transaction is expected to close on or around June 1st, 2026, subject to customary closing conditions. From a financial perspective, the acquisition reflects ResMed’s robust capital position; the company reported a cash balance of $1.7 Billion and a net cash position of nearly $1 Billion as of March 31, 2026. This liquidity allows the firm to pursue high-growth assets without compromising its commitment to shareholder returns, evidenced by the planned $175 Million in share buybacks for the fourth quarter of fiscal 2026. Transaction Component Detail Source Purchase Price Approximately $340 Million Various Expected Closing Date June 1, 2026 Various Current Annual Revenue (Noctrix) Approximately $24 Million Various Reporting Category Americas Devices Various Near-term EPS Impact $0.02 Dilution (Q4 FY26) Various Growth Profile Higher than ResMed Core Business Various The valuation of Noctrix Health at $340 Million implies a significant multiple on its current annual revenue run rate of $24 million. This premium is justified by the scarcity of FDA-authorised non-pharmacological treatments for refractory RLS and the anticipated gross margin accretion. ResMed management has indicated that Noctrix currently operates at higher gross margins than ResMed’s traditional business lines and is growing at a faster rate. While the deal is expected to be modestly dilutive to non-GAAP earnings per share in the immediate term—specifically a $0.02 reduction in the fourth quarter of 2026, the long-term trajectory is focused on margin expansion and revenue diversification. The Pathophysiology of Restless Legs Syndrome and the Clinical Imperative To appreciate the strategic significance of the Nidra™ system, it is necessary to examine the clinical burden of restless legs syndrome. RLS is a chronic neurological sensorimotor disorder characterized by an overwhelming urge to move the limbs, often accompanied by uncomfortable sensations such as tingling, burning, or aching. These symptoms typically follow a circadian rhythm, peaking in the evening and night, which directly disrupts sleep onset and maintenance. The disorder affects an estimated 7% of the adult population globally, representing millions of underserved patients who suffer from impaired quality of life and significant daytime dysfunction. Historically, the pharmacological management of RLS has relied heavily on dopamine agonists and alpha-2-delta ligands (such as gabapentin and pregabalin). However, the long-term use of dopaminergic drugs is frequently complicated by "augmentation", a medication-induced worsening of symptoms where RLS becomes more severe, occurs earlier in the day, and spreads to other body parts. This paradoxical effect has led clinical bodies, including the American Academy of Sleep Medicine (AASM), to increasingly recommend against the use of dopamine agonists for standard long-term treatment. For patients who are drug-refractory, meaning they have failed or cannot tolerate these medications, the treatment options have been historically limited, often necessitating the use of high-risk opioids. The evidence also suggests a significant correlation between RLS and other serious neurological and cardiovascular conditions. Patients with Multiple Sclerosis (MS) show a higher incidence of RLS, particularly those with pyramidal tract involvement. Furthermore, chronic sleep disruption from RLS is a known contributor to hypertension and prediabetes. ResMed’s research highlights that untreated sleep disorders are linked to a 37% higher risk of all-cause mortality, emphasising that RLS is not merely a condition of discomfort but a critical health priority. The Nidra™ TOMAC System: Mechanism of Action and Technological Innovation Noctrix Health’s development of the Nidra™ system addresses the "augmentation paradox" by offering a non-invasive, drug-free alternative. The technology is categorised as Tonic Motor Activation (TOMAC) therapy, which utilises a novel form of neuro-stimulation to suppress the symptoms of moderate-to-severe refractory RLS. The system consists of two wearable units worn externally on each lower extremity, positioned specifically to target the peroneal nerves just below the knees. The mechanism of action behind TOMAC therapy is rooted in the "spinal hyperexcitability" theory of RLS. It is hypothesized that RLS symptoms result from an overactive motor-sensory circuit in the lower spinal cord. When an individual walks or moves their legs, they engage inhibitory circuits that temporarily suppress this hyperexcitability. The Nidra™ device mimics this natural process by delivering high-frequency neurostimulation, approximately 4,000 pulses per second, which selectively activates the peroneal nerve without triggering cutaneous pain fibers. This leads to a sustained, tonic activation of the muscles that effectively cancels the RLS urge, allowing the patient to remain still and transition into sleep. Technical Specification Detail Source Therapy Type Tonic Motor Activation (TOMAC) Various Form Factor Bilateral Wearable Device Various Anatomical Target Peroneal Nerve (Head of Fibula) Various Stimulation Frequency High-Frequency (~4,000 pulses/sec) Various Treatment Duration 30-Minute Sessions Various Duration of Relief Up to 2 Hours Post-Session Various The user experience of Nidra™ is central to its clinical success. Unlike implantable neurostimulators, Nidra™ is entirely non-invasive and can be applied by the patient in the home setting. Relief is typically reported as immediate upon device activation, and the low-risk profile, characterised by a lack of systemic side effects—differentiates it from every existing pharmacological intervention. Clinical Validation and the RESTFUL Study Program The FDA’s de novo authorisation of the Nidra™ system was supported by the landmark RESTFUL clinical trial program, which provided the first randomised, double-blind, sham-controlled evidence for wearable neuro-modulation in RLS. The RESTFUL study (NCT04874155) enrolled 133 adult participants with medication-refractory primary RLS. RESTFUL Phase 1: Efficacy and Responder Rates In the first stage of the RESTFUL study, participants were randomized 1:1 to either active TOMAC or a sham device for a four-week period. The primary endpoint was the Clinical Global Impressions-Improvement (CGI-I) responder rate, a measure of clinically meaningful change. The active group demonstrated a 45% responder rate, compared to 16% for the sham group (p = 0.00011). The mean International RLS Rating Scale (IRLS) total score improved by -7.2 points in the active group, versus -3.8 points in the sham group (p = 0.00093). By the end of Stage 2 (an open-label phase), the CGI-I responder rate for the active group further increased to 61%. Long-term Durability: The 24-Week Extension Study Long-term management is the primary challenge in RLS care. The RESTFUL open-label extension study (NCT05196828) evaluated the durability of the Nidra™ system over 24 weeks. The results indicated not just maintenance of effect, but continued improvement over time. Outcome Measure 24-Week Results Source CGI-I Responder Rate 72.7% Various Mean IRLS Score Reduction -11.3 Points Various MOS-II Sleep Scale Reduction -17.2 Points Various Symptom Frequency Reduction 5.9 to 3.2 Days per Week Various Symptom-Free Days 3.5-fold Increase Various These findings suggest that TOMAC therapy may have a disease-modifying effect, reducing the overall severity of the condition beyond the immediate period of stimulation. The safety profile was similarly robust, with no serious or severe device-related adverse events reported. The most frequent issues were mild administration site irritation or transient discomfort, which typically decreased as patients became accustomed to the therapy. Economic Evaluation and Cost-Effectiveness The adoption of high-cost medical technology like Nidra™ requires a clear economic rationale. An analysis based on the RESTFUL extension data modeled the lifetime cost-effectiveness of TOMAC therapy in the United States. The study used Quality-Adjusted Life Years (QALYs) to quantify the clinical benefits relative to the costs. The findings demonstrated that TOMAC therapy added 0.73 QALYs over a lifetime. The incremental cost-effectiveness ratio (ICER) was calculated at $37,823 per QALY gained. In the context of U.S. healthcare economics, this is well below the common "highly cost-effective" threshold of $50,000 per QALY. This data is a powerful tool for ResMed as it engages with private payers and Medicare to secure broad coverage, arguing that the upfront investment in Nidra™ technology offsets the long-term costs of chronic RLS management and its associated co-morbidities. Strategic Integration: Leveraging ResMed’s Global Ecosystem The rationale for ResMed’s acquisition of Noctrix Health is deeply rooted in the concept of "commercial synergy." ResMed does not merely acquire the Nidra™ device; it acquires a therapeutic platform that fits perfectly into its existing distribution and digital health infrastructure. Distribution and Provider Relationships The Nidra™ device is prescribed by sleep physicians and distributed through home medical equipment (HME) channels, the exact ecosystem where ResMed already holds a dominant market position. ResMed CEO Mick Farrell highlighted that the company's brand reach makes it the "best owner of this scarce asset," as ResMed can immediately scale the therapy through its existing relationships with thousands of HME providers and sleep clinics worldwide. The Digital Health Moat: AirView and myAir ResMed’s transition from a hardware manufacturer to a digital health company is a defining feature of its corporate strategy. The company currently manages 28 Million patients in its AirView software ecosystem and has collected data from over 20 billion nights of sleep. The integration of Noctrix into this ecosystem offers several advantages: Adherence Monitoring: By connecting the Nidra™ device to ResMed’s digital platforms, clinicians can track patient adherence in real-time, much like they do with CPAP therapy. Connected-device patients typically show adherence rates above 87%. Generative AI Insights: ResMed has integrated generative AI into AirView to perform large-scale pattern analysis, flagging at-risk patients faster for clinical intervention. Applying this to RLS data could help identify patients who are not responding to therapy or who may have co-morbid sleep apnea. Unified Patient Experience: Through the myAir app, ResMed can provide a single interface for patients to manage both their OSA and RLS therapies, fostering long-term engagement and reducing "therapy fatigue". Complementary Acquisitions: The Case of VirtuOx ResMed’s acquisition strategy is focused on owning the entire patient journey. The May 2025 acquisition of VirtuOx, a software-enabled independent diagnostic testing facility, serves as a vital precursor to the Noctrix deal. VirtuOx provides home-based testing for sleep, respiratory, and cardiac conditions. This allows ResMed to offer an end-to-end solution: diagnosing RLS and OSA in the home via VirtuOx, and treating them via Nidra™ or AirSense devices, all managed through a unified software backend. The Strategic Integration of Neuromodulation in Sleep Medicine: An Analysis of ResMed’s Acquisition of Noctrix Health Reimbursement and the Evolving Policy Landscape The commercial success of the Nidra™ system depends on the establishment of a robust reimbursement framework. Noctrix Health made significant progress in this area prior to the acquisition, which likely bolstered its valuation. CMS Coding and Coverage The Centers for Medicare & Medicaid Services (CMS) has established dedicated codes for the Nidra™ system. Effective in late 2024 and expanded in 2026, these codes allow for standardised billing and payment across the US healthcare system. Code Description Source E0743 Non-invasive Peripheral Nerve Stimulator (Nidra Device) Various HCPCS Supply Code Charge Dispersing Interface (Monthly Supplies) Various ICD-10-CM Z45.42 Encounter for Adjustment and Management of Neurostimulator Various Despite these codes, the out-of-pocket cost for patients remains variable. The base price for the Nidra™ system is approximately $7,500, with monthly supply costs for replacement interfaces around $75. To mitigate this, ResMed is expected to use its significant "payer relations" expertise to navigate the prior-authorization requirements that currently vary by insurer. For instance, Kaiser Permanente and CarePartners of Connecticut have established specific utilisation management criteria that require patients to be 18 years or older and to have failed a trial of at least one pharmacological agent before Nidra™ is approved. Corporate Transformation and Long-term Growth Outlook The acquisition of Noctrix Health is a cornerstone of ResMed's broader mission to move beyond "breathing" and toward "total sleep health". This transformation is occurring alongside a significant leadership shift; the appointment of Aaron Bloomer as CFO, following the retirement of Brett Sandercock, signals a new era of capital allocation focused on high-margin neurology and software assets. Strategic Rationale and Portfolio Diversification ResMed operates in a market where only 20% of the U.S. population and 5% of the European population with sleep disorders have been diagnosed and treated. By expanding into RLS, ResMed is targeting an "adjacent" condition that often overlaps with its core OSA patient base. This reduces the company’s vulnerability to single-market fluctuations and positions it to benefit from the rising global awareness of sleep as a fundamental pillar of health. Future Catalysts and Research Frontiers The long-term value of the Noctrix acquisition may lie in the expansion of TOMAC therapy to other indications. Research is ongoing into the link between RLS and other neurological conditions, such as MS and Parkinson’s disease. If the Nidra™ platform can be validated for these broader populations, the total addressable market for ResMed’s "neuromodulation" segment would expand significantly. Furthermore, ResMed’s target to achieve gross margin accretion through 2030 is predicated on the integration of such high-margin, innovative products that command premium pricing due to their unique clinical benefits. Conclusion: The New Frontier of Sleep Health The $340 Million acquisition of Noctrix Health by ResMed represents more than a simple product expansion; it is a strategic repositioning of the company as a provider of comprehensive, non-invasive, and digital-first healthcare solutions. The Nidra™ system is the first and only device of its kind to offer a drug-free alternative for the millions of patients suffering from refractory RLS. By combining this innovative technology with its global distribution, digital ecosystem, and diagnostic capabilities, ResMed is creating a dominant moat in the sleep medicine market. As ResMed integrates Noctrix into its "Americas Devices" category and begins to report revenue from this high-growth segment, the focus will shift to execution, securing broad payer coverage, educating sleep physicians, and expanding the therapy into international markets. In a world where pharmacological treatments are increasingly scrutinised for their long-term side effects, the "patient-centred" innovation represented by Nidra™ stands as a compelling model for the future of chronic disease management. ResMed’s evolution into a neuro-sleep health powerhouse is now firmly underway, underpinned by the clinical validation of TOMAC therapy and a clear strategic vision for 2030 and beyond. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk